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Abstract
Bystander lymphocytes generated in vitro by cytokine stimulation (IL-2, IL-6, TNFα) 
have previously been shown to demonstrate significant identity in phenotype and 
activation of monocyte signalling pathways to T cells isolated from rheumatoid 
arthritis (RA) synovial tissue.  Tck are a therefore relevant surrogate model for 
studying the RA T cell.   
The results presented in this thesis extend previous studies of cytokine- activated T 
cells (Tck) through phenotypic analysis and determination of migratory 
responsiveness.  Cytokine stimulation upregulated expression of chemokine receptors 
and integrins on Tck, including CXCR4, VLA-4 and LFA-1.  Results of in vitro 
chemotaxis and extravasation studies revealed that increased expression of CXCR4 
and VLA-4 integrin resulted in concentration-dependent Tck migration to their 
ligands, CXCL12 and VCAM-1, which could be blocked through specific inhibitors 
and neutralizing antibodies.  Increased expression of VLA-4 and LFA-1 also resulted 
in increased Tck extravasation, inhibited through blockade of VLA-1, LFA-1 or their 
ligands.  Moreover, Tck demonstrated an increased chemotactic response to RA 
fibroblast- like synoviocytes cultured in vitro, which could be decreased using 
inhibitors against VLA-4 and CXCR4.  The RA/ SCID mouse model was established 
to assess Tck migratory responsiveness in vivo; however the model did not prove 
sufficiently robust to definitively determine if the in vitro results reflected the 
situation in vivo.    
The activated phenotype of Tck results in increased migratory responsiveness to 
chemokines and proteins found in the RA synovial joint environment.  Tcks elicit 
proinflammatory cytokine production from monocytes, which was further increased in 
the migrated Tck subset.  Tck also exhibit a phenotype similar to RA synovial tissue T 
cells, indicating that cytokine activation of T cells could contribute to RA 
pathogenicity by migration and subsequent cell-cell interactions, perpetuating the 
inflammatory cascade in RA.  The CXCR4/ CXCL12 and VLA-4/ VCAM-1 axes 
could also potentially be exploited for therapeutic gain in treatment of RA.   
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JCV   John Cunningham Virus 
MAPK   Mitogen- activated protein kinase 
Mg    Magnesium 
MHC    Major histocompatability complex 
MIDAS  Medal ion dependent adhesion site 
MIP-3α   Macrophage inflammatory protein- 3α 
MMP   Matrix metalloproteinase 
Mn   Manganese 
MS   Multiple sclerosis 
NCS   Newborn calf serum 
NFκB   Nuclear factor kappa B 
NK cell   Natural killer cell 
NKT   Natural killer T cells 
NLR   NOD- like receptor 
nTreg   Naturally occurring regulatory T cell  
OA   Osteoarthritis 
p190RhoGEF  190 kDa guanine nucleotide exchange factor 
p38- MAPK  Protein 38- mitogen activated protein kinase 
PAMP   Pathogen- associated molecular pattern 
PBL   Peripheral blood lymphocytes 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
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PDK-1   3- phosphoinositide- dependent kinase-1 
PE   Phycoerythrin 
PECAM-1  Platelet endothelial cellular adhesion molecule- 1 
PH   Pleckstrin homology 
PI3K   Phosphatidylinositol- 3 kinase 
PKB   Protein kinase B 
PKC   Protein kinase C 
PLC   Phospholipase C 
PMA   Phorbol- 12 myristate 13- acetate 
PRR   Pattern recognition receptors  
PtdIns   Phosphatidylinositol 
PTPN22  Protein tyrosine phosphatise non- receptor 22 
RA   Rheumatoid arthritis 
Rac1   Ras- related C3 Botulinum toxin substrate-1 
RANKL  Receptor activator of NFκB ligand 
RANTES Regulated upon activation, Normal T cell- expressed, and Secreted 
Rap1   Ras- related protein-1 
RF   Rheumatoid factor 
RhoA   Ras homolog gene family, member A 
RIAM   Rap1- GTP- interacting adaptor molecule 
RNAi   RNA interference 
RORγ   Retinoid acid- related orphan receptor 
RPMI   Roswell Park Memorial Institute 
S1P   Sphingosine- 1 phosphate 
SCID   Severe combined immune deficiency  
SDF-1   Stromal cell-derived factor-1 
Ser   Serine 
SH2   Src homology 2 
 19 
 
siRNA   Short interefering RNA 
SKAP-55  Src kinase- associated phosphoprotein of 55 kDa 
SLE   Systemic lupus erythematosis 
SLP-76   SH2- domain containing leukocyte phosphoprotein of 76 kDa 
Src   Rous sarcoma oncogene cellular homolog 
SSC   Side Scatter 
STAT   Signal transducer and activator of transcription 
Syk   Spleen tyrosine kinase 
T- bet   T box expressed in T cells 
Tck   Cytokine- activated T cells 
TCR   T cell receptor 
TEM   Transendothelial migration 
TGFβ   Transforming growth factor beta 
Th   T helper cell 
Thr   Threonine 
TLR   Toll- like receptor 
TMB   3,3’5,5’- tetramethylbenzidine 
TNFRp55/ 75  Tumour necrosis alpha receptor p55/ p75 
TNFα   Tumour necrosis alpha 
TNFβ   Tumour necrosis factor β 
Ttcr   T cells activated through the TCR 
VCAM-1  Vascular cell- adhesion molecule 1 
VEGF   Vascular endothelial growth factor 
VLA-1/ 4/ 5  Very late antigen-1/ 4/ 5 
ZAP-70  Zeta- chain associated protein kinase- 70 
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1.0   The Immune System 
Humans have a highly complex immune system, consisting of innate and adaptive 
protective components.  Both arms of the immune system function to protect the body 
from pathogens, a system operated through inflammatory processes initialized by the 
innate system, by pathogen recognition receptors and cytokine production.  The 
adaptive immune response is then triggered, which confers specificity and memory.  
However these processes can be incorrectly triggered and aberrant inflammation can 
lead to conditions such as rheumatoid arthritis.  
 
1.0.1   Cellular components of the immune system 
The main components of the immune system comprise cells which are derived from 
haematopoietic stem cells generated in the bone marrow, termed the common myeloid 
and lymphoid progenitors (Prchal et al. 1978).  Cells which are derived from the 
myeloid progenitor are cells of the innate immune system which function as sentinels 
for infection, and act as antigen presenting cells during an immune response.  These 
cells include dendritic cells, neutrophils, monocytes, and macrophages.  Cells that 
derive from the common lymphoid progenitor include T cells and B cells; cells of the 
adaptive immune system, in addition to innate natural killer cells.    
 
1.0.1.1   Dendritic cells (DC) 
The main functions of dendritic cells are to act as phagocytes for invading pathogens, 
and to establish central and peripheral tolerance.  Immature dendritic cells recognise 
antigens in the tissues through their pattern recognition receptor expression, and are 
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constantly in recirculation, bearing either self antigens and inducing tolerance, or 
bearing peptides derived from pathogens to mediate antigen specific T cell activation.  
Engulfment of pathogenic antigens induces DC migration to the T cell area of the 
spleen or lymph nodes, maturation and their expression of co-stimulatory molecules 
necessary to activate T cells (Steinman 1991).  During their maturation, their ability to 
phagocytose antigens is decreased, and adhesion molecules necessary for cell- cell 
contact and major histocompatability complex (MHC) class II expression are 
upregulated (Witmer-Pack et al. 1988; Larsen et al. 1994).  Dendritic cells can also be 
derived from classical monocytes (Heath et al. 2009).  
 
1.0.1.2   Monocyte/ Macrophages 
Monocytes and macrophages function to engulf invading pathogens to act as antigen 
presenting cells in the activation of T cells, and to ingest dead cells and debris during 
an inflammatory response.  Monocytes encompass approximately 10 % of circulating 
leukocytes, and can be divided into two subclasses; CD16 
–
 (classical) and CD16 
+ 
(non classical) (Rees 2010).
 
 Stimulation of CD16 
– 
monocytes by microbial products 
leads to production of cytokines such as IL-10 and expression of the chemokine 
receptor CCR2 (receptor for CCL2), whereas CD16 
+
 monocytes produce cytokines 
including TNFα and IL-12 and express the chemokine receptor CX3CR1 (receptor for 
the chemokine CX3CL1/ fractalkine).  Studies have shown that while CD16
-
 
monocytes are the precursors for tissue macrophages, CD16 
+
 monocytes patrol the 
endothelium and are more prone to immediately extravasate into inflamed tissues 
during an inflammatory response through their expression of the chemokine receptor 
CX3CR1, where they differentiate into macrophages (Auffray et al. 2007).  These 
macrophages, which are activated under pro-inflammatory conditions by 
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lipopolysaccharide (LPS) and interferon γ (IFNγ) (M1 macrophages), produce 
cytokines and chemokines including tumour necrosis factor α (TNFα), interleukin- 6 
(IL-6), IL-12, IL-10, CCL5, CXCL10, CCL2 and metalloproteinases in addition to 
upregulating co-stimulatory molecules such as CD80 and CD86 to enable T cell 
activation (Rees 2010).  These macrophages can also then recruit further CD16
–
 
monocytes through their expression of CCR2 (Auffray et al. 2007).   
 
1.0.1.3   B cells 
B cells are derived from the common lymphoid progenitor and originate in the bone 
marrow.  B cells mediate the humoral adaptive immune response, which results in 
production of immunoglobulins against specific antigens.  These immunoglobulins 
(Ig) can be neutralizing or opsonising, identifying the cells for clearance by 
phagocytes or killer cells.  The majority of immature B cells reside in secondary 
lymphoid tissue, with a pool of cells circulating through the periphery until they 
encounter an invading pathogen (Parkin et al. 2001).  B cells recognise pathogen 
through membrane bound IgM, engulf the pathogen and act as antigen presenting 
cells to present antigen peptides to T cells.  This occurs in germinal centres located in 
the lymph nodes, where B cell migration is induced through the chemokine CXCL13 
which attracts B cells bearing its receptor, CXCR5 (Legler et al. 1998).  Interaction of 
B cells with T cells subsequently occurs through CD40 ligation, leading to B cell 
activation through T cell secretion of cytokines such as IL-4 (Valle et al. 1989).  Two 
signals are required to activate B cells; activation through the B cell receptor 
(membrane bound IgM) through encounter with pathogens, and subsequent 
interaction with IL-4- producing Th2 cells.  B cells then undergo affinity maturation 
and class switching, where the cells produce high affinity antibodies of a different 
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isotype to immature B cells (i.e. IgA, IgG and IgE as opposed to IgD and IgM).  
These processes induce the maturation of B cells into plasma cells which then migrate 
to the site of infection to produce antigen- specific immunoglobulin and pro-
inflammatory cytokines (Glimcher et al. 1982; Williamson et al. 1983).  Although 
many plasma cells will undergo apoptosis after the infection had been resolved, a pool 
of cells will become long-lived memory B cells which will rapidly become activated 
on re-infection.  
 
1.0.1.4   T cells 
T cells, derived from the common lymphoid progenitor and matured in the thymus, 
are characterized by expression of CD4 or CD8 molecules.  CD4
+
 T cells are 
activated in two ways; through the T cell receptor (TCR) (antigen- dependent) and in 
an antigen- independent manner.  In the antigen- dependent pathway, the clonally 
diverse TCR recognizes antigen peptides bound to MHC class II molecules presented 
by antigen presenting cells (APC) such as B cells, macrophages and dendritic cells 
while the naive T cells reside in the T cell zone of secondary lymphoid organs.  To 
complete T cell activation, co- stimulatory signals on the T cell and APC must 
interact; the most common is binding of CD28 (T cell) to CD80 and CD86 (APC).  
Co-stimulation is required to prevent T cell activation in response to a self- antigen 
and development of autoimmunity (Mincheff et al. 1990).    
Phosphorylation cascades are then activated which lead to T cell antigen- specific 
clonal expansion, memory cell generation, IL-2 production and differentiation of cells 
into either Th1 or Th2 subtypes (Ledbetter et al. 1990).  This depends on the type of 
APC presenting antigenic peptides to the T cell (macrophage- Th1, B cell- Th2) and 
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the cytokine environment (IFNγ- Th1, IL-4- Th2); however there is some overlap 
(Chang et al. 1990; Gilbert et al. 1990).  These conditions establish the correct 
immune response required to eliminate the pathogen.   
Memory T cells can also be generated from clonal expansion of T cells during an 
immune response.  These cells can be mobilized quickly if the pathogen is re-
encountered.  In order to maintain this efficient immune surveillance, memory T cells 
must be able to recirculate through blood and lymph to secondary lymphoid organs 
such as the lymph nodes and spleen, but also to non-lymphoid tissues and sites of 
inflammation in the event of re-infection.  The pattern of T cell migration is defined 
by their expression of homing receptors, and this classifies them into three groups; 
central memory (Tcm), effector (Teff) and effector memory (Tem).  Tcm express 
secondary lymphoid organ- homing chemokine receptors and selectins such as CCR7 
and CD62L, however they can also migrate to sites of inflammation (reviewed in 
(Marelli-Berg et al. 2010)).  In contrast, Teff and Tem lose expression of CCR7 and 
CD62L and migrate preferentially to non- lymphoid organs and sites of inflammation 
(Marelli-Berg et al. 2010).  During inflammation, endothelia become activated by pro-
inflammatory mediators and normal immune cell migration is increased (Mackay 
1992).  Increased migration of lymphocytes, in particularly memory T cells, has been 
implicated in the pathogenesis of chronic inflammatory and autoimmune diseases 
such as rheumatoid arthritis (RA), MS and psoriasis.     
T cells can also be activated in an antigen- independent manner, where activation 
occurs by soluble mediators such as cytokines; most often termed a ‘bystander 
response’.  T cells can be activated by combinations of IL-2, TNFα, IL-6, IL-15 and 
IFNγ, and have been shown to function in immune responses under chronic 
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inflammatory conditions such as in multiple sclerosis or RA (Unutmaz et al. 1994; 
McInnes et al. 1996; Brennan et al. 2008; Bar-Or et al. 2010). 
 
1.0.1.5   T helper (Th) subtypes 
1.0.1.5.1   Th1 cells 
Th1 development depends on the expression of the transcription factors T box 
expressed in T cell (T-bet) and signal transducer and activator of transcription 4 
(STAT4), and the presence of macrophage- derived IL-12 and natural killer (NK) and 
T cell- derived IFNγ (Zhou et al. 2009), (shown in Figure 1.1).  The target genes of 
T-bet, a member of the T box transcription factor family, include activation of the Th1 
signature genes, ifng and cxcr3, and inhibition of gata3, which represses Th2 
differentiation (Beima et al. 2006; Usui et al. 2006).  Th1 cells produce IL-2 to induce 
proliferation of other T cells and IFNγ which increases antigen presentation by 
macrophages and express the chemokine receptors CXCR3 and CCR5, which induce 
migration to the chemokines CXCL10 and CCL5 respectively.  IFNγ also suppresses 
Th2 function, and promotes further Th1 differentiation.  Th1 cells activate 
macrophages to eliminate intracellular bacterial pathogens.   
 
1.0.1.5.2   Th2 cells 
Th2 differentiation depends on the zinc- finger- type transcription factor GATA-3, 
which binds target genes including the Th2 signature genes il4, il5 and il13 and 
inhibits stat4, which suppresses Th1 differentiation (Hosoya et al. 2010).  The 
transcription factor STAT6 and the presence of the basophil and T cell- derived 
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cytokine IL-4 is also required for Th2 differentiation.  Th2 cells produce IL-4, IL-5, 
IL-9, IL-13 and IL-25 which activate B cells to produce antibodies in order to 
eliminate extracellular bacteria and parasites.  Th2 cell also express the chemokine 
receptors CCR4 and CCR8, which induce migration to the chemokines CCL22 and 
CCL1 respectively (Tiffany et al. 1997; Andrew et al. 1998; Imai et al. 1998).  This is 
summarized in Figure 1.1. 
 
1.0.1.5.3   Regulatory T cells (Treg) 
Naturally occurring regulatory T cells which develop in the thymus, are characterized 
by the expression of transcription factor FoxP3, which is required for development 
and maintenance of suppressive function (Williams et al. 2007) and high expression 
of the IL-2 receptor (CD25).  Inducible regulatory T cells (iTreg), differentiated from 
naive CD4 cells in the periphery, are also dependent on FoxP3 expression and the 
presence of TGFβ.  Regulatory T cells function to induce tolerance and dampen 
inflammatory immune reactions; mutations in Foxp3 causes a multiorgan 
inflammatory condition called immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome (IPEX) in humans, and mice with this defect die soon after birth 
(Bennett et al. 2001).  Regulatory T cells express a number of chemokine receptors 
including CCR4, CCR6, CXCR3 and CXCR4 which induces their migration to sites 
of inflammation (illustrated in Figure 1.1).  At sites of inflammation, T regs function 
by producing anti-inflammatory cytokines such as IL-10 and TGFβ to dampen 
immune responses and granzymes which induce killing of tumour- specific cytotoxic 
lymphocytes, and by mediating blockade of effector T cell priming by DCs through 
Treg expression of cytotoxic T lymphocyte antigen- 4 (CTLA-4) (Wing et al. 2008; 
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Campbell et al. 2011).  CTLA-4 is an inhibitory receptor of T cell activation which 
appears on the surface of recently activated T cells; CTLA4 specifically binds to 
CD80 and CD86 on the surface of APCs, interrupting co-stimulatory interactions 
(Smolen 2007). 
 
1.0.1.5.4   Th17 cells 
The recently defined Th17 subset produce the pro-inflammatory cytokine IL-17 and 
Th17 differentiation is dependent on the transcription factors retinoid acid- related 
orphan receptor γt (RORγt) and STAT3, and the presence of TGFβ and IL-6 (Yang et 
al. 2007).  Th17 cells also produce IL-21 and IL-22 and express the cytokine receptor 
for IL-23 and the chemokine receptors CCR4 and CCR6 (summarized in figure 1.1).  
This confers responsiveness to the chemokines CCL22 and CCL20 respectively.  IL-
17 induces production of other pro-inflammatory cytokines including TNFα and IL-6 
and chemokines including IL-8 which attracts neutrophils, thus perpetuating 
inflammation.   
Interestingly, a proportion of Th17 cells have also been shown to produce the Th1 
cytokine, IFNγ which suggests interplay in subset differentiation (Annunziato et al. 
2007).  An axis between differentiation of regulatory T cells and Th17 has also been 
suggested.  The presence of TGFβ is required for differentiation of both subsets, with 
the additional necessity for IL-6 in Th17 development.  IL-6 functions to induce 
STAT3 expression, which in turn increases RORγ, inducing Th17 differentiation 
(Yang et al. 2007) while IL-2 suppresses Th17 differentiation and promotes Treg 
development (Laurence et al. 2007), and although FoxP3 can bind and antagonize 
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RORγt function, cells co-expressing these transcription factors have been observed in 
the gut (Zhou et al. 2008).  This suggests reciprocal control of subset differentiation.  
Th0 Th1
Th2
Treg
Th17
IFNγ, 
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IL-4, 
IL-5, 
IL-13
IL-17
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TGFβ
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T- bet/ 
STAT4
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Figure 1.1 Th subtype development from Th0 cells 
Th1 (red), Th2 (blue), Treg (yellow) and Th17 (green) cells can be differentiated from naïve 
CD4 T cells (Th0, purple) through the presence of cytokines (shown left hand side) and 
activation of transcription factors (shown in bold).  Differentiated T cells then express a panel 
of chemokine receptors which mediate their migration to sites of inflammation, whereby they 
produce cytokines (shown on the right hand side) in response to the invading pathogen.      
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1.0.2   Inflammation 
1.0.2.1   Acute inflammation 
In the event of breach of the body’s natural defences with a microbial pathogen, the 
innate immune system is the first point of pathogen recognition.  Invading pathogens 
are engulfed by phagocytes such as dendritic cells, monocytes, macrophages and 
neutrophils, followed by maturation of dendritic cells and their migration to draining 
lymph nodes.  This phagocytosis is stimulated by recognition of pathogen- associated 
molecular patterns (PAMPs) on the pathogen by pattern recognition receptors (PRRs) 
such as Toll-like receptors (TLR) or NOD- like receptors (NLR) expressed on 
phagocytic cells, and elicits signalling pathways which culminate in activation of 
transcription factors such as nuclear factor κB (NFκB) and activator protein- 1 (AP-
1).  This results in production of pro-inflammatory mediators such as TNFα, IL-1 and 
IL-6 which act on the endothelia of local blood vessels to increase their permeability 
and their expression of cellular adhesion molecules, which facilitates the migration of 
further immune cells such as macrophages and neutrophils to the site of infection.  
This migration is stimulated by production of chemokines by activated macrophages, 
such as IL-8.  This phase of the inflammatory response reflects the swelling, heat and 
redness associated with an infection.    
This phase of inflammation also increases the flow of lymph through the lymphatic 
system, which carries dendritic cells which have engulfed antigen to draining 
lymphoid tissues, where they will present antigen to and activate naive T cells.  Once 
the T cell has become activated, it will proliferate and clonal expansion will occur to 
produce a large number of T cells with the same antigen specificity.  Depending on 
the nature of the infection, the activated T cells will become effector T cells which, as 
described previously, can respond to chemokines to migrate to the site of infection, 
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produce cytokines and help to other immune cells to function in clearing the 
pathogen.  This is summarized in Figure 1.2.  Once the infection is resolved, the 
majority of effector T cells will undergo apoptosis, however a small population will 
be retained, termed memory T cells which can be mobilized extremely quickly should 
reinfection occur.  
 
1.0.2.2   Chronic inflammation 
Dysregulation of pro-inflammatory cytokine production, increased influx of cells into 
the site of infection, failure of regulatory T cells to suppress effector T cell responses, 
and resistance of cells to apoptosis can lead to development of chronic inflammation.  
The processes that usually serve to eliminate a pathogen become destructive to the 
host and can cause extensive damage.  Chronic inflammation is a hallmark of many 
autoimmune diseases and arises due to a failure of tolerance mechanisms that function 
to delete self reactive T and B cells.  In these cases, inflammation persists through the 
constant activation of self reactive T and B cells by antigen- presenting cells such as 
macrophages and dendritic cells, leading to production of pro-inflammatory 
cytokines, chemokines and immunoglobulins, which attracts further immune cells in 
an inflammatory loop.  This leads to tissue destruction.     
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Figure 1.2 Effector functions of T helper subsets and their role in immunity 
Once T cell activation has occurred and clonal expansion has taken place, T cells bearing 
chemokine receptors migrate to the corresponding chemokine expressed at the site of 
inflammation.  Th1 cells express bind macrophages through T cell expression of CD28 and 
macrophage CD80/ CD86, and through production of IFNγ, induce further macrophage 
activation.  The IL-12 produced by activated macrophages then feeds back to activate further 
Th1 cells.  Th2 cells activate B cells through IL-4 production and CD40L/ CD40 ligation.  
Activated B cells then produce antibodies which can neutralize the pathogen, or target an 
infected cell for opsonisation.  Th1 and Th2 subsets function to eliminate intracellular and 
extracellular pathogens respectively.  T regs function to dampen unchecked immune 
responses.  They do this in two ways; production of anti-inflammatory cytokines such as IL-
10 which directly suppress effector T cell function, or by preventing T cell priming by 
dendritic cells through direct binding to the dendritic cell through CTLA-4 expression.  Th17 
cells protect against extracellular pathogens and fungal infections by IL-17- mediated 
production of the chemokine CXCL8, which recruits neutrophils to the site of infection where 
they clear the pathogen (Pelletier et al. 2010)   
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1.0.3   Tolerance 
Tolerance to ubiquitous self-antigens is crucial to prevent the immune system 
mounting an inappropriate immune response leading to the development of 
autoimmunity, and dendritic cells play a crucial role in mediating both central 
(thymus) and peripheral (other parts of the body) tolerance (Steinman et al. 2002).  T 
and B cells that bear T or B cell receptors which recognise peptides from self- 
antigens are usually deleted or inactivated in the thymus, where an affinity threshold 
for self reactive cell deletion regulates which T cells survive and which are deleted 
(Ramsdell et al. 1990; Hogquist et al. 2005).  Studies by Matzinger et al demonstrated 
that when the thymus was depleted of APCs, self- reactive T cells were inactivated 
only after reconstitution with DCs purified from the spleen compared to unseparated 
splenocytes or thymocytes (Matzinger et al. 1989).  More recent data showed that 
tolerance to the autoantigen implicated in experimental autoimmune 
encephalomyelitis (EAE), the mouse model of multiple sclerosis, was conferred only 
after its initial injection into the thymus as compared with other routes of 
administration (Goss et al. 1994).  This data indicates the essential role that DCs play 
in central tolerance.   
Tolerance must also be mounted in the periphery; the absence of some self antigens in 
the thymus requires tolerance to be induced elsewhere.  As previously described, if T 
cells become activated by antigen presenting cells which present peptides derived 
from self antigens, co stimulation will not follow and the cell will become anergised.  
Phenotypic analysis of DCs has shown that co-stimulatory molecule expression is 
upregulated only after encounter with a pathogen and maturation (Larsen et al. 1994).  
It is therefore possible that under normal conditions that although immature DCs will 
present self-antigens to self reactive T cells which have not already been deleted 
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through central tolerance mechanisms, the absence of a co-stimulatory signal will 
render the cell unresponsive or anergised through peripheral tolerance mechanisms 
(Schwartz 1990; Steptoe et al. 1996; Steinman et al. 2003).  A further mechanism by 
which DCs induce peripheral tolerance is through the induction of regulatory cells.  
These antigen- specific regulatory T cells secrete the anti-inflammatory cytokine IL-
10 and are capable of suppressing the effector function of IFNγ- producing T cells.  
This was observed only on administration of immature DCs and was not observed in 
the presence of mature DCs, further indicating the importance of the maturation state 
of the DC in the balance of inducing tolerance in their immature state, and activating 
T cells in their mature state (Dhodapkar et al. 2001; Steinman et al. 2002; Steinman et 
al. 2003). 
 
1.0.4   Autoimmunity 
When tolerance fails, autoimmunity is at risk of development.  Autoimmunity is 
characterized by systemic and local chronic inflammation, the presence of 
autoreactive T cells and autoantibodies, and includes diseases such as multiple 
sclerosis, psoriasis and systemic lupus erythematosis (SLE).  The presence of 
autoreactive T cells indicates a defect in deletion of these cells in the thymus, and 
many gene polymorphisms associated with autoimmune diseases are related to 
lymphocyte activation and function including MHC2TA, the MHC Class II 
transactivator gene, CTLA-4, a negative regulator of lymphocyte activation, and 
PTPN22, a protein tyrosine phosphatase which functions in TCR signalling (2007; 
Thomas 2010).  Sakaguchi’s SKG mouse model of spontaneous autoimmune arthritis, 
demonstrates the role of defective tolerance.  SKG mice have a mutation in the gene 
encoding ZAP-70, a protein tyrosine kinase which functions in T cell activation after 
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TCR engagement (Sakaguchi et al. 2003).  These mice demonstrate a lymphocyte 
repertoire enriched with CD4
+
 effector T cells with high affinity for self antigen 
which have not been subjected to deletion in the thymus (Sakaguchi et al. 2003; 
Hirota et al. 2007).  These cells then become activated by APCs in the periphery and 
inflammation is mediated by the pro-inflammatory cytokines IL-6 and IL-17 (Hirota 
et al. 2007).  This model demonstrates the effect of a failure of tolerance which leads 
to autoimmunity and chronic inflammation. 
 
1.1   Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a disease characterised by chronic inflammation 
perpetuated by pro-inflammatory mediators generated through cell-cell interactions 
within the synovial tissue (Janossy et al. 1981).  This results in joint pain and 
swelling, followed by joint damage and disability.  The disease has a prevalence of 
approximately 1% of the population in the UK and results in reduced mobility and 
significant morbidity (Firestein 2003).  All diarthrodial joints can be affected; 
however the most common are the knee, the hand and the hip.  The economic burden 
is large due to the high costs of knee and hip replacement surgeries and 60 % of 
patients cannot work up to 10 years after onset of disease (Rat et al. 2004).  RA is a 
multifactorial disease, prevalent in females, and where a history of smoking, a family 
history of RA, a genetic susceptibility locus and the presence of antibodies against a 
class of post translationally modified proteins can significantly increase the possibility 
of developing the disease (Rojas-Villarraga et al. 2009).  
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The RA synovium has been well characterised.  In healthy individuals, the synovial 
membrane intima, consisting of fibroblast and macrophages, is one cell thick.  
However in RA there is an influx of immune cells which maintains inflammation.  
Cell populations include macrophages, B cells, plasma cells and memory T cells in 
addition to an increase in endothelial cells and synovial membrane intima fibroblast 
proliferation (Duke et al. 1982; Poulter et al. 1982).  This leads to a thickening of the 
small blood vessels within the joint and upregulation of various cytokines, 
chemokines, complement proteins and acute phase proteins which results in a highly 
inflammatory environment (Feldmann et al. 1996; Neumann et al. 2002).  It is these 
processes that lead to the characteristic joint pain, swelling, pannus formation and 
eventual destruction of the joint (Weyand 2000).  The differences between a normal 
and rheumatoid joint are illustrated in Figure 1.3. 
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Figure 1.3 Comparison of normal and rheumatoid joints 
As illustrated on the left, the synovial tissue of healthy joints is only one cell layer thick, and 
there is a lack of swelling or cellular infiltrate.  However, in the rheumatoid joint (right hand 
side), synovial cell proliferation is accompanied by infiltration of lymphocytes, plasma cells, 
neutrophils and macrophages.  This infiltration and proliferation of cells leads to pannus 
formation, which results in pain and swelling of the knee.  Taken from (Feldmann 2002) 
 
1.1.1   Cytokines in RA 
Cytokines play a crucial role in maintaining the pro-inflammatory environment within 
the synovium.  There is a predominance of pro-inflammatory cytokines which reflect 
the presence of cell types such as Th1, Th17 and macrophages.  Anti- cytokine 
therapies have proved extremely efficacious in RA treatment, although not all patients 
respond to these treatments.  This section will summarize the main pro-inflammatory 
cytokines implicated in RA pathogenesis and the therapies directed against them. 
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1.1.1.1   Tumour Necrosis Factor α (TNFα) 
TNFα, a pro-inflammatory cytokine, has been shown to play a critical role in the 
pathogenesis of RA, both directly and as an upstream regulator of other factors 
(Brennan et al. 1989; Neumann et al. 1996).  TNFα is a pleiotropic cytokine which 
acts as a host defence factor in inflammatory responses (Old 1985; Vassalli 1992).  
Levels of both TNFα and its receptors were found to be upregulated at both the 
protein and mRNA level in RA synovial tissue (Brennan et al. 1992; Chu et al. 1992).  
TNFα signals through two cell surface receptors- TNFRp55, and TNFRp75, which 
have a mass of 55 kDa and 75 kDa respectively (Loetscher et al. 1990; Smith et al. 
1990; Lewis et al. 1991), and which are involved in distinct processes.  TNFα is 
produced by activated macrophages within the rheumatoid synovium and is involved 
in the induction of other pro-inflammatory cytokines in the joint including IL-6 
(Hirano et al. 1988; Butler et al. 1994), IL-1 (Fontana et al. 1982), GM-CSF (Xu et al. 
1989; Haworth et al. 1991), IFNγ, IL-2 and IL-12 and chemokines (Miltenburg et al. 
1992; Hornung et al. 2000; Chabaud et al. 2001).   
TNFα production by, and effect on monocytes and macrophages has been well 
documented.  In addition to cell- cell interactions, LPS induces monocyte and 
macrophage TNFα production through the NFκB pathway, whereas ligation of 
monocyte CD45 results in TNFα production in an NFκB– independent manner 
(Foxwell et al. 1998; Hayes et al. 1999).  TNFα in turn acts on macrophages in 
synergy with CSF-1 to enhance their proliferation and prevent their apoptosis (Branch 
et al. 1989; Mangan et al. 1991).  TNFα has been shown to increase endothelial cell-
surface expression of molecules such as E-selectin (Bevilacqua et al. 1987), VCAM-1 
(Osborn et al. 1989; Carlos et al. 1990) , and ICAM-1 (Pober et al. 1986), which 
suggests it is an important mediator of cell influx into the joint.  Use of the TNFR p55 
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knockout mouse and blocking antibodies revealed this receptor to be the predominant 
receptor required for these functions (Butler et al. 1994; Neumann et al. 1996).  In 
addition, TNFα has been shown to act directly in the human joint to inhibit bone 
formation and stimulate cartilage and bone resorption (Bertolini et al. 1986; 
Saklatvala 1986).  Furthermore, blockade of TNFα (but not TNFβ or IL-6) was shown 
to inhibit the production of IL-1β in rheumatoid cell cultures, however the reverse 
was not found to occur, indicating TNFα is crucial in initiating a pro-inflammatory 
cascade (Butler et al. 1995).  Thus, TNFα plays a key role in the initiation and 
progression of inflammation and cell recruitment to the rheumatoid synovium and its 
blockade provides an important route of therapy for RA. 
 
1.1.1.2   Interleukin -6 (IL-6) 
IL-6 is a proinflammatory cytokine produced by T and B cells, monocytes, fibroblast-
like synoviocytes and endothelial cells, induced by TNFα and IL-1 stimulation and 
through cell- cell interactions (Hirano et al. 1988; Guerne et al. 1989; Beech et al. 
2006; Tran et al. 2007).  IL-6 signals through an IL-6 receptor subunit and a gp130 
homodimer (Taga et al. 1987).  IL-6 stimulates B cell maturation, T cell proliferation, 
the acute phase response in hepatocytes and increases RANKL production by 
fibroblast-like synoviocytes to stimulate osteoclastogenesis (Hirano et al. 1985; 
Andus et al. 1988; Lotz et al. 1988; Palmqvist et al. 2002).  Elevated levels of IL-6 
and its receptor have been detected in the synovial fluid, synovial tissue and 
peripheral blood of RA patients compared to healthy controls and osteoarthritis 
patients, and moreover, higher circulating levels of IL-6 could be detected prior to 
disease onset in RA patients compared to healthy controls (Hirano et al. 1988; Guerne 
et al. 1989; Wood et al. 1992; Kotake et al. 1996; Kokkonen et al. 2010).   
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Its effects in animal models of arthritis have also been documented.  Studies of 
antigen- induced arthritis revealed IL-6 -/- mice displayed reduced disease severity 
and decreased numbers of osteoclasts at bone erosion sites compared to wild type 
mice.  In addition, IL-6 -/- CD4
+
 T cells exhibited reduced antigen- dependent 
proliferation and RANKL production (Wong et al. 2006).  Furthermore IL-6 -/- SKG 
mice exhibited no joint swelling or destruction with a decrease in IgG- anti- type II 
collagen autoantibody production compared to wild type SKG mice.  
Immunohistochemical analysis of wild type arthritis joints revealed expression of IL-
6- expressing cells to be distinct from those expressing IL-1 or TNFα, and to correlate 
with the localization of CD4
+
 T cells and macrophages.  Interestingly IgM- 
Rheumatoid factor (RF) antibody titre was unaffected by IL-6 deficiency, indicating 
RF titre does not mediate joint inflammation in this model (Hata et al. 2004).  
Collagen- induced arthritis (CIA) - affected mice exhibited high levels of serum IL-6 
after immunization and which could be correlated with onset of disease.  In addition, 
early treatment of mice (at days zero or three after immunization) with a monoclonal 
antibody against IL-6R resulted in inhibition of disease development, however this 
was not efficacious at later time points (Takagi et al. 1998).  This data indicates that 
IL-6 plays an important role in disease development through its effects on T and B 
cells; leading to further pro-inflammatory and destructive mediators through cell-cell 
interactions within the joint.  Blockade of IL-6 receptor has proved efficacious in 
treatment of human RA (section 1.2.2).   
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1.1.1.3   Interleukin -17 (IL-17) 
IL-17 is a pro-inflammatory cytokine which has been more recently characterized.  It 
is produced by activated CD4
+ 
(Th17), NKT and γδ T cells which bind its 
ubiquitously expressed receptor IL-17R (Yao et al. 1995; Yao et al. 1995).  
Production of IL-17 by these cell types is induced by macrophage- derived IL-23, 
fibroblast- derived IL-15, microbial stimuli and is enhanced by T cell- fibroblast 
interactions (Infante-Duarte et al. 2000; Thiele et al. 2000; Ziolkowska et al. 2000; 
Aggarwal et al. 2003).  It has been detected in synovial fluid and the T cell rich area 
of the synovial tissue in RA but not OA patients (Chabaud et al. 1999; Kotake et al. 
1999; Chabaud et al. 2000).  In addition, IL-17 was produced by peripheral blood 
CD4
+
 T cells in patients with early RA (Colin et al. 2010).  IL-17 stimulates 
fibroblast- like synoviocytes to produce IL-6, IL-8, prostaglandin E2, G-CSF and 
MMP-1 (Fossiez et al. 1996; Kotake et al. 1999; Chabaud et al. 2000).  IL-17 also 
synergizes with TNFα in the production of IL-6, IL-1β and MMP-1 (Chabaud et al. 
1999; Chabaud et al. 2000).   
IL-17 has also been shown to mediate disease in animal models of arthritis.  Increased 
IL-17 levels in the inguinal lymph nodes of rats at the initiation phase of adjuvant- 
induced arthritis indicated a role in disease initiation (Bush et al. 2001).  Studies of 
IL-17 -/- mice revealed a lower incidence of collagen- induced arthritis compared to 
wild type animals concomitant with reduced levels of circulating IgG2a anti-collagen 
antibodies.  Proliferative responses of collagen II- specific lymph node T cells were 
also significantly abrogated compared to wild type mice, indicating IL-17 is required 
for T and B cell responses during the initiation of CIA (Nakae et al. 2003).  
Furthermore, treatment of arthritic mice with an anti- IL-17 antibody at onset of 
disease resulted in significant abrogation of cell influx into the joint, serum IL-6 
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levels and joint destruction compared to control animals.  Interestingly, anti- IL-17 
treatment 28 days after the first immunization also significantly reduced disease 
progression in affected joints, indicating the importance of IL-17 in the initiation and 
maintenance of the disease in this model (Lubberts et al. 2004).  This data suggests 
that IL-17 blockade could be a beneficial route of therapy in human RA.   
 
1.1.2   Anti- cytokine therapies 
1.1.2.1   Anti- Tumour Necrosis Factor α 
The first anti- TNFα study was conducted using cA2, a neutralizing chimeric 
monoclonal anti-TNF antibody, which showed very positive results and few 
deleterious side effects (Elliott et al. 1993).  After only one week of treatment there 
was a significant decrease in pain score, swollen joint count and duration of morning 
stiffness.  Reduced serum levels of C-reactive protein (CRP) and IL-6 were also 
observed after treatment.  Subsequent immunohistochemical analysis of synovial 
tissue of treated patients revealed a significant decrease in synovial and serum 
adhesion molecule expression concomitant with a decrease in the presence of synovial 
tissue CD3
+
 T cells and macrophages (Tak et al. 1996; Paleolog 1997; Taylor et al. 
2000).  The effects of anti- TNFα therapy are illustrated in Figure 1.4. 
There are currently five registered TNFα antagonists in the USA and EU (etanercept, 
adalimumab and infliximab), with another two more recently licensed (certolizumab 
and golimumab) (Smolen et al. 2007).  Infliximab and adalimumab are monoclonal 
antibodies that specifically bind TNFα, and etanercept is a TNF-receptor Fc fusion 
protein that binds TNF family members (Smolen et al. 2007).  Adalimumab and 
infliximab work in a similar way and are not only efficacious in RA but in other forms 
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of arthritis and autoimmune conditions.  Clinical studies have also shown that treating 
RA patients with TNFα antagonists in combination with low dose methotrexate can 
be more efficacious than either alone (Maini et al. 2004).  However, approximately 
one third of patients do not respond to anti-TNFα and these biologics are expensive.  
Therefore, it is important that alternative therapies continue to be developed. 
 
1.1.2.2   Anti- Interleukin -6 
More recently, an anti IL-6 therapy, Tocilizumab has been licensed for use in human 
RA in combination with methotrexate, indicated in patients who were inadequate or 
non-responders to anti TNFα therapy.  Initial studies of IL-6 blockade entailed 
engraftment of human tissue into SCID mice, followed by treatment of the tissue 
using a reshaping human monoclonal antibody against the IL-6 receptor (Matsuno et 
al. 1998).  Results of this study revealed a significant reduction in the volume of the 
engrafted tissue in the animals treated with anti-IL6R, concomitant with a significant 
decrease in the presence of lymphocytes, monocytes, osteoclasts and MMP- 
expressing cells compared to the control group.  Moreover, treatment of RA patients 
with a humanized anti IL-6R monoclonal antibody (tocilizumab) resulted in 
significantly decreased serum levels of the angiogenic factor VEGF in human RA 
patients compared to levels observed before treatment concomitant with a reduction in 
serum CRP levels, erythrocyte sedimentation rate (ESR), painful/ swollen joint scores 
and Disease Activity Score (DAS) (Nakahara et al. 2003; Straub et al. 2006).  Results 
from a double- blind randomized controlled clinical trial of tocilizumab revealed that 
patients receiving 8 mg/kg tocilizumab in combination with methotrexate achieved an 
American College of Rheumatology 70 % (ACR70) response rate of more than 
double of either monotherapy after only four infusions and was generally well 
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tolerated (Maini et al. 2006).  This showed that more than double the patients 
experienced a reduction in tender or swollen joint counts of 70 % and achieved 
improvement in three out of five of the following criteria; ESR/ CRP, patient 
assessment, physician assessment, pain scale and disability questionnaire result.  This 
data, and data from other trials (Nishimoto et al. 2007; Nishimoto et al. 2009) exhibits 
the efficacy of IL-6 blockade as a treatment for RA in combination with methotrexate, 
and it has now been licensed for use in Europe, the USA and Japan.  The effects of 
Tocilizumab are illustrated in Figure 1.4.   
 
1.1.2.3   Anti- Interleukin -17 
Mouse and human data implicating the role of IL-17 in RA pathogenesis has lead to 
the generation of humanized anti- IL-17 monoclonal antibodies (LY2439821 and 
AIN457) for therapeutic use.  Results from clinical trials of LY2439821 revealed an 
ACR70 response was achieved by approximately 23 % of patients compared to 5 % of 
patients who received the placebo after ten weeks of treatment.  Few serious adverse 
effects were observed (Genovese et al. 2010).  Treatment of patients with AIN457 
resulted in an ACR20 response of 47 % of patients compared to 27 % of patients 
receiving placebo; this response was observed after only four weeks and was 
sustained at sixteen weeks.  There were no serious adverse effects (Hueber et al. 
2010).  These early clinical trials, in addition to data obtained in mouse models of 
arthritis indicate that blockade of IL-17 could be efficacious in reducing inflammation 
and disease progression in RA patients, however further trials must be completed to 
confirm this.   
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Figure 1.4 A summary of current biologic therapies used in RA treatment 
The effects of anti- TNFα therapy include reduction of TNFα, IL-6 and IL-1 levels in the 
synovium, reduced angiogenesis, reduced infiltration of immune cells into the joint through 
reduction of chemokines and adhesion molecules, and decreased joint destruction.  Anti IL-6 
therapy also decreases immune cell infiltration and lowers levels of IL-6 in the synovium.  
Anti- IL-17 and anti- IL-1 also lower cytokine levels and inflammation.  Anti- CD20 therapy 
(Rituximab) functions to deplete CD20- expressing B cells, thus reducing inflammation and 
autoantibody production.  Abatacept (CTLA-4- Ig) functions to interrupt co- stimulation of T 
cells, and in doing so, reduces their capacity to be further activated by APCs, and to activate 
macrophages to produce pro-inflammatory cytokines.  Anti- RANKL decreases bone 
resorption and joint destruction.  Adapted from (Iwamoto et al. 2008) 
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1.1.3   RA: a T cell driven disease? 
The RA synovium is characterized by influx of T cells, B cells and macrophages, and 
the proliferation of resident fibroblast- like synoviocytes and macrophage- like 
synoviocytes.  Cytokines and chemokines produced by these cells as they interact 
with other cell types drive inflammation within the joint, and osteoclastogenesis 
drives bone destruction through release of collagenases.  Historically the role of T 
cells in RA was debated, based on the lack of efficacy of T cell depletion therapies in 
RA; however more recent evidence from human and mouse models of arthritis 
suggest that T cells are central to these processes. 
 
1.1.3.1   T cells in RA 
The role of macrophages in RA and their part in cytokine-driven inflammatory 
pathogenesis has been clearly defined, however the roles of T and B cells in disease 
pathogenesis is under debate.  There is ongoing evidence based research continuing in 
the field of T cells in RA.  Although RA is considered to be an autoimmune disease, 
one predominant and definitive autoantigen has not been forthcoming despite studies 
indicating T cell reactivity against components of collagen type II and cartilage, and 
citrullinated proteins (Klareskog et al. 1983; Londei et al. 1989; Hill et al. 2003; van 
Lierop et al. 2007; Ria et al. 2008).  Citrullinated proteins contain a post-translational 
modification which converts peptidyl arginine to peptidyl citrulline, and have 
emerged as the subject of the most specific predictive test for development of RA, 
with a specificity of 98 % and a sensitivity of 80 % (Lundberg et al. 2008).  
Evidence implicating RA as a T cell-driven disease includes the shared epitope 
consensus which is conserved across HLA- DR1 and DR4 (0101, 0401, 0404, and 
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1402) in 80% of Caucasian RA patients (Ollier et al. 1984; Woodrow 1986).  This 
indicates a HLA- restricted T cell response.  Moreover, more recently defined genetic 
risk factors for RA include CTLA-4 and PTPN22, involved in T cell signalling and 
regulation (Ueda et al. 2003; Plenge et al. 2005).   
It has been shown that large numbers of T cells are recruited to the synovium in 
clinical disease, and depletion of T cells from synovial tissue ex vivo resulted in 
decrease of TNFα levels (Janossy et al. 1981; Brennan et al. 1988; Cush 1988; 
Brennan et al. 2002).  Although CD8 expressing T cells have been detected in the RA 
synovial tissue, the predominant T cell subtypes express CD4 (Cush 1988).  
Immunohistochemical analysis of synovial tissue has revealed three patterns of T cell 
arrangement in RA patients; T and B cells arranged in follicles resembling germinal 
centres, aggregates of T and B cells without germinal centres, and diffuse 
arrangements of T cells (Young et al. 1984; Takemura et al. 2001; Weyand et al. 
2003).  This germinal centre- like architecture resembles that of secondary lymphoid 
organs, is dependent of antigen- activated CD4
+
 T cells and is indicative of 
lymphoneogenesis (Klimiuk et al. 1999; Takemura et al. 2001; Humby et al. 2009).  
Inflammatory cytokine transcripts including IL-1β, TNFα, lymphotoxin α and β were 
highest in tissues with germinal centres- like structures, followed by aggregates 
without germinal centres (Klimiuk et al. 1997; Takemura et al. 2001).   
T cell- depleted human synovial tissue implanted into SCID mice was characterized 
by a significant decrease in transcription of macrophage- derived TNFα, IL-1β, IL-15 
and MMP-1 and -3, which was restored on addition of recombinant of IFNγ (Klimiuk 
et al. 1999).  This study also revealed that T cell- /IFNγ- dependent macrophage 
activation was abrogated using a neutralizing antibody against GM-CSF, indicating T 
cell- macrophage interactions are required for inflammatory cytokine production in 
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the synovium (Klimiuk et al. 1999).  Moreover, activated CD4
+
 T cells were shown to 
directly stimulate osteoclast differentiation from monocytes in an in vitro co-culture 
system and furthermore, Fas mediated apoptosis of synovial CD4
+
 T cells inhibited 
osteoclastogenesis in synovial tissue (Kotake et al. 2001; Ogawa et al. 2003).   
Further evidence has emerged from mouse models of arthritis.  In Sakaguchi’s mouse 
model of spontaneous arthritis, a point mutation in the ZAP-70 gene resulted in 
development of many of the manifestations of human RA.  This indicates that 
defective TCR signalling results in a T cell dependent arthritis in SKG mice, or on 
adoptive transfer of SKG T cells to immunodeficient mice (Sakaguchi et al. 2003; 
Zhao et al. 2004).  Additional evidence of T cell involvement comes from the IL-1 
receptor antagonist (IL-1Ra) mouse model.  IL-1Ra is an endogenous IL-1 antagonist; 
however mice deficient in this molecule do not develop disease despite losing this 
natural IL-1 regulation.  However when mature T cells from IL-1Ra deficient mice 
were adoptively transferred into nude mice, an autoimmune T cell- dependent arthritis 
was induced in the recipient animals through activation of OX40 or CD40 on T cells 
by TNFα.  Development of arthritis was abrogated by anti- TNFα treatment (Horai et 
al. 2004).  This data collectively implicates T cells in development of disease, and 
suggests anti-TNFα restores T cell tolerance mechanisms through downregulation of 
molecules such as CD40 and OX40 and upregulation of co-stimulatory molecules 
such as CD28 (Murata et al. 2002; Zheng et al. 2010).   
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1.1.3.2   T helper subtypes in RA 
Extensive phenotypic analysis of synovial T cells has been performed.  The pro-
inflammatory environment in the joint suggests that the CD4
+ 
T cells are Th1/ Th17 in 
nature due to the presence of the cytokines that they produce (IFNγ, IL-17, IL-2).  
Depletion and reconstitution of synovial tissue with T cells correlated with levels of 
the Th1 cytokine, IFNγ (Takemura et al. 2001).  Although the Th2 cytokine IL-4 was 
detected in synovial tissue, higher numbers of T cells secreting Th1 cytokines IFNγ 
and IL-2 were observed (Dolhain et al. 1996).  To determine whether the Th subtypes 
were stable, memory T cell clones isolated from synovial tissue of RA patients were 
stimulated with Th1 and Th2 polarizing mediators.  Results of the study revealed that 
Th2 clones cultured in Th1 polarizing conditions switched to a Th1 phenotype as 
measured by IFNγ production; however Th1 clones could not be converted to a Th2 
phenotype (Aarvak et al. 1999).  This indicates that although Th2 cells are present 
within the joint capable of producing anti-inflammatory mediators (Steiner et al. 
1999), they are not stable and could be converted to pro-inflammatory cytokine- 
producing cells under specific conditions.   
Naturally occurring regulatory T cells (CD25
+ 
FoxP3
+
) play a role in maintaining self 
tolerance, and thus their breakdown can cause autoimmunity (Sakaguchi et al. 1995).  
High levels of regulatory T cells are found in the peripheral blood of RA patients 
(Han et al. 2008); however it is unclear why they do not function properly.  Increased 
levels of regulatory T cells were detected in the synovial fluid of RA patients 
compared to healthy controls and paired peripheral blood, and suppression assays 
demonstrated that they were capable of suppressing pro-inflammatory cytokine 
production in responder cells (van Amelsfort et al. 2004).  These regulatory T cells 
also expressed a distinct chemokine receptor profile, consistent with those associated 
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with inflammation- CXCR4, CCR5 and CCR4 (Jiao et al. 2007).  It is possible that 
although regulatory T cells can migrate to synovial tissue and are capable of 
suppression, the responder cells in the joint are refractory to suppression due to their 
state of activation (van Amelsfort et al. 2004).   
Studies by Weyand et al and others revealed that T cells found in the synovium 
express very low levels of the costimulatory molecule CD28, are expanded within the 
rheumatoid synovium and are capable of secreting IFNγ (Schmidt et al. 1996).  Loss 
of CD28 expression has been observed with age in healthy individuals, thus the low 
CD28 expression in RA indicates premature ageing of the immune system.  
Additionally, CD28 expression was normalized on treatment with anti-TNFα therapy 
(Schmidt et al. 1996; Fasth et al. 2004; Bryl et al. 2005; Zhang et al. 2005).  
Furthermore, they have shown that there is a sustained overexpression of the molecule 
CD70, ligand of CD27; a further co-stimulatory molecule which mediates T cell 
activation.  They hypothesise that this overexpression results in a decrease in the 
threshold of tolerance mechanisms that control T cell autoreactivity, and allows low 
avidity T cells to become activated (Lee et al. 2007). 
 
1.1.3.3   Cell surface phenotype of RA T cells 
Phenotypic analysis of synovial CD4
+
 T cells revealed the majority were of a memory 
phenotype, expressing CD45RO and low levels of CD45RB.  Activation markers such 
as HLA-DR and CD69 were also expressed and these cells were capable of producing 
higher levels of IFNγ than T cell expressing naive T cell marker CD45RA (Thomas et 
al. 1992; Fernandez-Gutierrez et al. 1995; Dolhain et al. 1996).  Synovial T cells also 
showed increased expression of the adhesion molecules CD29, CD49d, CD49a, 
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CD11a, CD18 and CD54 compared to matched peripheral blood T cells and T cells 
from healthy controls.  Expression of chemokine receptors CXCR3, CXCR4 and 
CCR5 by T cell clones isolated from RA synovial tissue was also observed (Cush 
1988; Cush et al. 1992; Thomas et al. 1992; Shadidi et al. 2003).  These cells 
demonstrated an increased intrinsic capacity to extravasate compared to peripheral 
blood T cells from RA and healthy controls (Cush et al. 1992; Shadidi et al. 2003).  
Although a small number of cells producing IL-2 in RA synovial samples were 
observed, expression of the IL-2 receptor, CD25 was detected only in some patients 
with more severe disease, and was minimal or undetectable in the majority of tissues 
tested (Cush 1988; Cush et al. 1992).  However other studies reported a significant 
increase in peripheral blood T cell expression of CD25 compared to other forms of 
arthritis and healthy controls, which was mainly restricted to the CD4
+
 CD45RO
-
 
subset, however expression was also detected within the CD4
+
 CD45RO
+ 
subset 
(Maurer et al. 1992). 
 
1.1.3.4   Bystander activation of T cells 
It has been shown that T cells can also be activated independently of antigen.  These 
cells are termed bystander cells and are defined as the activation of a T cell to produce 
phenotypic or functional changes through soluble or membrane bound factors binding 
receptors other than the TCR (Bangs et al. 2006).  Bystander- activated T cells have 
been demonstrated to secrete pro-inflammatory mediators and participate in the 
inflammatory response in a number of conditions including virus- induced CNS 
disease (McGavern et al. 2004), dengue infection (Suwannasaen et al. 2010), 
Hashimoto’s thyroiditis (Mori et al. 2010), and MS (Bar-Or et al. 2010).  Mediators 
such as IFNγ, IL-2, and IL-15 have been demonstrated to activate CD4+ effector 
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memory T cells in an antigen- independent manner, and in some cases, stimulating the 
conversion of central memory T cells to effector memory T cells (Geginat et al. 2001; 
Di Genova et al. 2010).   
The low expression of co-stimulatory molecules on synovial T cells and their 
hyporesponsiveness to TCR stimulation (Emery et al. 1984; Malone et al. 1984) 
indicates that cytokine stimulation of T cells may lead to their activation within the 
joint.  The first report that T cells could be activated independently of antigen through 
stimulation with IL-2, IL-6 and TNFα was in 1994; Unutmaz et al demonstrated that 
peripheral blood T cells activated in this manner could deliver a contact-dependent 
signal to B cells for antibody production (Unutmaz et al. 1994).  It was later found 
that IL-15 could mimic these effects (McInnes et al. 1997).   
 
1.1.3.4.1   Cytokine- activated T cells (Tck) 
This system was later adapted by Brennan and colleagues (Sebbag et al. 1997), who 
demonstrated that cytokine stimulation of peripheral blood T cells for eight days, 
could stimulate the secretion of proinflammatory cytokines from monocytes in a 
contact-dependent manner.  Furthermore, these cytokine-activated T cells (Tck) 
demonstrated identical effector function to T cells isolated from the RA synovium 
(Sebbag et al. 1997; Brennan et al. 2002).  The monocyte cytokine profile induced by 
RA T cells and Tck differed from monocytes activated by antigen- activated T cells 
(Ttcr); while both induced TNFα production, only Ttcr cells induced monocyte- 
derived IL-10 (Parry et al. 1997).  This observation may account for the pro-
inflammatory milieu in the joint; as inflammation persisted, T cells could be 
increasingly activated by monocyte- derived pro-inflammatory cytokines, in turn 
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activating monocytes and macrophages to produce only pro-inflammatory mediators.  
Contact- dependent Tck and monocytes interactions also resulted in production of 
chemokines including CCL2, CCL3, CCL4, CCL5, CXCL1 and CXCL10 (Beech et 
al. 2006).  Cytokines were also directly produced by Tck; significant levels of GM-
CSF (2095 pg/ml), IFNγ (534 pg/ml) and LT (358 pg/ml) were detected.  IL-17 was 
detected after addition of recombinant IL-23 to the cultures on day five of culture 
(Brennan et al. 2008).   
Further studies revealed differences in the activation of signalling molecules in Tck 
and Ttcr stimulation of monocytes; PI3K inhibitors increased monocyte TNFα 
production on stimulation by Tck and RA synovial cells whereas the opposite was 
true for Ttcr cells.  Furthermore, overexpression of IκBα in monocytes inhibited 
monocyte TNFα production induced by Tck and RA synovial cells but not that 
induced by Ttcr cells, indicating that Tck- induced monocyte TNFα is NFκB 
dependent (Brennan et al. 2002).  Additionally, p38 MAPK activation which occurs 
upstream of NFκB, was shown to be crucial for acquisition of Tck effector function; 
Tck pretreated with a p38 inhibitor induced 80 % less TNFα from monocytes than 
control Tck.  Additionally, a significant decrease in Tck- derived cytokines IFNγ, LTα 
and GM-CSF was observed in p38 inhibitor- treated Tck compared to control Tck (Li 
et al. 2011). 
 
1.3.4.1.2   Tck cell surface phenotype 
Phenotypic analysis revealed that the precursor of Tck resided within the ‘effector 
memory ‘CD4+ CD45RO+ CCR7- subset (Brennan et al. 2008).  Furthermore, 
several surface molecules were differentially up regulated after cytokine stimulation; 
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a seven-fold increase in CD25, an eight-fold with CD69, a three-fold increase in 
HLA-DR, a fifteen-fold increase in the selectin CD62L, a three-fold increase in the 
integrin CD49d and a five-fold increase in the chemokine receptor CXCR4 were 
observed with reference to resting T cells.  Of interest was the observation that 
CD49d was the only ligand expressed on Tck to positively correlate with the ability to 
induce monocyte production of TNFα (Brennan et al. 2008), which may indicate its 
importance in the effecter function of Tck.  Microarray studies also revealed further 
molecules to be up-regulated after cytokine stimulation, including the adhesion 
marker CD38 (15-fold), the chemokine receptors CCR1 (15-fold) and the 
chemoattractant receptor CRTH2 (15-fold).  Blockade of Tck cell-surface CD69 and 
CD18 resulted in a significant decrease in Tck contact- dependent monocyte- derived 
TNFα, indicating these molecules are functionally relevant in Tck effector function 
(Brennan et al. 2008).   
The phenotype of Tck was then compared to RA synovial T cells.  Expression of 
adhesion molecules CD18, CD29 and CD49d, and activation markers HLA-DR and 
CD69 were observed in similar levels on Tck and RA T cells.  CD25 expression was 
detected on both cell types but was higher on Tck.  CD62L was not expressed by RA 
T cells but was expressed on Tck.  Although effector memory T cells do not usually 
express L-selectin, soluble L-selectin was detected in Tck supernatants indicating that 
it was shed from the cell surface (Brennan et al. 2008).  Analysis of chemokine 
receptor expression revealed that CCR7 was absent from both Tck and RA T cells, 
but  CXCR3, CXCR4 and CCR5 were expressed on Tck and on RA T cells according 
to both the results from this study and other published results (Szekanecz et al. 2003; 
Brennan et al. 2008).  This data demonstrated that Tck displayed a phenotype similar 
to RA synovial T cells indicating their suitability as a surrogate model of these 
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pathogenic T cells for ex vivo and in vivo study.  A description of Tck effector 
function and phenotype is summarized in Figure 1.5.  
TNFα
Parry et al (1997) J Imm 158: 
3673
CXCL8
CXCL10
CCL3
CCL4
CXCL1
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Figure 1.5 Cytokine stimulated T cells; effector function and phenotype 
a) Freshly elutriated T cells (Resting T cells) were stimulated with TNFα, Il-6 and IL-2 for 
eight days (cytokine activated T cell/ Tck).  Contact- dependent co-culture of monocytes 
induced production of monocyte proinflammatory cytokines and chemokines.  Additionally, 
T cells isolated from synovial tissue by collagenase dissociation, when co-cultured with 
monocytes in the same manner as Tck, resulted in production of the same panel of pro-
inflammatory mediators.  This, along with other data, indicates Tck can be used as a surrogate 
model for the RA T cell (adapted from FM Brennan)   
b) The absolute expression of a panel of activation markers (CD25, CD38, CD69, CD62L), 
chemokine receptors (CCR5, CCR7, CXCR3, CXCR4) and integrins (CD29, CD18, CD49d) 
were measured on freshly elutriated T cells (Resting) and after activation of the cells with 
TNFα, IL-6 and IL-2 for eight days (Tck).  All activation markers were upregulated by more 
than 2- fold (<+), while CCR5 and CD49d were upregulated by 2- fold (+).  The expression 
of CXCR4, CD29, and CD18 was also upregulated by more than 2-fold after cytokine 
stimulation (<+), while expression of CXCR3 and CCR7 was unchanged (=).    
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1.1.4   Cell- cell Interactions in RA 
1.1.4.1   T cell- B cell interactions 
It is known that B cells play an important role in RA pathogenesis.  Activated B cells 
have been detected in synovial tissue, either in diffuse patterns, or in approximately 
20 % of patients, within germinal centre- like aggregates in the presence of follicular 
dendritic cells (Youinou et al. 1984; Humby et al. 2009).  These germinal centre 
structures have been shown to support autoreactive B cell maturation, somatic 
hypermutation and class switching (Humby et al. 2009).  The B cell- attracting 
chemokine CXCL13; synthesized by antigen- activated synovial fluid and tissue T 
cells, and B cells expressing its receptor, CXCR5 have been identified in synovial 
tissue, particularly within the germinal centre- like structures (Shi et al. 2001; 
Schmutz et al. 2005; Manzo et al. 2008).  This indicates these mediators, in addition 
to TNFα and lymphotoxin (LT), play a role in formation and maintenance of these 
aggregates (Klimiuk et al. 1997).   
Furthermore, a population of B cell- differentiated CD20
-
 CD38
+
 plasma cells which 
are capable of actively producing IgM rheumatoid factor (RF) autoantibody in the 
absence of a stimulus have been detected in the synovial tissue of seropositive 
patients (Reparon-Schuijt et al. 1998).  This IgM- RF production was enhanced when 
this population of B cells were co-cultured with RA fibroblast- like synoviocytes or in 
the presence of IL-10.  Additionally serum IgA and IgM RF titres were shown to 
correlate with severity of erosions and joint destruction (Winska Wiloch et al. 1988). 
Detection of IgG autoantibodies against cyclic citrullinated peptides (CCP) has also 
emerged as a diagnostic tool, a prognostic marker of disease severity and can be 
identified for up to nine years prior to onset of disease (Rantapaa-Dahlqvist et al. 
2003; Snir et al. 2010).  Further evidence for RA as a B- cell driven disease comes 
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from the efficacy of B cell depleting therapy (rituximab).  Rituximab is a chimeric 
monoclonal antibody against CD20- expressing B cells and results in their depletion 
from peripheral blood, concomitant with a decrease in serum levels of IgM RF and 
anti- CCP autoantibodies (De Vita et al. 2002; Cambridge et al. 2003; Edwards et al. 
2004).  Re-population of peripheral blood with naive and memory B cells and a rise in 
serum autoantibody levels after treatment correlated with disease relapse, indicating 
that B cells play a role in RA pathogenesis (Cambridge et al. 2003; Leandro et al. 
2006).   
Although B cells are known to provide help for T cell through their APC function, 
synovial T cells have also been shown to provide help for B cell activation.  
Stimulation of peripheral blood T cells obtained from healthy controls with anti- CD3 
or cytokines, or synovial T cells could activate B cells and induce immunoglobulin 
production and class switching (Thomas et al. 1992; Unutmaz et al. 1994).  
Furthermore, activated memory T cells isolated from synovial tissue, but not 
peripheral blood of RA patients or healthy controls, could stimulate B cell production 
of immunoglobulin (Thomas et al. 1992).  Additionally, although B cell depletion is 
efficacious in treatment of RA, administration of anti- CD20 also resulted in depletion 
of T cells and follicular dendritic cells, in addition to a decrease in CD4 
+
 T cell 
reactivity in a mouse model of arthritis (Takemura et al. 2001; Hamel et al. 2008; 
Thurlings et al. 2008).  This indicates a role for B cells in maintaining the structure of 
germinal centre- like aggregates and a reciprocal relationship between T and B cells; 
blockade of the T cell co-stimulation using abatacept resulted in a decrease in 
synovial B cells and a decrease in autoantibody production (Buch et al. 2009; Emery 
et al. 2010).   
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1.1.4.2   T cell- monocyte/ macrophage interactions 
Monocytes and macrophages are components of the mononuclear- phagocyte system 
capable of producing cytokines, chemokines and functioning as APC to activate T 
cells.  Under inflammatory conditions such as in RA, circulating peripheral blood 
monocytes extravasate into the joint tissue and can become activated, thus 
replenishing the population of synovial macrophages (Hogg et al. 1985; Thurlings et 
al. 2009).  Studies of bone marrow- derived monocytes and their precursors in RA 
patients revealed an increased rate of monocyte precursor formation and HLA-DR
+
 
monocytes in affected synovial tissue- adjacent bone marrow compared to OA tissue, 
which positively correlated with serum levels of IL-1 (Kotake et al. 1992; Hirohata et 
al. 1996).  Furthermore, a correlation was shown between the numbers of synovial 
macrophages present within RA synovial tissue and the degree of joint damage as 
determined by radiologic measurement (Mulherin et al. 1996).  
Monocytes and macrophages are also activated in a contact-dependent manner by T 
cells which have been pre-activated by stimuli either antigen- dependent or -
independent in nature.  This results in production of TNFα, IL-6, chemokines such as 
CCL5 and CXCL10; and if the T cells have been activated by antigen, IL-10 (Parry et 
al. 1997; Sebbag et al. 1997; Beech et al. 2006).  Given the proximity of T cells, and 
monocytes and macrophages within the synovium, it is possible that joint infiltrating 
monocytes and macrophages could be activated by T cells stimulated in an antigen- 
dependent manner, resulting in monocyte/ macrophage pro-inflammatory cytokine 
production with the capacity to activate other T cells in a contact- dependent, antigen-
independent manner (Wagner et al. 2004; Tran et al. 2005).   
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1.1.4.3   T cell- fibroblast- like synoviocyte (FLS) interactions 
Fibroblast- like synoviocytes are a layer of resident cells in the joint situated in the 
synovial intimal lining, made up of type A macrophage- like synoviocytes, and type B 
fibroblast- like synoviocytes (Elices et al. 1994).  RA is characterized by proliferation 
of these cells, predominantly fibroblast- like synoviocytes, which leads to pannus 
formation (Qu et al. 1994).  FLS are activated by macrophage- derived cytokines such 
as IL-1 and TNFα to produce pro-inflammatory mediators including IL-6, GM-CSF, 
IL-8, IL-15, MMPs, and expression of adhesion molecules and chemokines such as 
VCAM-1, fibronectin, VLA-4 and ICAM-1 and CXCL12 (Dayer et al. 1985; Guerne 
et al. 1989; Alvaro-Gracia et al. 1991; Elices et al. 1994; Harada et al. 1999; Bradfield 
et al. 2003).  Extracellular matrix protein- FLS interactions lead to FLS proliferation 
and collagenase expression through binding of β1 integrins to ligands such as laminin, 
collagen and fibronectin (Sarkissian et al. 1999).  The ability of RA FLS to invade 
and destroy cartilage was demonstrated using the SCID mouse model, where RA FLS 
displayed a significantly increased ability to invade normal cartilage compared to OA 
and normal FLS.  This was concomitant with expression of VCAM-1, matrix- 
degrading proteins, and occurred in the absence of circulating immune cells (Muller-
Ladner et al. 1996).  Moreover, results from in vitro invasion assays revealed that RA 
FLS expressing MMPs-1, -3, -9 and -10 were two to three times more invasive than 
cells which expressed low levels of these molecules (Tolboom et al. 2002).   
T cell- FLS interactions have been shown to be of importance in perpetuation of 
synovial inflammation through retention of extravasated cells and cytokine 
production.  FLS expression of ICAM-1 and VCAM-1 was induced in a T cell-contact 
dependent manner (Bombara et al. 1993).  Moreover, synovial and cytokine- 
stimulated T cell- FLS interactions resulted in selectively increased production of 
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TNFα, IL-6, IL-15, IL-17, IFNγ, MMPs and chemokines IL-8, CCL2 and CCL3 
compared to either cell type alone (Bombara et al. 1993; Cho et al. 2004; Min et al. 
2004; Tran et al. 2007; Schurigt et al. 2008).  Blockade of cell contact, neutralizing 
antibodies against co- stimulatory molecule CD40 and anti- TNFα treatment 
significantly inhibited or abrogated these effects (Bombara et al. 1993; Cho et al. 
2004; Min et al. 2004; Tran et al. 2007).  IFNγ and TNFα stimulation of FLS 
additionally upregulated expression of the T cell chemokine and adhesion molecule 
fractalkine, which enhanced the APC function of FLS in CD4
+
 CD28
-
 T cell 
activation and proliferation (Sawai et al. 2005).  In light of the reduced CD28 
expression on a subset of expanded T cells in RA patients, an alternative co-
stimulatory molecule has been implicated in T cell co-stimulation by FLS.  
Expression of the B7- H3, a member of the B7 family of co- stimulatory molecules 
has been detected at the point of contact between cytokine-activated T cells and FLS, 
and siRNA knock down of its expression significantly decreased Tck- induced FLS 
production of IFNγ, IL-2 and TNFα (Tran et al. 2008).  
In addition to reciprocal activation and cytokine production resulting from T cell- FLS 
interactions, FLS also play a role in T cell influx into the joint, their arrangement into 
germinal centre- like follicle, and their retention in the joint.  The presence of RA FLS 
in co-culture experiments with endothelial cells induced adhesion and migration of 
lymphocytes from healthy volunteers in the absence of exogenous cytokines 
(McGettrick et al. 2009; McGettrick et al. 2010).  Lymphocyte adhesion was 
significantly inhibited on IL-6, CD49d and CXCR4 blockade; however migration was 
unaffected, indicating other mechanisms play a role (McGettrick et al. 2009; 
McGettrick et al.).  Immunohistochemical analysis of synovial tissue revealed that 
CXCL12 expression by rheumatoid endothelial cells also correlated with the presence 
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of CXCR4
+ 
expressing synovial T cells in lymphoid aggregates in the areas around 
the blood vessels (Buckley et al. 2000).  Moreover RA FLS were shown to effectively 
support migration of T cells beneath them in a process termed pseudoemperipolesis; 
which was dependent on CXCL12 expression by FLS and which was not replicated 
using FLS from other sources (Bradfield et al. 2003).  Additionally, CXCL12 
production by RA FLS was further enhanced in a T cell contact- dependent manner 
and in response to stromal- derived IL-15 (Nanki et al. 2000; Kim et al. 2007).  In 
addition to FLS chemokine- induced influx and arrangement of T cells within the 
synovium, T cell- FLS interactions also resulted in inhibition of T cell apoptosis 
through maintenance of anti-apoptotic protein Bcl-XL (Salmon et al. 1997).  
Furthermore, CXCL12 was shown to inhibit activation- induced apoptosis, playing a 
role in T cell retention within the joint (Nanki et al. 2000).  The roles of FLS are 
illustrated in Figure 1.6. 
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a) Cytokine- stimulated pro-inflammatory mediator production
TNFα,  IL-1,  IFNγ
IL-6, IL-15,  GM-CSF,  CXCL8, CXCL12, CX3CL1, MMPs, 
VCAM-1, ICAM-1 
Tck
b) T cell- contact- induced pro-inflammatory mediator production
TNFα, IL-6, IL-15, IL-17, IFNγ, IL-8, CCL2, CCL3
Increased FLS expression of ICAM-1, VCAM-1, 
VLA-4
Cell Contact blockade,
anti CD40,
anti TNFα,
anti B7- H3
RA T cell
c) T cell adhesion, chemotaxis and retention in the synovial tissue
anti IL-6,
anti CD49d, 
anti CXCR4
CXCL12/ CXCR4
VLA-4/ VCAM-1
T cell
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Figure 1.6 The roles of Fibroblast- like synoviocytes (FLS) in RA 
a) FLS are activated by cytokines such as IL-1, TNFα IFNγ to produce pro-inflammatory 
mediators including IL-6, GM-CSF, CXCL8, IL-15, MMPs, and FLS expression of adhesion 
molecules and chemokines such as VCAM-1, ICAM-1, CXCL12 and CX3CL1 
b) FLS expression of ICAM-1 and VCAM-1 is induced in a T cell-contact dependent manner.  
Synovial and Tck- FLS interactions result in increased production of TNFα, IL-6, IL-15, IL-
17, IFNγ, MMPs and chemokines IL-8, CCL2 and CCL3 compared to either cell type alone. 
Blockade of cell contact, neutralizing antibodies against co- stimulatory molecule CD40, anti- 
TNFα and B7-H3 knockdown significantly inhibit/ abrogate these effects  
c) FLS also play a role in T cell influx and retention in the joint.  Co- culture of endothelial 
cells with RA FLS induces lymphocyte adhesion and migration. This adhesion is significantly 
inhibited on IL-6, CD49d and CXCR4 blockade.  Aggregates of CXCR4
+ 
expressing T cells 
in the synovium surround the blood vessels where RA- FLS- derived CXCL12 is present.  RA 
FLS also support migration of T cells beneath them (pseudoemperipolesis), dependent on 
CXCL12 expression by FLS 
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1.1.5   T cell- directed therapies 
T cell therapies have been developed and successfully licensed for use in RA.  Early 
attempts at T cell- directed therapies centred on synovial tissue CD4
+
 cell depletion, 
using monoclonal antibodies.  Initial improvements in clinical disease were 
encouraging, concomitant with a drop in T cell and monocyte numbers in the joint.  
Disease improvement was observed in approximately 50 % of patients and was 
sustained for up to five months (Herzog et al. 1989; Walker et al. 1989; Choy et al. 
1995).  However, subsequent studies using a murine lupus model suggested that there 
was a population of CD4
+
 T cells that were refractory to ablation and that these cells 
were capable of promoting autoimmunity after treatment (Connolly et al. 1992).  
Further studies in RA reported that synovial lymphocytes were more difficult to 
deplete than peripheral lymphocytes, and it was hypothesized that a large amount of 
antibody would be required to eliminate all CD4
+
 T cells with the additional risk of 
severe immunosuppression (Choy et al. 1993).  Furthermore, CD4
+
 T cell depletion 
would result in elimination of beneficial regulatory T cells in addition to the 
pathogenic effector T cells.  It was therefore suggested that CD4
+
 T cell depletion was 
not a viable strategy for treating RA   
A more successful strategy has been to block T cell co-stimulation, and this has been 
investigated using Abatacept, a fusion protein of CTLA-4 (extracellular domain) and 
the Fc portion of human IgG.  Results of CIA studies revealed that treatment of mice 
with CTLA4- Ig on the same day as immunization with collagen significantly reduced 
the incidence of disease, completely inhibited joint destruction compared to control- 
treated mice and suppressed production of anti- collagen antibodies.  Moreover, cells 
from excised lymph nodes could not be expanded in vitro and produced significantly 
less IFNγ than control mice (Webb et al. 1996).   
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Phase II clinical trials of Abatacept with methotrexate showed that after 6 months, 
abatacept patients experienced significantly increased improvements in symptoms, 
with approximately double the patients achieving ACR20, 50 and 70 compared to 
patients receiving the placebo (Kremer et al. 2005).  These responses were sustained 
for more than 1 year and showed a good safety profile (Kremer et al. 2005)  Phase III 
clinical trials showed that abatacept also slowed radiographic progression in patients 
who had previously shown an inadequate response to methotrexate (Weyand et al. 
2006).  Combination therapy of abatacept and methotrexate showed significantly 
increased radiographic improvements compared to monotherapy after two years of 
treatment (Kremer et al. 2008), indicating combination therapy is more efficacious 
than single therapy.   
Therapies directed at blocking T cell activation are efficacious, especially in light of 
the T cell- dependent B cell help which leads to anti- citrullinated protein antigens 
(ACPA).  However, due to the influx of immune cells into the joint and their roles in 
disease perpetuation, therapies directed at the pathways of chemotaxis and 
transendothelial migration of T cells may provide further targets for therapeutic 
intervention.   
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1.2   Leukocyte Extravasation 
Leukocyte extravasation is a controlled, multi-step process involving ligation of 
selectins, integrins and junctional adhesion molecules resulting in diapedesis of cells 
(Lawrence et al. 1991; Springer 1995; Alon et al. 1996; Weber et al. 1996; Weber et 
al. 1997).  Leukocytes are released from the bone marrow and enter the peripheral 
blood circulation system.  From here, leukocytes must populate the tissues and 
secondary lymphoid organs and traffic to sites of inflammation and infection.  The 
migration of leukocytes from the blood is controlled by chemoattractant gradients 
derived from specific tissues or sites of inflammation.  Release of chemoattractants is 
tightly controlled to prevent inappropriate trafficking of immune cells.  Once a 
chemoattractant gradient is encountered, leukocytes in the blood must cross the 
endothelium in order to reach tissues, in a process known as extravasation.  Leukocyte 
extravasation has been demonstrated to occur via a multistep process involving 
rolling, tethering, adhesion, diapedesis and migration (illustrated in Figure 1.9). 
 
Cell capture and rolling on activated endothelia is mediated by selectins, followed by 
activation of integrins such as VLA-4 and LFA-1 by chemokines to induce firm 
adhesion of cells to integrin ligands such as VCAM-1 and ICAM-1 on the endothelial 
cell surface.  Cross- linking of ICAM-1 and VCAM-1 on the endothelial cell surface 
also initiates RhoA and Rac1 signalling respectively, leading to increase in cytosolic 
calcium ions and reactive oxygen species, which result in weakening of endothelial 
tight junctions (Miller et al. 1995; Reilly et al. 1995; Cook-Mills 2002; Muller 2009).  
Homo- and heterophilic interactions of molecules such as JAM-A and –C and 
PECAM-1 on the endothelial cell surface and lymphocytes then allow cells to 
transmigrate through the endothelial tight junctions (Mamdouh et al. 2003).   
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The following section will concentrate on the roles of chemokines and adhesion 
molecules in T cell transendothelial migration under inflammatory conditions, and 
how this impacts rheumatoid arthritis pathogenesis. 
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1.3   Chemokines 
Chemokines are small chemoattractant proteins which direct cell migration, by 
activating integrins and creating chemoattractant gradients under both normal and 
inflammatory conditions.  Fifty two chemokines have been identified to date and can 
be broadly divided into two classes; homeostatic and inflammatory.  Homeostatic 
chemokines are expressed in organs and tissues under normal conditions, whereas 
inflammatory chemokines are induced on a variety of cells and tissues under 
inflammatory conditions.  They are further classified according to the positioning of 
one to two conserved N- terminal cysteine residues; in the CC family the cysteine 
residues are adjacent to each other, whereas there is a variable amino acid separating 
them in the CXC family.  The CX3C family consists of two cysteine residues 
separated by three variable amino acids, while the C family contains two conserved 
cysteines (Kelner et al. 1994; Bazan et al. 1997; Commins et al. 2010).  The 
chemokine C terminus is required for immobilization on the endothelial cell surface 
through binding of heparan polysaccharide components called glycosaminoglycans 
(GAGs), resulting in immobilized chemotactic gradients (Witt et al. 1994).  
Chemokines bind 7- transmembrane G- protein coupled receptors which are classified 
in the same manner as the chemokines.  Twenty chemokine receptors have been 
identified to date.  There is a high level of promiscuity between chemokine and 
chemokine receptor interactions; however chemokines which bind only one receptor 
have been identified.  Table 1.1 summarizes chemokine- receptor binding pairs and 
their cell distribution.  This is also illustrated in Figure 1.7. 
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Chemokine  
Receptor  
Chemokine Cell type expressing 
chemokine receptor 
References 
    
CCR1 CCL3 5, 7, 14 Lymphocytes, 
macrophages, DCs, 
neutrophils 
(Cheng et al. 2001; 
Kaufmann et al. 
2001) 
CCR2 CCL2, 7, 8, 12, 13 Th1 and Th2 cells, B 
cells, endothelial cells, 
monocytes  
(Frade et al. 1997; 
Weber et al. 1999; 
Shadidi et al. 2003) 
CCR3 CCL5, 7, 11, 13, 24, 
2 
Eosinophils, Th2 cells, 
mast cells 
(Sallusto et al. 
1997; Romagnani 
et al. 1999) 
CCR4 CCL2, 3, 5, 17, 22 Tregs, Th17, Th1, Th2 
cells, NK cells 
(Inngjerdingen et 
al. 2000; Andrew et 
al. 2001) 
CCR5 CCL3, 4, 5, 8 Th1 cells, macrophages, 
DCs 
(Loetscher et al. 
1998; Kaufmann et 
al. 2001) 
CCR6 CCL20 Tregs, Th17 cells, DCs (Greaves et al. 
1997; Hirota et al. 
2007) 
CCR7 CCL19, 21 Naive and central 
memory CD4
+
 T cells, 
DCs 
(Ueno et al. 2002; 
Hansson et al. 
2006; Kerdiles et 
al. 2009) 
CCR8 CCL1 Tregs, Th2 cells  (Zingoni et al. 
1998; Iellem et al. 
2001) 
CCR9 CCL25 CD4 T cells (intestine), 
B cells, CD8
+
 T cells, 
NKT cells 
(Carramolino et al. 
2001; Uehara et al. 
2002; Sen et al. 
2005) 
CCR10 CCL27 CD4
+
 T cells (skin) (Homey et al. 2000) 
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CCRL1 CCL19, 21, 25 CD4
+
 T cells, immature 
DCs 
(Gosling et al. 
2000) 
    
CXCR1 CXCL6, 8 Neutrophils, monocytes, 
CD4
+ 
T cells  
(Holmes et al. 
1991) 
CXCR2 CXCL1, 2, 3, 5, 7, 8 Neutrophils, mast cells (Nilsson et al. 
1999; Rose et al. 
2004) 
CXCR3 CXCL 4, 9, 10, 11 Th1 cells, CD8
+
 T cells,  (Qin et al. 1998; 
Kobayashi et al. 
2006; Mueller et al. 
2008) 
CXCR4 CXCL12 CD4
+
 T cells (naive, 
memory), B cells, 
monocytes, 
haematopoietic stem 
cells 
(Ma et al. 1999; 
Jourdan et al. 2000; 
Blades et al. 2002; 
Miller et al. 2008) 
CXCR5 CXCL13 B cells, CD4
+
 T cells 
(memory) 
(Legler et al. 1998; 
MacLeod et al. 
2011) 
CXCR6 CXCL16 Th1 cells (Latta et al. 2007) 
CXCR7 CXCL11, 12 CD4
+
 T cells, B cells, 
DCs 
(Balabanian et al. 
2005; Infantino et 
al. 2006) 
CX3CR1 CX3CL1 CD4
+
 T cells, DCs, NK 
cells, monocytes, CD8
+
 
T cells 
(Foussat et al. 
2000; Umehara et 
al. 2001; Guo et al. 
2003) 
XCR1 XCL1, 2 CD4
+
 T cells, CD8
+
 T 
cells, neutrophils 
(Cairns et al. 2001) 
 
Table 1.1 Chemokine receptors, their ligands and cell distribution of receptors 
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1.3.1   Chemokine receptor- ligand signalling 
Chemokine- receptor interaction activates a number of pathways which lead to cell 
polarization, activation of integrins, cytoskeletal rearrangements and cell migration 
during an inflammatory response.  Different inflammatory chemokines are induced on 
endothelial cells, immune cells and in tissues based on the type of response elicited.  
During a Th1 immune response, IFNγ induces CXCL9, -10 and -11, whereas during 
Th2 responses, IL-4 and IL-13 induce expression of CCL11, CCL2 and CCL3 and 
moreover, these signals are antagonistic to each other (Loetscher et al. 2001; Moser et 
al. 2004).  These chemokines attract activated immune cells expressing the 
corresponding chemokine receptors by forming gradients, either soluble or 
immobilized on the endothelium and inflamed tissue, which are sensed by the cells.  
Directional cell migration over a soluble chemotactic gradient is termed chemotaxis, 
or an immobilized gradient is termed haptotaxis, while non-directional migration in 
response to a chemoattractant is termed chemokinesis (McCutcheon 1946; Witt et al. 
1994).  The recruited cells in turn can play a role in further cytokine and chemokine 
production and additional cell recruitment to the inflammatory site.   
 
1.3.1.1   G protein coupled receptors 
Chemokine receptors are seven transmembrane G protein- coupled receptors (GPCR).  
GPCR are a superfamily of receptors that link extracellular signals to intracellular 
pathways through activation of heterotrimeric G proteins, many of which have been 
successfully targeted by drugs for therapeutic intervention (Pierce et al. 2002).   
After chemokine binding, the chemokine receptor undergoes a conformational change 
that promotes exchange of the Gα subunit-associated GDP to GTP by a guanine 
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exchange factor.  This results in separation of the Gα subunit from the Gβγ subunits.  
Both subunits are then free to interact with signalling proteins to activate the 
downstream pathways which result in integrin activation, cytoskeletal rearrangements 
and cell migration.     
 
1.3.1.2   G protein α subunits  
Gα subunits can be classed according to their function.  The Gαi subunit regulates 
chemotactic gradient sensing and migration at the leading edge of the cell through the 
small GTPase Rac1 and can be inhibited by pertussis toxin (Goldman et al. 1985; 
Shefcyk et al. 1985; Viola et al. 2006).  The Gα12-13 subunit regulates migration at the 
rear end of the cell through the small GTPase Rho (Xu et al. 2003).  This creates cell 
polarity in migrating cells.  Gα subunits have also been shown to bind and activate Src 
family kinases and MAP kinases, including ERK 1/2 (Sotsios et al. 1999; Ma et al. 
2000). 
 
1.3.1.3   G protein βγ subunits  
The major effectors of Gβγ subunits are phospholipase C β 2 and 3 (PLCβ) and 
Phosphatidylinositol kinase 3 γ (PI3Kγ).  The importance of PI3K in T cell 
chemotaxis was demonstrated by early studies of CCL5- induced T cell chemotaxis, 
where treatment of the cells with PI3K kinase inhibitors Wortmannin and LY294002 
inhibited cell polarization and migration in addition to PI3K activity (Turner et al. 
1995). This effect was later confirmed by studies of CXCL12- induced T cell 
chemotaxis (Sotsios et al. 1999).  PI3Kγ is an enzyme which regulates its activities by 
phosphorylation of phosphoinositide lipids to form 3- phosphoinoside lipids 
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(Vanhaesebroeck et al. 2001).  These lipids include PtdIns (3) P, which is 
constitutively produced independent of cell stimulus, and PtdIns (3, 4) P2 and PtdIns 
(3,4,5) P3 which are present only in activated cells (Curnock et al. 2002).  Their rapid 
accumulation in peripheral blood T cells has been detected on stimulation with 
CXCL12 (Sotsios et al. 1999).  These lipids bind plekstrin homology (PH) domain- 
containing effector proteins (Lemmon et al. 2000).  PI3K subunits control cell 
migration at the level of tissue tropism through PKB activation and FOXO 
inactivation, and through regulation of the small GTPases Rac1 and RhoA, leading to 
cytoskeletal rearrangements which results in cell migration.  
 
1.3.2   Chemokine signalling termination  
Once cells have extravasated into the inflammatory milieu, polarized cells continue to 
sense the chemokine gradient which they follow to its source, at which time 
desensitization occurs.  Desensitization can be homologous or heterologous in nature.  
Homologous desensitization occurs when G- protein coupled receptor kinases (GRKs) 
phosphorylate ligand- bound chemokine receptors, leading to receptor internalization.  
Heterologous desensitization occurs when a non G-protein coupled receptor kinase 
phosphorylates ligand free chemokine receptors which leads to the inability of the 
chemokine to bind the receptor (Commins et al. 2010).  This is an important negative 
regulatory step in chemokine signalling as the migrating cells will express more than 
one chemokine receptor and encounter more than one chemokine as it migrates 
through the inflamed tissue.   
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1.3.2.1   Homologous desensitization 
Homologous desensitization is performed through the actions of GRKs; GRK 2, 3, 5 
and 6 are ubiquitously expressed and modulate desensitization of chemokine receptors 
such as CCR5, CXCR2 and CXCR4 (Penela et al. 2009).  GRKs phosphorylate 
residues on the chemokine receptor, which allows recruitment and high affinity 
binding of β- arrestin 1 and 2 to the phosphorylated receptor.  β- arrestins act as 
scaffolds for recruitment of c-Src leading to activation of the ERK/ MAPK pathway, 
and interact with elements of components of  clathrin- coated- pit machinery 
(Goodman et al. 1996; Luttrell et al. 1999).  This terminates ligand binding and 
signalling through steric hindrance, and mediates internalization and either 
degradation or recycling of the receptor through clathrin- coated pits (Ferguson et al. 
1996; Pierce et al. 2001).  Surprisingly, although T cells from β- arrestin 2- deficient 
mice demonstrated increased G protein activation compared to cells from wild type 
mice, reduced chemotaxis and transendothelial migration to CXCL12 was observed in 
T cells from the knock out animals.  This could indicate that although β- arrestins 
mediate chemokine receptor signalling termination, they mediate positive regulation 
of T cell migration (Fong et al. 2002).  Additionally, GRK 2 and 3 act as GTPase- 
activating proteins (GAPs) to convert Gα- GTP to GDP, thus recoupling the G protein 
heterotrimer and mediating cessation of signalling (Kehrl 1998).   
 
1.3.2.2   Heterologous desensitization 
Heterologous desensitization of chemokine receptors can occur within ECM in the 
presence of more than one chemokine.  A study by Hecht et al demonstrated that 
chemotaxis of T cells exposed to combinations of CXCL12, CCL4 or CCL5 was 
significantly reduced compared to either chemokine alone.  The authors found that 
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this was not mediated through receptor internalization but through reduction of Ca
2+
 
mobilization and ERK 1/2 phosphorylation (Hecht et al. 2003).  As stated above, 
heterologous activation of PKC also acts as a negative feedback mechanism by 
mediating desensitization in PMA treated monocytes and T cells (Signoret et al. 1997; 
Fine et al. 2001).  This desensitization may be important in inflammatory conditions 
where more than one chemokine is synthesized to allow cells to be retained in the 
tissue.   
 
1.3.3   Chemokines in Rheumatoid Arthritis 
As RA is characterized by an infiltration of immune cells into the joint, it is thought 
that chemokines may be involved in the disease pathogenesis through recruitment and 
retention of monocytes and T cells into the joint, including mediating cell-cell 
interactions within the joint (Iwamoto et al. 2008; Miossec 2008).  Chemokines 
detected in the synovial tissue, fluid and peripheral blood of RA patients are both 
homeostatic and inflammatory in nature, and are predominantly Th1-type 
chemokines; however Th2-type chemokines have also been detected.  The majority of 
these chemokines recruit monocytes and T cells (Shadidi et al. 2003; Beech et al. 
2006).  A summary of all chemokines, with chemokine receptors and ligands 
implicated in RA pathogenesis is illustrated in Figure 1.7. 
 
1.3.3.1   CXCR4/ CXCL12 
SDF-1/ CXCL12 is a chemokine produced by T cells, B cells, monocytes, endothelial 
cells and fibroblasts which engages in both homeostatic and inflammatory functions 
through ligation of its receptor CXCR4 (Forster et al. 1998; Santiago et al. 2006; 
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Santiago et al. 2011).  Its role in homeostatic regulation is demonstrated by the 
embryonic lethality of CXCL12 knockout mice after 15-18 days; in addition, early 
embryos show profound defects in large vessel formation and cardiac and brain 
development (Nagasawa et al. 1996; Tachibana et al. 1998).  CXCL12 also mediates 
aggregation of T cells in secondary lymphoid organs under normal conditions by 
organisation of lymphoid follicles and is a chemoattractant for stem cells, stimulating 
their migration to the bone marrow (Aiuti et al. 1997; Armengol et al. 2003).  
CXCL12 also plays a role in inflammatory conditions by inducing cell polarization, 
migration of T and B cells bearing CXCR4, and activation of integrins through its 
immobilization on the endothelium (Bleul et al. 1996; Santiago et al. 2006).  This 
results in transendothelial migration of CXCR4 positive cells into inflamed tissues.   
CXCL12 has been detected in the RA synovium, and is especially of interest as it 
predominantly chemoattracts CD4+ memory T cells, the main T cell subset 
implicated in pathogenesis (Nanki et al. 2000).  It has been shown to mediate influx of 
CD4
+
 T cells into the rheumatoid joint, direct their accumulation into aggregates 
within the synovial tissue, mediate cell-cell interactions with FLS and inhibit 
activation-induced apoptosis of T cells (Nanki et al. 2000; Bradfield et al. 2003; 
Zhang et al. 2005).  This data suggests it could play a role in maintaining T cell 
numbers in the synovium.  CXCL12 production by cultured RA FLS was augmented 
on stimulation by IL-17 and co-culture with CD4
+
 T cells, while CXCR4 expression 
on CD4
+
 memory T cells was increased and maintained by factors present in synovial 
fluid, including TGF-β (Buckley et al. 2000; Burman et al. 2005; Kim et al. 2007).  
CXCL12 stimulation of chondrocytes and RA FLS resulted in upregulation 
collagenase and gelatinase MMP production, and proliferation of FLS (Garcia-Vicuna 
et al. 2004; Kanbe et al. 2004).  Serum CXCL12 levels in RA patients were 
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significantly reduced after synovectomy (Kanbe et al. 2004),  moreover, conditional 
CXCR4 knockout mice developed a decreased incidence of CIA concomitant with 
reduced CXCL12 induced T cell chemotaxis (Chung et al. 2010).  This data indicates 
that CXCL12 plays a role not only in stimulating migration of immune cells into the 
joint, but also mediating joint destruction. 
 
1.3.3.2   CCR5/ CCL5 
RANTES (Regulated on activation, normal T cell expressed and secreted) /CCL5 is 
an inflammatory chemokine which predominantly attracts CD4
+
 memory T cells, 
monocytes, NK cells and DCs through ligation of its receptors CCR1, CCR3, CCR4 
and CCR5.  CCL5 is expressed by a variety of cells and tissues including 
macrophages, fibroblasts and endothelial cells (Schall 1991; Appay et al. 2001; Levy 
2009).   
CCL5 could be detected extensively in the synovial lining, sublining layers and 
synovial fluid of RA joints (Robinson et al. 1995; Shadidi et al. 2003), and its 
expression in cultured RA FLS increased in a time and dose- dependent manner on 
stimulation with TNFα and IL-1β (Rathanaswami et al. 1993).  Furthermore, synovial 
T cells that infiltrate the synovium in RA expressed two of its ligands, CCL3 and 
CCL5, and T cell- monocyte interactions mediated further upregulation of CCL5 
production (Shadidi et al. 2003; Szekanecz et al. 2003; Beech et al. 2006).  CCL5 was 
also reported to stimulate FLS to produce inflammatory mediators including IL-6, IL-
8 and MMPs (Nanki et al. 2001; Garcia-Vicuna et al. 2004).   
CIA studies revealed increased CCL5 mRNA detection in both affected and 
unaffected paws of immunized mice compared to control mice (Thornton et al. 1999).  
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Moreover, treatment of adjuvant- arthritic Lewis rats with a polyclonal antibody 
against CCL5 resulted in decreased joint destruction and symptoms of disease, and 
treatment of mice with CIA with a CCR5 antagonist markedly reduced incidence and 
severity of disease compared to control animals (Barnes et al. 1998; Yang et al. 2002).   
It has previously been shown that TNFα results in a decrease of CCR5 expression on 
T cells through its induction of CCL5, and that decreased levels of CCR1- and CCR5- 
expressing monocytes could be detected in RA patients compared to healthy controls 
(Hornung et al. 2000; Haringman et al. 2006).  Treatment with infliximab resulted in 
an increase in circulating CCR3 and CCR5- expressing T cells and monocytes in 
patients compared to levels detected prior to treatment (Nissinen et al. 2004), 
indicating one effect of TNFα blockade may be reduction of chemokine production.  
It has also been hypothesized that an increase in circulating lymphocytes after TNFα 
blockade may be a result of diminished migration to the joints due to reduced 
production of inflammatory mediators (Paleolog et al. 1996). 
 
1.3.3.3   CXCR3/ CXCL10 
Interferon-γ-inducible protein-10 (IP-10) /CXCL10 is an inflammatory chemokine 
induced by IFNγ on endothelial cells, FLS and monocytes (Luster et al. 1987) and 
mediates chemotaxis of Th1, NK cells and monocytes bearing its receptor CXCR3 
(Qin et al. 1998; Byrne et al. 2009).  CXCL10 was shown to stimulate 
transendothelial migration of effector CD4
+
 memory T cells under shear stress, which 
was inhibited by the TCR stop signal (Manes et al. 2006; Manes et al. 2007; Cernuda-
Morollon et al. 2010).  This indicates CXCL10 mediation of T cell migration is 
dependent on their activation state.  CXCL10 has been detected in serum, synovial 
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fluid and synovial tissue in RA patient; in healthy controls, the gradient of CXCL10 is 
from the synovium to the blood however in RA patients the gradient is present from 
the blood to the synovium (Patel et al. 2001; Hanaoka et al. 2003; Iwamoto et al. 
2008).  Moreover, CXCR3
+
 T cells have been detected in the synovial tissue (Qin et 
al. 1998; Patel et al. 2001; Norii et al. 2006).  Both monocyte- FLS, and monocyte- T 
cell interactions resulted in CXCL10 production, indicating cell- cell interactions 
within the synovial tissue perpetuates CXCL10 release (Hanaoka et al. 2003; Beech et 
al. 2006).  In addition, CXCL10 was demonstrated to induce MMP release from FLS, 
FLS proliferation, osteoclast precursor migration and enhancement of osteoclast 
differentiation; thus playing a role in joint destruction (Garcia-Vicuna et al. 2004; 
Kwak et al. 2008).  Treatment with etanercept reduced serum levels of CXCL10.  
Antibodies against CXCL10 significantly impaired CXCR3- mediated cell 
chemotaxis; however they demonstrated varied efficacy in affecting disease 
development in the CIA disease model (Kwak et al. 2008; Byrne et al. 2009; Ichikawa 
et al. 2010).     
 
1.3.3.4   CCR6/ CCL20 
Macrophage inflammatory protein 3α (MIP3α)/ CCL20 is an inflammatory 
chemokine which attracts Th17 cells, naive B cells and immature dendritic cells 
through their expression of its receptor CCR6 (Greaves et al. 1997; Liao et al. 1999; 
Nanki et al. 2009).  It is induced by IL-1, TNFα and IL-17 stimulation and expression 
is reduced in the presence of IL-4 (Chabaud et al. 2001).  CCL20 is expressed by a 
broad range of cells and tissues including endothelial cells, activated T cells, 
monocytes, macrophages and synovial fibroblasts (Schutyser et al. 2003).  Increased 
CCL20 was detected in RA synovial fluid and synovial tissue compared to OA and 
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healthy controls and was inhibited up to 95 % on use of blocking antibodies against 
IL-1, TNFα and IL-17 receptors (Chabaud et al. 2001; Matsui et al. 2001).  CCR6+ 
cells were present within the synovial tissue and it was shown that treatment of Th17 
cells with a neutralizing antibody against CCR6 had a protective effect in a mouse 
model of arthritis (Matsui et al. 2001; Hirota et al. 2007).  Furthermore, stimulation of 
FLS with both CCL20 and IL-17 dose-dependently induced IL-6 production, 
indicating these pro-inflammatory mediators play a role in perpetuation of the chronic 
inflammation in RA (Tanida et al. 2009).  Moreover treatment of RA patients with 
etanercept resulted in a decrease in serum CCL20 but not IL-17 concentrations, 
potentially inhibiting this proinflammatory cascade (Kageyama et al. 2007).  
The data detailed provides evidence that chemokines not only mediate influx of 
immune cells into the joint, but also participate in joint destruction.  The fact that 
TNFα blockade decreases chemokine production reflects its efficacy in inhibiting 
joint damage.    
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Figure 1.7 Chemokine receptors and chemokines implicated in RA pathogenesis 
Chemokines and their receptors can be divided into CC (pink), CXC (yellow), XC (purple) 
and CX3CR1 (green) subfamilies, with many of these receptor/ ligand pairs demonstrating 
promiscuity.  Shown above is an illustration of all the chemokine receptors which have been 
identified, with the chemokines that they bind.  Highlighted in bold are the chemokine 
receptors and ligands which have been implicated in RA pathogenesis. Adapted from FM 
Brennan 
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1.3.4   Chemokine- directed therapies 
Blockade of chemokine receptor and ligand binding is an attractive route of therapy in 
human diseases, including RA.  Although the fact that multiple chemokines can bind 
chemokine receptors (with some exceptions) suggests redundancy of function, 
ligation of receptors often result in different functions under specific circumstances 
with different affinities and in distinct tissues and organs in vivo  (Schall et al. 2011).  
Additionally, it has been shown that small molecule inhibitors which have activity at 
more than one chemokine receptor, although showing receptor homology at most 
helical residues, showed different mechanisms of action between receptors (Wise et 
al. 2007).  This data indicates that targeting chemokines and their receptors can yield 
more specificity of inhibition than the receptor- ligand promiscuity would suggest.  
While data from animal models have suggested that blockade of a number of 
chemokine- receptor interactions could be efficacious, results from studies in human 
disease have not yet produced beneficial outcomes, perhaps due to issues associated 
with optimal dosing, time of intervention, oral absorption, rapid elimination, species 
differences and suitability of targets (Pease et al. 2005; Schall et al. 2011). 
 
1.3.4.1   Chemokine- directed therapies in animal arthritis models 
Many chemokines and chemokine receptors have been targeted in animal models of 
arthritis, using both the CIA and antigen- induced arthritis (AIA) models to determine 
treatment efficacy (reviewed in (Szekanecz et al. 2003)).   
Blockade of CXCL1 and CXCL2 in CIA- affected mice resulted in delayed onset and 
severity of CIA (Kasama et al. 1995).  Treatment of CIA- affected mice with an anti- 
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CXCL16 antibody decreased infiltration of mononuclear cells, joint synovitis and 
bone destruction compared to control mice (Nanki et al. 2005).   
It has been hypothesized that dual blockade of chemokines or receptors could be more 
efficacious in reducing disease than monotherapy.  It has been reported that dual 
blockade of CCL2 and CXCL1 was more beneficial than CCL2 alone reducing 
disease severity and further cell infiltration in AIA- affected mice (Gong et al. 2004).  
Moreover, in a rabbit endotoxin- induced arthritis model, dual blockade of CXCL8 
and CXCL1 was more efficacious in reducing severity of knee arthritis than either 
treatment alone; co- blockade resulted in a significant decrease in both initial (2 
hours) and late (9 hours) leukocyte accumulation in the knee compared to 
monotherapy (Matsukawa et al. 1999).  Treatment of CIA- affected mice with Met-
RANTES, an N- terminally modified form of CCL5 and a potent inhibitor and 
selective of both Th1- type chemokine receptors CCR1 and CCR5 reduced both onset 
and severity of disease compared to control mice (Plater-Zyberk et al. 1997).  In 
addition, treatment of AIA- affected rats with Met-RANTES after immunization 
decreased recruitment of neutrophils and macrophages to the synovium, reduced 
levels of TNFα, IL-1 and RANKL and inhibited swelling and bone erosion compared 
to control- treated rats (Shahrara et al. 2005).  This indicates dual therapy in some 
disease models could increase the beneficial effects seen with monotherapies.  
Blockade of chemokine receptors has also been performed.  Use of the small molecule 
inhibitor of CXCR4, AMD3100 in treatment of CIA in IFNγ deficient mice resulted 
in significant inhibition of cell infiltration and synovial cell proliferation, and reduced 
disease severity.  Additionally, although AMD3100 treatment did not affect anti- 
collagen antibody production, it did reduce delayed- type hypersensitivity (DTH) 
reactivity in mice which had been treated with AMD3100 and rechallenged with 
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collagen injection into the hind limbs.  Interestingly, there was also a reduced DTH 
reactivity when mice had been treated with AMD3100 for only two days prior to re-
challenge, indicating a role for T cells in this model (Matthys et al. 2001).  However 
later studies by the same authors using wild type mice revealed that, while AMD3100 
treatment after onset of disease did reduce severity of disease, it did not affect DTH 
reactivity to collagen rechallenge or the production of anti- collagen antibodies.  
However, induction of air pouches into CIA- affected, AMD3100- treated mice, and 
stimulation of the air pouch with CXCL12 or control buffer revealed that in the CIA 
and AMD3100- treated mice, there were significantly fewer cells present in the 
CXCL12- stimulated air pouch exudates than the CXCL12- stimulated pouches of 
CIA and PBS- treated animals.  This indicates that while AMD3100 does not interfere 
with cellular or humoral mediated immunity, it does inhibit the CXCL12- mediated 
cell infiltration into sites of inflammation in this model (De Klerck et al. 2005).  
Although CXCR4 only binds CXCL12, more recently the chemokine receptor 
CXCR7 has been shown to also bind CXCL12 and may play a role in RA 
pathogenesis through enhancing synovial angiogenesis in CIA- affected mice 
(Watanabe et al. 2010).   
 
1.3.4.2   Chemokine- directed therapies in rheumatoid arthritis 
Many chemokine and receptor antagonists have been developed over the last number 
of years; however few have got past early clinical trials due to poor efficacy.  A phase 
IIb clinical trial of an oral CCR1 antagonist (CP481, 715) was performed with 16 RA 
patients to evaluate the effect of CCR1 blockade on infiltration of monocytes and 
macrophages into the joint.  A reduction of 90 % of monocyte chemotactic activity in 
the synovial fluid was observed, in addition to a decrease in synovial macrophage 
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numbers and a trend toward clinical improvement in treated patients (Haringman et al. 
2003).  However a larger Phase II trial failed to show efficacy after six weeks of 
treatment (Pease et al. 2005). This drug was further tested in patients with allergic 
contact dermatitis.  In this trial, not all symptoms were ameliorated, indicating that 
blockade of one chemokine only is not sufficient for clinical benefit in this disease 
(Borregaard et al. 2008).  
Clinical trials of two monoclonal antibodies against the chemokine receptor CCR2 
(MLN1202) and the chemokine CCL2 (ABN912) were performed in an effort to 
reduce monocyte infiltration into the synovium.  Both trials reported no clinical 
benefit of these antibodies, and moreover in the case of ABN912, there was an 
increase in CRP levels and increased numbers of synovial macrophages (Haringman 
et al. 2006; Vergunst et al. 2008; Voulgari 2008). 
Two small molecule CCR5 antagonists, SCH351125 and AZD5672 were also 
recently trialled in RA, where parameters such as a response rate of ACR20 and 
synovial biopsy analysis were examnined.  However no differences in these 
parameters were observed in either study between patients receiving the drugs and the 
placebos (Gerlag et al. 2010; van Kuijk et al. 2010). 
Although chemokine and receptor- directed therapies have been slow to be licenced, 
Figure 1.8 illustrates the potential of targeting chemokine receptors in distinct 
microenvironments. The therapies detailed above are summarized in Table 1.2. 
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1.3.4.3   Chemokine- directed therapies in other human diseases 
CCR5 is an attractive target for therapeutic intervention in both inflammatory diseases 
and HIV.  Many CCR5 anatagonists have been developed, however only one 
(marviroc) has been licenced for use in HIV treatment; this is a non competitive 
inhibitor which prevents a component of the virus binding to CD4 T cells.  In all 
patients treated a reduction in viral load was observed which, after cessation of 
treatment, did not rebound for a mean of 10- 15 days (Fatkenheuer et al. 2005).   
Blockade of CXCR4 has proved efficacious in treating a number of cancers and is 
specifically licensed in treatment of lymphoma and myeloma.  Treatment of patients 
with a small molecule antagonist of CXCR4 (AMD3100, also known as plerixafor) 
increases the mobilization of CD34
+
 stem cells from the bone marrow into the 
peripheral blood, which enables higher cell numbers to be collected prior to stem cell 
autotransplantation (Lemery et al. 2011).  CXCR4 blockade has also been implicated 
in treatment of HIV, as it is a co-receptor for virus entry to CD4
+
 T cells.  The data 
from RA as detailed above suggests that CXCR4 blockade may also be efficacious in 
treatment of RA.   
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Species Target (Drug/ 
antibody name) 
Disease/ 
Model 
Outcome Reference 
Mouse CXCL1/ CXCL2 CIA Decreased disease 
onset and severity 
compared to control 
(Kasama et al. 
1995) 
Mouse CXCL16 CIA Decreased 
mononuclear 
infiltration and bone 
destruction compared 
to control 
(Nanki et al. 
2005) 
Mouse CCL2 and 
CXCL1 
AIA 
 
Decreased cell 
infiltration compared 
to monotherapy 
(Gong et al. 
2004) 
Rabbit CXCL8 and 
CXCL1 
Endotxin- 
induced 
arthritis 
Decreased severity of 
knee arthritis, 
leukocyte 
accumulation 
compared to 
monotherapy 
(Matsukawa et 
al. 1999) 
Mouse CCR5 and 
CCR1 (Met 
RANTES) 
CIA Decreased onset and 
severity of disease 
compared to control 
(Plater-Zyberk 
et al. 1997) 
Rat CCR5 and 
CCR1 (Met 
RANTES) 
AIA Decreased neutrophil 
and macrophage 
infiltration and 
synovial TNFα, IL-1 
and RANKL levels 
compared to control 
(Shahrara et al. 
2005) 
Mouse CXCR4 
(AMD3100) 
CIA Decreased cell 
infiltration, synovial 
cell proliferation, 
disease severity 
compared to control 
(Matthys et al. 
2001; De 
Klerck et al. 
2005) 
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Human CCR1 
(CP481,715) 
RA Decreased synovial 
fluid monocyte 
chemotactic activity 
and macrophage 
accumulation 
compared to controls 
in early study 
(Haringman et 
al. 2003) 
Human CCR2 
(MLN1202 
RA No clinical benefit 
compared to placebo 
(Vergunst et al. 
2008) 
Human CCL2 
(ABN912) 
RA No clinical benefit 
compared to placebo 
(Haringman et 
al. 2006) 
Human CCR5 
(SCH351125) 
RA No clinical benefit 
compared to placebo 
(van Kuijk et 
al. 2010) 
Human CCR5 
(AZD5672) 
RA No clinical benefit 
compared to placebo 
(Gerlag et al. 
2010) 
 
Table 1.2 Chemokine and chemokine receptor- directed therapies in disease models of 
arthritis and in RA 
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Figure 1.8 Potential of chemokine receptor targets in organs and tissues 
Shown above is a ‘tube map’ of tissues and organs where chemokine receptors could be 
therapeutically targeted in different diseases.  The closed circles represent receptors of which 
their function in disease is not completely characterized, where open circles denote 
chemokine receptors that, based on pre clinical and clinical data, are potentially more 
attractive therapeutic targets. Taken from (Schall et al. 2011) 
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1.4   Selectins 
Initial cell adhesion and rolling to the endothelium is mediated by the selectin family 
(Alon et al. 1997). Selectins are a family of receptors expressed on endothelial cells, 
platelets and circulating leukocytes which mediate cell tethering and rolling in the 
direction of shear flow exerted by the blood stream (Lawrence et al. 1991).  E-selectin 
expression on vascular endothelial cells is induced by proinflammatory mediators 
including TNFα, IL-1 and LPS, and recognizes carbohydrate structures related to 
sialyl Lewis
x 
moieties (sialylated and fucosylated carbohydrate structures) on 
glycoprotein counter receptors such as CD44 and ESL-1 (Katayama et al. 2005).      
P-selectin is expressed in Weibel- Palade bodies of endothelial cells and mobilized to 
the plasma membrane on stimulation with proinflammatory mediators such as 
thrombin or histamine (Springer 1994).  CD62P/ P-selectin and CD62E/ E-selectin 
mediate tethering of circulating leukocytes by binding their ligands, PSGL-1, CD44 
and ESL-1 (Hidalgo et al. 2007).   
CD62L/ L-selectin is expressed on the majority of circulating leukocytes and binds 
glycoprotein ligands on endothelial cells such as cell surface- bound CD34 and 
secreted glycosylation- dependent cell adhesion molecule-1 (GlyCAM-1).  CD62L 
also contains an enzymatic cleavage site, allowing shedding which mediates efficient 
rolling of tethered cells (Walcheck et al. 1996; Grailer et al. 2009).  Under normal 
conditions, CD62L plays an important role in mediating lymphocyte recirculation 
between blood and lymph through its ligand expression on high endothelial venules 
(HEVs) of the peripheral lymph nodes.  This was demonstrated through studies of 
CD62L 
-/-
 mice, where CD62L 
-/-
 lymphocytes did not bind to HEV and demonstrated 
severe defects in migration to peripheral lymph nodes (Arbones et al. 1994).  Ligation 
of CD62L preceding transmigration also results in activation of β1 and β2 integrins to 
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mediate firm adhesion of rolling leukocytes (Giblin et al. 1997; Steeber et al. 1997).  
The distinct roles of selectins and integrins in adhesion were demonstrated by 
Lawrence and Springer in 1991 (Lawrence et al. 1991).  Neutrophil rolling under 
shear stress occurred on endothelia containing lipid bilayers rich in P- selectin, and P-
selectin and ICAM-1 but not those containing ICAM-1 only.  However, when a 
chemoattractant was added to bilayers containing CD62P and ICAM-1, the 
neutrophils were arrested and became firmly adhered, however this did not occur 
when only CD62P was present.  This demonstrates the requirement for sequential 
activation of selectins, followed by activation of integrins by a chemoattractant to 
mediate firm adherence and migration of leukocytes.   
 
1.5   Integrins 
Integrins are type I transmembrane glycoprotein heterodimers, consisting of an α and 
β subunit.  Their transmembrane structure connects the interior and exterior of the cell 
to mediate bidirectional signalling (inside-out and outside-in).  There are currently 18 
α and 8 β subunits which associate into 24 integrin heterodimers with distinct roles in 
cell adhesion, cell migration and cell activation.  In the absence of cell activation by 
antigen or chemokine, integrins remain in an inactive conformation where the 
extracellular domains are folded (Luo et al. 2007).  In this conformation integrins 
have a low affinity for their ligands and are unable to mediate cell adhesion to the 
extracellular matrix.  It is thought that integrin-ligand binding occurs through a 
combination of affinity modulation and receptor clustering (Diamond et al. 1994).  
However it is still unclear whether these mechanisms are of equal importance in the 
function of the integrins (Hato et al. 1998; Krauss et al. 1999).  Although 
conventional cell activation increases expression of integrins and chemokine receptors 
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to determine their route of migration, antigen or chemokine presented by the 
endothelium can enhance cell activation and increase the rate of transmigration 
(Marelli-Berg et al. 1999).  Cell activation by these means induces signalling 
pathways lead to conformational changes within the integrin subunits which allow 
ligand binding.  It has been shown that the presence of divalent cations such as Mn
2+
 
Mg
2+
 can also directly activate integrins (Dransfield et al. 1992). 
 
1.5.1   Integrin ligands 
Integrins ligands consist of extracellular matrix proteins such as collagen and 
fibronectin, and members of the Ig super family.  The Ig family of cellular adhesion 
molecules (CAMs) are characterized by Ig- like repeats in their extracellular domain 
which contain residues necessary for integrin binding (Springer 1990; Carlos et al. 
1994; Springer 1994).  Intracellular adhesion molecules (ICAMs) 1, 2 and 3 contain 
between two and five Ig- like repeats, with the second repeat crucial for binding to 
their receptors, LFA-1 and Mac-1 (Diamond et al. 1991; Hayflick et al. 1998).  
Vascular cell adhesion molecule-1 (VCAM-1) exists in two forms, with six or seven 
Ig- like domains, where the first and fourth are necessary for binding of the integrins 
very late antigen- 4 (VLA-4) and α4β7 (Petruzzelli et al. 1999).  Although ICAM-2 is 
constitutively expressed on the vascular endothelium, inflammatory mediators such as 
LPS or TNFα can upregulate the expression of ICAM-1 and VCAM-1 which 
increases cell migration under inflammatory conditions (Springer 1994).  T cell 
integrins and their ligands are summarized in Table 1.3 and Figure 1.9. 
 
 
Chapter One: Introduction 
 
95 
 
Integrin 
Alternative 
Nomenclature 
 Ligand (s) References 
CD49a/ 
CD29 
α1β1 VLA-1 
Collagen Type 
I, IV 
(Hemler et al. 
1985; Hemler et al. 
1985; Bank et al. 
1991) 
 
CD49b/ 
CD29 
 
α2β1 
 
VLA-2 
 
Collagen, 
Laminin  
 
(Hemler et al. 
1985; Goldman et 
al. 1992) 
 
CD49d/ 
CD29 
 
α4β1 
 
VLA-4 
 
VCAM-1, 
JAM-B 
 
(Shimizu et al. 
1991; Shimizu et 
al. 1991; Ludwig 
et al. 2009) 
 
CD49e/ 
CD29 
 
α5β1 
 
VLA-5 
 
Fibronectin 
 
(Takada et al. 
1987) 
 
CD49d/ β7 
 
α4β7 
 
- 
 
MadCAM-1, 
VCAM-1, 
Fibronectin 
 
(Ruegg et al. 1992; 
Erle et al. 1994) 
 
CD103/ β7 
 
αEβ7 
 
- 
 
E- Cadherin 
 
(Cepek et al. 1994) 
 
CD11a/ 
CD18 
 
αLβ2 
 
LFA-1 
 
ICAM-1, -2, -
3, JAM-A 
 
(Binnerts et al. 
1994; Huang et al. 
1995; Fraemohs et 
al. 2004) 
CD11b/ 
CD18 
 
αMβ2 
 
Mac-1 ICAM-1, -2 (Li et al. 1993) 
Table 1.3: T cell integrins and their ligands 
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Selectins
L- selectin
Ligand: Sialyl Lewisx
Distribution: Leukocytes
E- selectin
Ligand: Sialyl Lewisx
Distribution: Activated 
Endothelium
Integrins
α β α β α β
LFA-1 (αLβ2)
Ligand: ICAM-1, ICAM-2
Distribution: Monocytes, T 
cells, DCs, Macrophages
Integrin
Ligands
ICAM-1
Receptor: LFA-
1, Mac1
Distribution: 
Activated 
Endothelium
ICAM-2
Receptor: LFA-1
Distribution:
Resting
Endothelium,
DCs
Mac1 (αMβ2)
Ligand: ICAM-1
Distribution: Monocytes, 
Macrophages, Neutrophils
VCAM-1
Receptor: VLA-4
Distribution:
Activated
Endothelium
VLA-4 (α4β1)
Ligand: VCAM-1, 
Fibronectin
Distribution: T cells, 
Monocytes
Endothelium
 
Figure 1.9 Distribution of selectins, integrins and their ligands 
Selectins mediate initial tethering and rolling of leukocytes on the endothelium. L- selectin is 
expressed on leukocytes and binds sialyl Lewis
x
 moieties on endothelial cells. E- selectin is 
expressed on activated endothelial cells and also binds sialyl Lewis
x
 structures on leukocytes.  
Integrins LFA-1, Mac1 and VLA-4 are expressed on a range of leukocytes and mediate 
binding to endothelial cells and other leukocytes which through binding ICAM-1, ICAM-2 
and VCAM-1 (Adapted from Janeway et al, Immunobiology 7
th
 Edition) 
 
1.5.2   Integrin Structure 
Each integrin subunit contains a large extracellular domain consisting of a globular 
head (N terminal), an 18nm stalk transcending the plasma membrane and a shorter 
cytoplasmic domain (C terminal) (Weisel et al. 1992; Erb et al. 1997; Emsley et al. 
2000).  The α subunits 1, 2, 10, 11, D, E, L, M and X contain an ‘inserted domain’ (I 
domain) within a 7 bladed beta-propeller structure in the globular head region which 
is central to ligand binding.   
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Two motifs were shown to be crucial for ligand and Mn
2+
 or Mg
2+
 binding to the I 
domains; the DXSXS motif, termed dinucleotide-binding fold, and the MIDAS (metal 
ion dependent adhesion site) motif respectively, resulting in an I domain 
conformational change (Lee et al. 1995; Luo et al. 2006).  This leads to the 
rearrangement of the I domain backbone and results in displacement of the I domain 
residues which directly recognise ligand, and ligand binding (Springer et al. 2004).  
Evidence for these observations came from studies conducted by Springer et al 
(Shimaoka et al. 2003).  They additionally observed that enzymatic disruption of the 
association between the α and β subunits caused separation of the subunits and 
unfolding of the extracellular domains.  This resulted in a five-fold increase in the 
affinity of the integrin (α5β1) for its ligand (fibronectin) in the absence of other 
molecules; suggesting that separation of the alpha and beta subunits in the presence of 
metal ions is sufficient for ligand binding (Takagi et al. 2001).   
 
1.5.3   Integrin Signalling 
The signalling pathways which lead to integrin function through affinity modulation 
and induction of receptor clustering are diverse.  Broadly these can be divided into 
‘inside out’ and ‘outside in’ signalling.  Briefly, the inside out pathway induces 
integrin conformational changes leading to separation of the heterodimers and binding 
of ligands with high affinity, and integrin clustering in the membrane leading to 
increased ligand avidity.  Integrin activation by divalent cations can bypass inside- out 
signalling by inducing heterodimer dissociation.  The outside in pathway begins as 
clustering takes place and leads to cell-specific integrin functions such as firm cell 
adherence, cytoskeleton rearrangement, cell migration, and cell-cell contacts.   
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1.5.3.1   Inside- out signalling 
Inside out signalling is triggered by cell activation through the BCR, TCR or by 
chemokine or cytokine stimulation within an inflammatory environment.  Following 
the initial separation of the alpha and beta subunits, conformational changes result in 
the integrin adopting an open or activated state as detailed above, allowing clustering 
of integrin receptors.  Inflammatory cells can then attach or detach from the 
endothelium as required.  A number of proteins have been demonstrated to play a role 
in this process.  Both α and β integrin cytoplasmic tails contain residues necessary for 
protein binding and different proteins specifically associate and phosphorylate both 
subunits.   
Chemokine stimulation or TCR engagement trigger a cascade of signalling pathways 
leading to recruitment of adaptor proteins to the cytoplasmic tails of the integrins.  
These include the PKC, PLCγ and ADAP/SKAP55 pathways which all lead to the 
activation of Rap1 GTPase, thought to be the master regulator of integrin inside out 
signalling (Boettner et al. 2009).   
 
1.5.3.1.1   Formation of signalling complex 
The initial events following TCR engagement are mediated through the activation of 
the Src family kinases which phosphorylate ITAMs (immunoreceptor tyrosine- based 
activation motifs) on the CD3 subunit cytoplasmic tails.  This leads to the recruitment 
of ZAP-70 (zeta- chain associated protein kinase 70 kDa) which is phosphorylated 
and activated by the Src kinases (Howe et al. 1995; Mustelin et al. 2003).  ZAP-70 
then phosphorylates LAT (linker of activation of T cells) which resides in plasma 
membrane lipid rafts, and forms a complex with Gads (Grb2- related adaptor 
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downstream of Shc), SLP-76 (SH2 domain containing leukocyte phosphoprotein of 
76kDa), ADAP (Adhesion- and Degranulation-Promoting Adaptor Protein), SKAP55 
(Src kinase- associated phosphoproteins of 55 kDA) to form a signalling complex 
with the Rho family guanine nucleotide exchange factor Vav1 (da Silva et al. 1997; 
Marie-Cardine et al. 1998; Fang et al. 1999; Koretzky et al. 2001; Horejsi et al. 2004; 
Koretzky et al. 2006).  This signalling complex is crucial for the recruitment of Rap1 
GTPase to the plasma membrane; interruption of the ADAP/SKAP55 complex in 
Jurkat T cells and knockdown of SKAP55 by siRNA abrogated Rap1-mediated cell 
adhesion to both β1 and β2 integrin ligands.  The authors also found this abrogation 
was not due to decreased Rap1 activation, but to displacement of Rap1 from the 
membrane (Kliche et al. 2006). 
 
1.5.3.1.2   The role of Rap1 GTPase 
Rap1 GTPase is a small molecular weight protein homologous to Ras GTPase.  It 
cycles between active (GTP-bound) and inactive (GDP- bound) forms, mediated by 
guanine exchange factors (GEF), including CalDAG- GEF1 (Bos et al. 2001; Bos 
2005).  The role of Rap1 in cell adhesion and migration has been demonstrated by 
gain and loss- of- function studies.  Constitutively active Rap1 results in increased T 
cell adhesion to ICAM-1 and fibronectin, conversely a dominant negative form of 
Rap1 abrogates TCR- induced integrin activation.  Furthermore, T cells from mice 
deficient in Rap1A exhibit decreased adhesion to ICAM-1 and fibronectin (Katagiri et 
al. 2002; Sebzda et al. 2002; Duchniewicz et al. 2006).  Rap1b- deficient neutrophils 
also demonstrated significantly impaired transendothelial migration, through defects 
in cell polarization (Carbo et al. 2010).   
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Rap1 GTPase is activated by TCR engagement and chemokine signalling through the 
increase in intracellular Ca
2+
 and production of second messengers which activate the 
GEF necessary for switching of GDP to GTP- bound Rap1  (Anthis et al. 2011).  
Rap1 is recruited to the plasma membrane through interaction of a Rap1 effector 
protein, RIAM (Rap1- GTP- interacting adaptor molecule) (Menasche et al. 2007).  
RIAM links active Rap1 to the ADAP/ SKAP55.  Interruption of this complex 
resulted in impairment of T cell conjugate formation and TCR-mediated cell adhesion 
in primary T cells (Menasche et al. 2007).  RIAM has also been shown to interact 
with and regulate activity of PLCγ, which controls release of DAG (Diacyl glycerol) 
and an increase in intracellular Ca
2+
, and activation of PKC (protein kinase C) 
(Patsoukis et al. 2009). 
 
1.5.3.1.3   Chemokine activation of integrins 
Integrins can also be activated by chemokines, and although the pathways are similar, 
some differences have been observed.  Studies using RNAi to reduce SLP-76 levels in 
primary human T cells demonstrated that while SLP-76 was crucial for TCR- 
mediated integrin activation as discussed, it was dispensable for recruitment of the 
ADAP/ SKAP55/ RIAM complex to the plasma membrane after CXCL12 stimulation 
of cells (Horn et al. 2009).  The Rho family of GTPase members RhoA and Rac, (and 
Vav1, GEF for Rac) were also shown to play a role in the CXCL12- mediated inside-
out pathway of LFA-1 and VLA-4 activation respectively (Garcia-Bernal et al. 2005; 
Pasvolsky et al. 2008).   
The RIAM- Rap1- GTP complex also has another important function in integrin 
activation; recruitment of the integrin- binding protein talin to the plasma membrane, 
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forming a ternary complex (Lee et al. 2009).  Inactive talin is maintained in an 
autoinhibited state, however activation by second messengers induces an activating 
conformational change (Goksoy et al. 2008).  The talin head contains a FERM (four 
point one, ezrin, radixin, moesin) domain, which binds to the NPxY motifs within the 
β integrin cytoplasmic tails, inducing separation of the α and β subunits (Bouaouina et 
al. 2008; Anthis et al. 2009).  
 
1.5.3.2   Outside- in Signalling 
Following inside out signalling, the integrin subunits are in an open conformation and 
able to bind their ligands with high affinity.  Outside-in signalling events lead to actin 
cytoskeletal rearrangements which result in cell adhesion, spreading and migration.  T 
cell specific responses also include cell proliferation, IL-2 production and 
stabilization of T cell/ APC conjugates (Abram et al. 2009).  
Central to outside- in integrin signalling is the recruitment and activation of tyrosine 
kinases such as Src and Syk (spleen tyrosine kinase) family members, and 
downstream activation of FAK (focal adhesion kinase), which regulates cycling of 
small GTPases necessary for actin cytoskeletal rearrangements.  This results in the 
focal adhesion assembly and disassembly required for cell motility. 
 
1.5.3.2.1   The role of focal adhesion kinase (FAK) 
Integrin clustering is believed to initiate outside- in signalling.  On integrin clustering, 
Src and Syk family kinases either directly bound to the cytoplasmic domains of β 
integrin chains, or coupled to integrins through ITAM- containing proteins within 
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lipid rafts phosphorylate and activate each other (Arias-Salgado et al. 2003; Marwali 
et al. 2003; Mocsai et al. 2006).  Integrin ligation also results in autophosphorylation 
of FAK at tyrosine residue 397.  This creates a binding site for active Src through its 
SH2 domain.  This complex formation leads to further phosphorylation of FAK on 
other residues (Huveneers et al. 2009).  Assembly of focal adhesions necessary for 
cell adhesion and motility are mediated by the interaction of phosphorylated FAK and 
integrin- bound talin, which results in unfolding of the talin rod domain followed by 
binding of actin filaments (Zhang et al. 2008).  The active FAK- Src complex 
subsequently recruits and phosphorylates a number of proteins which act as guanine 
exchange factors for the GTPases Rac1 (Ras-related C3 botulinum toxin substrate 1) 
and Cdc42 (cell division cycle 42) (Brugnera et al. 2002; Chodniewicz et al. 2004; ten 
Klooster et al. 2006; Huveneers et al. 2009).   
 
1.5.3.2.2   Cell motility 
The focal adhesion assembly and disassembly required for cell motility is mediated by 
FAK-Src regulation of GEFs for the small GTPases Rac1, Cdc42 and RhoA.  Rac1 
and Cdc42 activation is balanced with RhoA activation.  FAK interacts with 
p190ARhoGAP/ GRLF1 (glucocorticoid receptor DNA binding factor 1) to inactivate 
RhoA (concomitant with active Rac1 and Cdc42) to stimulate suppressed 
actinomyosin contractility, actin- mediated membrane protrusions and focal adhesion 
assembly at the cell leading edge (Huveneers et al. 2009; Tomar et al. 2009).  To 
stimulate focal adhesion disassembly at the trailing edge, FAK interacts with 
p190RhoGEF (190 kDa guanine nucleotide exchange factor) which activates RhoA 
and results in increased actinomyosin contractility (Gupton et al. 2006; Lim et al. 
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2008).  The importance of these molecules has been demonstrated in loss-of-function 
studies.  FAK null cells demonstrate decreased focal adhesion turnover at leading and 
trailing edges leading to reduced migration, and knockdown of p190RhoGEF in 
fibroblasts resulted in tail retraction defects and impaired migration (Webb et al. 
2004; Lim et al. 2008). 
 
1.5.4   Cell Extravasation 
In order for cells to traverse the endothelium, they must release interactions with cell-
surface integrin ligands, and mediate interactions with proteins present at endothelium 
tight junctions.  These include the junctional adhesion molecules JAM-A, -B and –C, 
PECAM-1 and CD99.  Activated integrins play a role in binding these molecules to 
allow cells to extravasate through the endothelium and into underlying tissues 
(Shimizu et al. 1991).  This can occur by transcellular or paracellular routes. 
 
1.5.4.1   Junctional adhesion molecule A (JAM-A) 
The junctional adhesion molecules (JAM) are part of the Ig- superfamily and are 
characterized by two extracellular Ig domains and a PSD-95/Discs-Large/ZO-1 (PDZ) 
binding motif.  They can form homo- or heterophilic interactions and play important 
roles in barrier permeability (Bazzoni et al. 2000).  JAM-A performs this function by 
homophilic interactions through its first Ig domain in either cis (between adjacent 
JAM-A molecules) or trans (across endothelial cells) configurations.  Si-RNA- 
mediated knockdown of JAM-1 markedly increased epithelial barrier permeability, an 
effect also observed in the gastrointestinal mucosa of JAM-A
-/- 
mice (Mandell et al. 
2004; Laukoetter et al. 2007).  In order to transmigrate, lymphocytes must disrupt the 
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JAM-A dimers (Ozaki et al. 1999; Williams et al. 1999).  While circulating 
lymphocytes also express JAM-A, LFA-1 has been implicated as a receptor for JAM-
A, binding through its I domain to the second Ig domain of JAM-A.  This was 
demonstrated through use of neutralizing antibodies to JAM-A which inhibited 
CXCL12- stimulated transmigration, but not adhesion of memory T cells mediated by 
LFA-1 (Ostermann et al. 2002).   
 
1.5.4.2   Junctional adhesion molecule B (JAM-B) 
JAM-B is also expressed on endothelial cells, and can form heterophilic interactions 
with JAM-C and VLA-4 expressed on lymphocytes (Cunningham et al. 2002).  
Neutralization of JAM-B resulted in a decrease in lymphocyte transmigration of up to 
80 % in a model of skin inflammation, with a moderate but significant decrease in cell 
transmigration using an in vivo model of contact hypersensitivity (Ludwig et al. 2005; 
Ludwig et al. 2009), indicating JAM-B also plays a role in transmigration.   
 
1.5.4.3   Platelet endothelial cell adhesion molecule-1 (PECAM-1) 
Platelet endothelial cell adhesion molecule-1 (PECAM-1), a type transmembrane 
glycoprotein, contains 6 Ig repeats, the first of which is crucial to formation of 
homophilic interactions between PECAM-1 molecules on both leukocytes and 
endothelial cells (Sun et al. 1996).  PECAM-1 is an important regulator of barrier 
permeability and transendothelial migration.  The importance of PECAM-1 in 
diapedesis was demonstrated in CIA studies, where blockade of PECAM-1 markedly 
reduced join infiltration of cells without affecting the total number of circulating cells.  
This resulted in decreased joint destruction and disease severity (Dasgupta et al. 
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2010).  Inhibition of PECAM-1 has also been efficacious in a number of other in vivo 
disease models by decreasing leukocyte extravasation into inflamed tissues 
(Privratsky et al. 2010).   
 
1.5.4.4   Paracellular and Transcellular routes of diapedesis 
Cells can undergo diapedesis by two routes; paracellular and transcellular.  Cells 
transmigrating by the paracellular route move through endothelial cell junctions, 
whereas transcellularly- migrating cells move straight through the endothelial cell 
membrane.  Evidence for both routes of migration have been demonstrated, with 
endothelial cell type implicated in the predominance of one route over the other 
(Carman et al. 2008).  JAM-A, PECAM-1 and CD99, a cell surface glycoprotein, are 
components of the lateral border recycling compartment (LBRC), which was first 
observed by Mamdouh et al (Mamdouh et al. 2003).  The LBRC is an interconnected 
network of membranes containing PECAM-1 and JAM-A at the endothelial cell 
borders and enables its recycling.  Mamdouh et al demonstrated that transmigrating 
monocytes expressing PECAM-1 were surrounded by PECAM-1 rich membranes 
connected to the endothelial cell surface, enabling the monocytes to extravasate 
between the cell junctions.  On blockade of monocyte PECAM-1, the cells adhered to 
the endothelium at the cell junctions but could not extravasate, and membranes 
containing endothelial PECAM-1 continued to recycle but were not enriched at the 
adhered monocyte.  Furthermore, the group later demonstrated that the LBRC also 
contained CD99 and JAM-A, was regulated by the kinesin motor family and also 
played a role in transcellular transmigration downstream of ICAM-1 mediated cell 
adhesion (Mamdouh et al. 2008; Mamdouh et al. 2009).  The LBRC was shown to 
surround cells adhered, not just at endothelial cell junctions, but at adjacent sites and 
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to mediate their migration through the cell membrane.  Other studies have indicated 
that PECAM-1 CD99 and JAM-1 also function in this manner during T cell 
transmigration, with PECAM-1 and CD99 playing a more predominant role in 
transmigration activated by antigen presented by the endothelium, and JAM-A 
predominating in transmigration stimulated by chemokines (Manes et al. 2011).  
T cell transendothelial migration is a complex, regulated series of events that take 
place to maintain normal immune responses, and to mobilize memory cells in the 
event of infection (Illustrated in Figure 1.10).  However these same inflammatory 
responses can be damaging if unchecked and can lead to autoimmune and chronic 
inflammatory diseases such as rheumatoid arthritis.  It is unclear exactly what initiates 
cell infiltration in rheumatoid arthritis; however integrins have been shown to play a 
role in pathogenesis in the continued infiltration of cells into the synovial tissue. 
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Figure 1.10 Leukocyte extravasation 
Leukocytes are released from the bone marrow and enter the peripheral blood circulation 
system.  The migration of leukocytes from the blood is controlled by chemoattractant 
gradients emanating from specific tissues or sites of inflammation.  Leukocyte extravasation 
occurs via a multistep process consisting of rolling, tethering, adhesion, diapedesis and 
migration. T cell capture and rolling on activated endothelia is mediated by CD62L (T cells) 
and CD62E (endothelium), followed by activation of integrins such as VLA-4 and LFA-1 by 
chemokines.  This mediates firm adhesion of cells to integrin ligands such as VCAM-1 and 
ICAM-1 on the endothelial cell surface.  Homo- and heterophilic interactions of PECAM-1 
and JAM-A at the endothelial cell tight junctions and T cells result in T cells traversing the 
endothelium to the underlying tissues. Adapted from Janeway et al, Immunobiology 6th
ED
 
 
 
1.5.5   The role of integrins and their ligands in RA 
Integrins have been implicated in RA pathogenesis, playing a role in inflammatory 
cell infiltration and retention in the joint, resident synovial cell activation and 
apoptosis.  Their blockade has proved efficacious in mouse models of arthritis and 
could provide an alternative therapeutic route. 
The integrin α1β1 (VLA-1), a receptor for collagen, is expressed by activated effector 
memory cells.  VLA-1
+
 cells have been found in inflammatory synovial tissue, and 
VLA-1 mediated interaction of T cells with collagen leads to release of IFNγ and 
TNFα, perpetuating the inflammatory environment (Chan et al. 1991; Bank et al. 
2002; Goldstein et al. 2008).  Moreover, synovial fluid of relapsing patients during 
anti TNFα therapy display high numbers of VLA-1+ T cells.  In contrast, fewer 
peripheral blood VLA-1
+
 T cells were observed in patients responding to anti TNFα 
compared to non-responders (Ben-Horin et al. 2007).   
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1.5.5.1   Beta- 1 Integrins 
The integrin α4β1 (VLA-4) plays a role in cell infiltration into the synovial tissue.  Its 
ligand VCAM-1 is expressed on cytokine activated endothelia and RA fibroblast-like 
synoviocytes (FLS) and VLA-4
+ 
cells have been detected in the synovium (Morales-
Ducret et al. 1992; Kitani et al. 1996; Pap 2003; Szekanecz et al. 2008).  VLA-4 
ligation mediates infiltration of endothelial progenitor cells to induce 
microvascularization of the joint, an event which precedes onset of clinical symptoms 
(Silverman et al. 2007).  Furthermore, the soluble form of VCAM-1 has been shown 
to induce migration of monocytes and activated T cells bearing high affinity VLA-4, 
and soluble VCAM-1 bound T cells within the joint have been demonstrated to be 
anergic (Kitani et al. 1996; Kitani et al. 1998; Tokuhira et al. 2000).  This reflects the 
activation state of T cells found in synovial tissue (Verwilghen et al. 1990; Howell et 
al. 1992).  VLA-4 ligation by VCAM-1 has also been implicated in transmigration of 
B cells under RA FLS (termed pseudoemperipolesis) (Burger et al. 2001), while 
blockade of VLA-4/ VCAM-1 in collagen- induce arthritis reduced B cell joint 
infiltration and severity of disease (Carter et al. 2002).  Treatment of RA patients with 
anti TNFα or methotrexate both reduced cell recruitment to the joint through a 
decrease in expression of circulating soluble VCAM-1 and α4 integrin on circulating 
T cells respectively (Johnston et al. 2005; Klimiuk et al. 2009).   
Synovial hyperplasia in RA has been hypothesized to be linked to decreased cell 
apoptosis (Matsumoto et al. 1996), and resistance of cells to apoptosis has been 
suggested to correlate with progression of joint destruction in RA (Ceponis et al. 
1999).  One pathway of cell apoptosis is through ligation of Fas by Fas Ligand (FasL) 
expressed on inflammatory cells.  Ligation of β1 integrins by components of the 
extracellular matrix have been implicated in Fas- mediated apoptosis of RA FLS 
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(Nakayamada et al. 2003; Kitagawa et al. 2006), however whether these interactions 
confer apoptosis or resistance is unclear.  While VLA-5 mediated adhesion of Fas- 
expressing FLS to fibronectin inhibited Fas- induced apoptosis (Kitagawa et al. 2006), 
engagement of synovial cell β1 integrin by the extracellular matrix components 
induced FAK- mediated upregulation of ICAM-1 and Fas on FLS and increased Fas- 
mediated apoptosis of FLS (Nakayamada et al. 2003).  However, soluble collagen 
detected in synovial fluid was found to induce T cell resistance to Fas- mediated 
apoptosis through β1- mediated interactions (Lin et al. 2009).  Resistance or induction 
of apoptosis within the synovial tissue might depend on the cell types present, and the 
context of cell- cell and cell- matrix interactions mediated by integrins.   
 
1.5.5.2   Beta- 2 Integrins 
Studies have also shown β2 integrins to be of importance in RA pathogenesis through 
mediating influx of cells into the joints and cell-cell interactions leading to cell 
proliferation and production of proinflammatory mediators.  LFA-1 expression was 
shown to be higher on the peripheral blood monocytes of RA patients compared to 
healthy controls, and in synovial fluid and tissue of affected joints in a mouse model 
of arthritis (Koller et al. 1999; Watts et al. 2005).  Moreover LFA-1 has been 
implicated to be of importance in T cell- monocyte interactions, T cell- FLS and cell- 
endothelium interactions through binding to its ligands ICAM-1 and ICAM-2 (Tsai et 
al. 1996; Nakatsuka et al. 1997; Oppenheimer-Marks et al. 1998; Brennan et al. 2008; 
Singh et al. 2008).  These interactions result in generation of FLS pro-survival signals 
and proliferation, cell influx into the joint and production of proinflammatory 
cytokines and chemokines (Grober et al. 1993; Beech et al. 2006; Brennan et al. 2008; 
Singh et al. 2008).   
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It was also reported that LFA-1 -/- mice displayed impaired disease development in 
the CIA model of arthritis, and CD18 null mice were protected from disease in the 
K/B x N serum transfer model of arthritis, while in normal mice, a neutralizing 
antibody against LFA-1 significantly decreased disease severity in established 
arthritis (Watts et al. 2005; Wang et al. 2008).  The authors of the former study 
postulate that their findings indicate requirement of LFA-1 to reduce the threshold for 
TCR activation; low doses of antigen failed to result in disease in LFA-1 -/- mice, 
however arthritis was observed with high antigen doses (Wang et al. 2008).  The 
findings of the latter study also show that LFA-1 ligands ICAM-1 and JAM-A are 
equally important in mediating neutrophil transendothelial migration; blockade of all 
three molecules reduced inflammation and severity of disease to similar extents 
(Watts et al. 2005).   
In addition to the importance of β2 ligands in arthritis pathogenesis, there has been an 
increase in the circulating soluble form of the LFA-1 ligand ICAM-1 detected in RA 
patients compared to healthy controls (Klimiuk et al. 2002; Klimiuk et al. 2007; 
Navarro-Hernandez et al. 2009).  Furthermore, levels of soluble ICAM-1 could be 
positively correlated with rheumatoid factor and were significantly decreased after 
treatment with etanercept (Klimiuk et al. 2009; Navarro-Hernandez et al. 2009).   
Integrins therefore play an important role in maintaining the inflammatory 
environment within the joint by mediating cell infiltration and cell interactions with 
resident FLS, inflammatory cells, and extracellular matrix proteins. 
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1.5.6   Integrin- based therapies 
Therapeutics based on integrin blockade have proved efficacious in a number of 
autoimmune diseases such as MS and psoriasis, however lethal side effects have lead 
to them being withdrawn from the market.  Natalizumab (Tysabri; Elan/ Biogen- 
Idec) is a monoclonal antibody which binds the α4 integrin and which was approved 
by the FDA for treatment of MS in 2003 (Cox et al. 2010).  However treatment with 
natalizumab caused reactivation of John Cunningham (JC) and herpes viruses which 
lead to cases of progressive multifocal leukoencephalopathy (PML), a potentially fatal 
disease of the CNS (Warnke et al. 2010) and was taken off the market in 2005.  
However its efficacy in preventing relapses in MS lead to its reintroduction in 2006.  
In 2004, a natalizumab trial in RA was initiated, however it was terminated in 2005 
due to lack of efficacy.  Care must be taken to avoid immunosuppression as a side 
effect of the blockade of the VLA-4/ VCAM-1 axis, due to its function in cell- cell 
interactions between T cells and APCs.  To that end, several companies are 
developing small molecule inhibitors and peptides to block ligand binding or 
downstream signalling pathways which are currently in preclinical or phase II trials 
(Vanderslice et al. 2006; Cox et al. 2010). 
Efalizumab (Raptiva; Genentech), a monoclonal antibody which binds the αL subunit 
of LFA-1 was licensed in 2003 for use in moderate to severe plaque psoriasis.  It was 
shown to sterically hinder ICAM-1 binding by stabilizing LFA-1 in its inactive 
conformation (Li et al. 2009). However, similar to natalizumab, it was withdrawn 
from the market in 2009 due to emergence of PML cases (Cox et al. 2010).  In 1994, a 
small Phase I/II of RA patients was performed using a murine anti-human ICAM-1 
mAb which was beneficial to some patients (Kavanaugh et al. 1994).  Small molecule 
inhibitors are now being developed to change the LFA-1 I domain conformation to 
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affect ligand binding in the treatment of psoriasis (Dunehoo et al. 2006; Vanderslice 
et al. 2006; Cox et al. 2010). 
Modulation of integrin signalling has also been exploited in treatment of cancers and 
atopic diseases, such as Syk in treatment of asthma and rhinitis (reviewed in (Ulanova 
et al. 2005)), FAK as an anticancer therapeutic target (Chatzizacharias et al. 2007), 
and Integrin- linked kinase (ILK) in treatment of breast cancer metastases (Hinton et 
al. 2008).  Integrins and their pathways consist of many potentially advantageous 
targets for therapeutic intervention; however the varied functions of integrins make 
avoiding serious side effects a challenge.  Nonetheless the continued development of 
small molecule inhibitors, neutralizing antibodies and peptides could help surmount 
these challenges.   
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1.6   Aims and hypothesis of project 
Previous work in the group has shown that cytokine activation of T cells upregulates 
activation markers and elements of the migratory machinery; moreover these cells are 
identical in phenotype and in the signalling pathways they elicit in monocytes to T 
cells isolated from RA synovial tissue. 
My hypothesis is that cytokine activation of T cells results in a phenotype that will 
support Tck migration in vitro and in vivo, that these cells will be pathogenic, and that 
specific blockade of these pathways could be targeted for therapeutic intervention. 
I will test this hypothesis through the following aims: 
 Confirm and extend phenotypic analysis of Tck to further chemokine 
receptors, integrins and integrin ligands 
 Investigation of Tck migratory responsiveness through in vitro chemotaxis and 
transendothelial migration assays 
 Establish RA/ SCID mouse model, and use it to investigate Tck migration in 
vivo, incorporating blockade of specific pathways identified through in vitro 
migration studies 
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2.0   Reagents 
2.0.1   Cell Culture 
Roswell Park Memorial Institute (RPMI) media containing 25 mM glutamine (PAA, 
Pasching, Austria) supplemented with heat inactivated foetal calf serum (FCS) 
(Biosera, East Sussex, UK) or pooled human AB serum (Sigma- Aldrich, St Louis, 
Missouri) were used in lymphocyte cell culture.  Human umbilical vein endothelial 
cells (HUVEC) were cultured in RPMI supplemented with FCS, Newborn calf serum 
(Sigma- Aldrich), endothelial cell growth supplement (Sigma- Aldrich), penicillin/ 
streptomycin (PAA) and heparin (Sigma- Aldrich).  Foetal calf serum and newborn 
calf serum were supplied heat inactivated, however human serum was heat inactivated 
at 56 °C for 45 minutes prior to use. 
Phosphate buffered saline (PBS) used in cell culture was made up from 10X PBS 
(PAA) using cell grade H2O (PAA).  DMSO used for cell cryopreservation was 
purchased from Sigma Aldrich.  Hanks Buffered Salt Solution (HBSS) used for 
isolation of the PBMC fraction for elutriation was obtained from PAA.  All reagents 
used in cell isolation and culture were shown to contain < 0.1 units/ ml of endotoxin 
as determined by the Limulus amoebocyte lysates assay (Lonza, Basel, Switzerland), 
kindly performed by Ms Patricia Green and Mr Sunil Modi. 
 
2.0.2   Cell stimulation 
The following cell culture grade, human recombinant cytokines used for cell 
stimulation were kindly gifted; TNFα from Boehringer Ingelheim (Ingelheim am 
Rhein, Germany), IL-6 from Novartis (Basel, Switzerland) and IL-2 from the National 
Institute of Health (Bethesda, Massachussetts).  LPS (purified from E coli) was 
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purchased from Alexis (Lausen, Switzerland).  Anti CD3 (OKT3) and anti CD28 
(CD28.2) antibodies used in cell stimulation were purchased from Insight 
Biotechnology (London, UK) and BD Pharmingen (San Diego, California) 
respectively. 
 
2.0.3   Antibodies for flow cytometry 
Flow cytometry antibodies listed in Table 2.1 were purchased from BD Pharmingen, 
with the exception of CXCR4- PE, CXCR7- PE, CCR6- APC, CCR8- PE, PECAM-1- 
PE, JAM-C- PE and CD49e- APC, which were purchased from R&D Systems 
(Minneapolis, Minnesota).  All antibodies were titrated on a relevant cell type to 
determine the optimum concentration for cell labelling.   
 
2.0.4   Immunomagnetic bead isolation 
CD3
+
 and CD4
+ 
cells were isolated by positive selection using Dynabeads (Invitrogen, 
San Diego, California).  The kits were used as per manufacturer’s instructions and cell 
purity was determined by flow cytometry. 
 
2.0.5   Blocking antibodies, inhibitors and recombinant human proteins 
Blocking antibodies to CD29 (clone 4B4), CD49d (HP2/1) and VCAM-1 (P8B1) used 
in migration assays and T cell- monocyte co-cultures were purchased from Beckman 
Coulter (Brea, California), Serotec (Kidlington, UK) and Millipore (Billerica, 
Massachussets) respectively.  Blocking antibodies against CD11a (HI111), CD18 
(TS1/18), ICAM-1 (HCD54), ICAM-2 (CBR-IC2/2) and ICAM-3 (CBR-IC3/1) used 
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in migration assays were purchased from Biolegend (San Diego, California).  Isotype 
control antibodies IgG1 (107.3) and IgG2a (G155-178) were purchased from BD 
Pharmingen.  CXCR4 antagonist AMD3100 used in migration assays was purchased 
from Sigma-Aldrich, reconstituted in cell culture grade H2O and stored at -20 °C.  
PI3K inhibitor LY294002 was purchased from Sigma- Aldrich, reconstituted in 
DMSO and stored in aliquots at -20 °C.   
The following recombinant human chemokines used in migration assays were 
purchased from Peprotech (Margravine Road, London, UK); CXCL10, CXCL12, 
CCL5 and CCL20.  Recombinant human VCAM-1 used in migration assays was 
purchased from R&D systems.  
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2.0.6   Buffers 
 
FACS Wash Buffer:   1X PBS 
     2 % (v/v) FCS 
0.1 % (v/v) NaN3 (Sigma- Aldrich) 
 
 
MACS Buffer :              1 X filter sterilised PBS 
     2 mM EDTA  (VWR, West Chester, 
USA) 
     0.5 % FCS  
 
 
Cell Freeze Buffer:   FCS 
10 % (v/v) Dimethyl sulphoxide 
 
 
ELISA Blocking Buffer:  1 X PBS 
2 % (w/v) BSA (PAA) 
 
 
 
ELISA Wash Buffer:   1 X PBS 
     0.1 % (v/v) Tween 20 (Sigma- Aldrich) 
 
 
Chemotaxis Assay Buffer  RPMI 1640 
     0.1 % (w/v) BSA  (PAA) 
 
 
HUVEC Media:   RPMI 1640 
     10% (v/v) FCS 
     10% (v/v) Newborn Calf Serum 
     15 µg/ml Endothelial Cell Growth Supplement 
     50 U/ml Heparin  
     100 U/ml Streptomycin, 100 µg/ml penicillin 
 
10 X TBS Buffer:   80 g/l (w/v) NaCl 
     100 mM Tris/ HCl   
     pH 7.5 
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Specificity Fluorochrome Clone Isotype 
CD4 FITC RPA-T4 Ms IgG1 
CD8 PeCy5 RPA-T8 Ms IgG1 
CD11a PE HI111 Ms IgG1 
CD18 PE 6.7 Ms IgG1 
CD19  FITC HIB19 Ms IgG1 
CD25 PE 2A3 Ms IgG1 
CD29 PE MAR4 Ms IgG1 
CD38 APC HIT2 Ms IgG1 
CD45RA PeCy5 HI100 Ms IgG2b 
CD45RO PE UCLH1 Ms IgG1 
CD49d PE 9F10 Ms IgG1 
CD49e APC 238307 Ms IgG1 
CD56 PE B159 Ms IgG1 
CD62L PE Dreg56 MsIgG1 
CD69 PE FN50 Ms IgG1 
Intβ7 PE FIB504 Rat IgG2a 
CXCR2 PE 6C6 Ms IgG1 
CXCR3 PE 1C6 Ms IgG1 
CXCR4 PE 12G5 Ms IgG2a 
CXCR7 PE 11G8 Ms IgG2a 
CCR5 PE 2D7 Ms IgG2a 
CCR6 APC 53103 Ms IgG2b 
CCR7 PE 3D12 Rat IgG2a 
CCR8 PE 191704 Rat IgG2b 
ICAM-1 PE HA58 Ms IgG1 
ICAM-2 PE CBR-1C2/2.1 Ms IgG2a 
VCAM-1 FITC 51-10C9 Ms IgG1 
E- Selectin APC 68-5H11 Ms IgG1 
PECAM-1 PE 9G11 Ms IgG1 
JAM-A PE M.AB.F11 Ms IgG1 
JAM-C PE 208212 Ms IgG2b 
pFAK (S910) PE K73-480 MsIgG1 
 
 
Table 2.1 Flow Cytometry Antibodies 
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2.0.7   ELISA Reagents 
Detection of cytokines in cell supernatants was performed using Enzyme- linked 
immunosorbent assay (ELISA).  ELISAs were undertaken in high protein binding 
EIA/ RIA 96 well plates (Costar, Corning, New York).  Antibody pairs were 
purchased from BD Pharmingen and are detailed in Table 2.3.  Streptavadin- 
horseradish peroxidase (HRP) (R & D), TMB substrate (KPL, Maryland, USA) and 
H2SO4 (VWR) were used in ELISA development. 
 
 
Table 2.2 ELISA Antibodies 
 
Specificity Nature of 
antibody 
Clone Concentration Range Source of 
Standard 
TNFα Capture 
Detection 
MAb1 
MAb11 
4 µg/ml 
0.5 µg/ml 
39- 3333.3 pg/ml Peprotech  
 
 
IL-6 Capture 
Detection 
MQ2-13A5 
MQ2-393C 
1 µg/ml 
0.5 µg/ml 
39- 3333.3 pg/ml Peprotech  
      
CXCL12 Capture 
Detection 
IP-10/CRG-2 
IP10/CRG-2 
 
1 µg/ml 
0.4 µg/ml 
30- 30000 pg/ml R & D  
 
 
 
VCAM-1 Capture 
Detection 
112734 
112731 
2 µg/ml 
0.2 µg/ml 
14- 1000 pg/ml R & D  
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2.1   Cell isolation and purification 
2.1.1   Preparation of peripheral blood mononuclear cells for elutriation 
Single donor plateletphoresis residues (buffy coats) were obtained from the North 
London Blood Transfusion service (Colindale, UK).  Human peripheral blood 
mononuclear cells were isolated from buffy coats by density gradient centrifugation 
which allows for the separation of PBMCs from erythrocytes and granulocytes.  Buffy 
coats (approximately 50 mls) were diluted to 100 ml with HBSS and layered onto 4 x 
20 ml lympholyte- H solution (Cedarline Laboratories, Ontario Canada) and 
centrifuged at 1000 g for 30 minutes with the brake off.  PBMCs, located at the 
interface between plasma and lympholyte- H, were carefully removed using a sterile 
Pasteur pipette and resuspended in 50 ml HBSS.  PBMCs were pelleted at 300 g for 
10 minutes and then resuspended in RPMI media supplemented with 1 % FCS prior to 
elutriation.  
 
2.1.2   Counterflow Centrifugation Elutriation 
Centrifugation elutriation is a technique of cell separation based on cell size. PBMC 
are resuspended in a buffer of RPMI 1640 supplemented with 1 % FCS and loaded 
into the flow system, where they enter the elutriation chamber. On entering the 
chamber, centrifugal force results in the cells remaining at the sides of the chamber. 
As the flow rate of buffer increases through the system, the counter flow drag force 
which forces the cells into the middle of the chamber overtakes the effect of 
centrifugal force, and cells begin to leave the chamber. At this point, the cells appear 
to sediment into layers depending on cell size, with the smallest cells at the top. Thus, 
as the flow rate increases, the small cells exit the chamber. The purity of the 
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populations exiting the flow system can be analysed using forward and side scatter on 
a flow cytometer. From a typical PBMC preparation, the erythrocytes will elute first, 
followed by the lymphocyte population, then the mononuclear cell and granulocyte 
population.  Advantages of this technique are that the cells are not manipulated or 
damaged during the separation and thus can be used for further experiments.  
Lymphocyte and monocyte fractions were collected at a purity of 85 % or greater 
between flow rates of 13 and 17 mls per minute and 19 and 23 mls per minute 
respectively.   
 
2.1.3   Positive isolation of CD4
+
 lymphocytes 
Isolation of CD4
+
 T cells using CD4 Dynabeads (Invitrogen) was performed as per 
manufacturer’s instructions.  Elutriated peripheral blood T cells were suspended in 
MACS buffer, beads added at a concentration of 25 µl/ 1x10
7
 cells and incubated at 4 
°C for 20 minutes.  Cells were placed in a Dynal MPC-L magnet and washed three 
times by addition of 2 mls MACS buffer and removal of supernatant.  Bead- bound 
cells were then resuspended in RPMI supplemented with 1% FCS and Detachabeads 
were added at the recommended concentration.  After a 45 minute incubation at room 
temperature, cells were applied to the Dynal MPC-L magnet for 2 minutes and 
washed three times.  Dynabeads attached to Detachabeads were retained on the Dynal 
MPC-L magnet while the supernatant containing CD4
+ 
T cells was carefully removed.  
Collected cells were then twice reapplied to the Dynal MPC-L magnet to remove 
residual Dynabeads.  The purity of the positively selected CD4
+
 population was 
determined using flow cytometry analysis. 
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2.1.4   Positive isolation of CD3
+
 lymphocytes 
Isolation of CD3
+
 T cells was performed using CD3 Dynabeads (Invitrogen) as per 
manufacturer’s instructions.  Peripheral blood lymphocytes obtained from elutriation 
were stained with FlowComp Human CD3 antibody at 4 °C for 15 minutes.  Cells 
were then washed in MACS buffer, supernatant discarded and the pellet resuspended 
in 1ml separation buffer.  FlowComp Dynabeads were added at the recommended 
concentration to the cell suspension.  After a 15 minute incubation, the bead- bound 
cells were twice added to a Dynal MPC-L magnet for 4 minutes and supernatant 
carefully removed.  The bead- bound cells were then resuspended in 1 ml FlowComp 
Release buffer and incubated at room temperature for 10 minutes.  Cells were mixed, 
added to MACS buffer and placed in the Dynal MCP-L magnet for 7 minutes.  The 
supernatant was carefully collected and reapplied to the Dynal MCP-L magnet to 
remove residual beads.  Purity of CD3
+
 isolated population was checked using flow 
cytometry analysis.  
 
2.1.5   Isolation of RA synovial membrane mononuclear cells  
Synovial RA tissues were procured from RA patients undergoing joint replacement 
surgery at Bath, Central Middlesex, Swleoc, Charing Cross and Edinburgh hospitals.  
All procedures received local ethics committee approval (Riverside Research Ethics 
Committee number 1752).  RA tissue was obtained from patients fulfilling the 
American College of Rheumatology criteria for RA.  Synovial membrane 
mononuclear cells were isolated according to the protocol published by our group 
(Beech et al. 2007).  Synovial cells were extracted by tissue digestion using 
collagenase (5 mg/ml) and DNase (0.15 mg/ml) dissolved in RPMI supplemented 
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with HEPES, for up to 90 minutes shaking at 37 °C.  The reaction was stopped using 
ice cold RPMI supplemented with 10 % FCS and 1 % penicillin/ streptomycin.  
Liberated cells were separated from the rest of the tissue using cell strainers, washed 
three times in RPMI 1640 for 10 minutes at 250 g, and counted.  Synovial membrane 
mononuclear cells were isolated from synovial tissue by Ms Renee Best and Ms 
Hayley Thompson  
 
2.1.6   Preparation of synovial fibroblast- like synoviocytes 
To obtain fibroblasts from synovial tissue, synovial membrane mononuclear cells 
isolated as in section 2.1.5 were seeded in a T25 culture flask in RPMI media 
supplemented with 10 % FCS and 1 % penicillin/ streptomycin and incubated at 37 
°C and 5 % CO2.  After approximately 24 hours, non adherent cells were removed and 
fresh culture media added.  Cells were split as appropriate using trypsin and re-seeded 
in fresh media.  Fibroblast- like synoviocytes cells were used at passage (P) 1 or P2 in 
all experiments. 
 
2.1.7   Isolation of Human Umbilical Vein Endothelial Cells (HUVEC) 
Human umbilical cords were collected from Chelsea and Westminster Hospital 
(London, UK) with informed consent, after approval by the Riverside Research Ethics 
Committee (RREC 2948).  HUVECs were isolated by enzymatic digestion as 
previously described (Paleolog et al. 1994).  Briefly, cords were digested in 0.05 % 
collagenase A (Boehringer Mannheim UK, East Sussex, UK) for 10 minutes and 
cultured as described in section 2.01.  To passage the HUVEC, the cells were washed 
with serum- free RPMI and 4 ml of trypsin (0.05 % w/v) was added and incubated for 
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3 minutes.  The cells were then resuspended in 30 mls HUVEC media.  Each T25 or 
T75 tissue culture flask was coated with 1 % gelatin for one hour, and 10 mls 
HUVEC were added to each flask.  The cells were cultured for two- five passages 
prior to use.  HUVEC were isolated from umbilical cords by Mr Leigh Madden and 
Ms Ilona Kruszynska- Ziaja. 
 
2.2   Stimulation of lymphocytes 
2.2.1   Stimulation of CD4
+
 T cells with TNFα, IL-2 and IL-6 
Purified CD4
+
 T lymphocytes isolated as described in section 2.1.3 were cultured at a 
cell density of 1x10
6
/ ml in RPMI supplemented with 10 % human serum obtained 
from donors of the AB blood group and IL-2 (25 ng/ml), TNFα (25 ng/ml) and IL-6 
(100 ng/ml) for 8 days at 37 °C and 5 % CO2.  In this thesis, T cells activated in this 
manner are referred to as cytokine activated T cells, or Tck. 
 
2.2.2   Stimulation of CD4
+
 T cells with anti CD3/ anti CD28 antibodies 
Prior to culture, 6 well plates were coated with anti CD3 (5 µg/ml) in sterile PBS and 
incubated for 24 hours at 4 °C.  The plates were then washed three times with sterile 
PBS before the cells were added.  CD4
+
 T lymphocytes were cultured on the plate 
bound anti CD3 at a concentration of 1x10
6
/ ml in RPMI supplemented with 10 % 
FCS and soluble anti CD28 (4 µg/ml) for 24 hours at 37 °C and 5 % CO2.  Cells were 
harvested by washing the plate three times.  In this thesis, T cells stimulated in this 
manner are referred to as T cell receptor activated T cells, or Ttcr.   
 
 
Chapter Two: Materials and Methods 
 
127 
 
2.3   Cell viability and cell counting 
For all studies cell viability was determined.  Trypan Blue is a dye that is excluded 
from cells with intact membranes, but is taken up by dead and dying cells.  For 
counting, cells were diluted 1:1 in 0.4 % trypan blue solution (Sigma- Aldrich) and 
applied to a haemocytometer for counting.  The number of cells in a 16 square area 
was counted in four different quadrants, averaged and multiplied by 1x10
4
 to calculate 
the number of cells/ ml.  This number was then multiplied by 2 to allow for the trypan 
blue dilution factor, and multiplied by the volume of cell suspension to determine 
total cell number. 
 
2.4   Cell cryopreservation 
In some instances it was necessary to cryopreserve CD4
+
 T cells, monocytes or RA 
synovial mononuclear cells for use in future experiments.  Cells were resuspended in 
ice cold FCS supplemented with 10 % DMSO at a cell density of 1x10
7
/ml and 
immediately transferred for storage at -80 °C.  To thaw frozen cells, they were 
warmed up rapidly in a water bath at 37 °C.  Pre- warmed RPMI 1640 supplemented 
with 10 % FCS was added dropwise to the thawing cells and DMSO removed by 
washing cells three times.  For some studies it was also necessary to rest thawed cells 
for 1-2 hours at 37 °C and 5 % CO2 prior to use to allow surface expression of some 
markers to be re-expressed.  
 
2.5   T cell: monocyte co-cultures 
Effector function analysis of Tck was performed as a measure of the ability of Tck to 
activate monocytes to produce pro-inflammatory mediators.  A cell- cell interaction 
assay using autologous T cells and monocytes was performed, followed by analysis of 
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mediators produced by the interaction. After the 8 days in culture in the presence of 
TNFα, IL-2 and IL-6, Tck were resuspended at a concentration of 8x106/ ml. 
Monocytes were thawed out and resuspended at a concentration of 1x10
6
/ ml. They 
were then plated at 100 µl/ well in a 96 well plate and incubated at 37 °C for 30 
minutes. The Tck were added to the monocytes at T cell to monocyte ratios ranging 
from 1:1 to 8:1. Monocytes were stimulated with 10 ng/ml LPS as a positive control. 
Volumes were made up to 200µl/ well and incubated at 37 °C and 5 % CO2 for 18 
hours. Supernatants were removed and frozen for ELISA analysis.  
 
2.6   Flow Cytometry 
2.6.1   Flow cytometry: principle of technique 
Flow cytometry is the measurement of cell phenotype on a single cell basis.  A flow 
cytometer consists of a flow cell, optics, lasers, detectors and an amplification system, 
and a computer to analyse the data.  Cells suspensions, labelled with fluorochrome- 
conjugated antibodies are passed through the flow cell which places the cells in single 
file to pass through a beam of light of a single wavelength.  Detectors are placed to 
measure forward and side scatter of the cells as a measure of size and granularity, and 
fluorescence.  The extent to which the cell scatters the light beam and cell-bound 
fluorochromes emit light of varying wavelengths are detected and translated into 
differences in brightness and fluorescent emission peaks which differentiate between 
each cell passing through the machine.  This data can be analysed on the computer to 
ascertain cell size, granularity and phenotype.  Machines can have different numbers 
of lasers allowing increasing combinations of fluorochromes to be used in a single 
cell suspension.  At present, up to four lasers and 18 fluorescent detectors are 
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available for one machine, with many types of fluorochrome congugates available to 
use with a given antibody.  
The advantages of the technique are that cells can be analysed in distinct populations, 
including accurate qualitative analysis of cell surface and intracellular phenotype, cell 
cycle analysis and changes in intracellular calcium.  Fixed cells and samples with very 
low cell numbers can also be analysed.  However, solid tissues cannot be analysed 
without their disintegration, and flow cytometers are expensive to buy and run.   
For all studies excluding chemotaxis and checkerboard studies, 10,000 events were 
acquired.  Once a sample has been acquired, the data can be uploaded to data analysis 
packages. For the studies described in this thesis, all data was analysed using FlowJo 
(Treestar, Ashland, Oregon). Initially, dead cells are excluded, as their 
autofluorescence would skew analysis of fluorochrome- bound cells. The live 
population can then be analysed for the cell-bound fluorochrome- conjugated 
antibody in question by measuring the mean fluorescent intensity (MFI), which is the 
area under the curve on the histogram divided by the events. 
 
2.6.2   Determination of cell surface phenotype by flow cytometry  
Flow cytometry was used to analyse the phenotypes of a number of cell types, 
including T cells, monocytes, macrophages, HUVEC and RA synovial cells.  Cells 
were counted and resuspended in FACS buffer, at approximately 5x10
5 
cells/ tube.  In 
the analysis of HUVEC and RA synovial cell phenotype, cells were first incubated for 
30 minutes in the presence of 10 % human serum to block the Fc receptors and reduce 
non-specific staining.  Antibodies were titrated and an optimum concentration was 
added to the cell suspension.  Cells were incubated on ice for 30 minutes.  Excess 
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antibody was washed off using centrifugation at 700 g for 3 minutes.  Stained cells 
were resuspended in FACS buffer for analysis.  Cells being kept overnight were fixed 
in 1 % paraformaldehyde.  In each case, 10,000 events were acquired on the BD 
CANTO II flow cytometer and dead cells excluded by propidium iodide (PI) staining 
to detect apoptotic cells.  Dead cells were also excluded using forward and side scatter 
analysis to separate the dead and live cell populations.  Data was analysed using 
FlowJo and graphed using mean fluorescent intensity (MFI) levels of each given 
molecule. 
 
2.6.3   Phosflow analysis of CD4
+
 T cells 
The phosphorylation status of T cell subtypes was determined using intracellular flow 
cytometry.   Cells were harvested and immediately fixed by adding an equal volume 
of pre-warmed cytofix buffer (BD Pharmingen) and inverting several times.  Cells 
were incubated for 15 minutes at 37 °C and then washed for 5 minutes at 400 g.  
Supernatants were removed; the cell pellet resuspended in 1 ml Perm buffer III (BD 
Pharmingen) and the samples incubated on ice for 30 minutes.  Cells were then 
washed twice and resuspended in TBS buffer.  Fluorochrome- conjugated antibodies 
and isotype controls were added at 10 µl/ sample and incubated at 4 °C for 25 
minutes.  Samples were then washed, the supernatant removed and resuspended in 
100 µl of TBS buffer for analysis on the CANTOII (BD). In each case, 10,000 events 
were acquired.   
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2.7   Enzyme-linked immunosorbent assay (ELISA) 
2.7.1   Principle of technique 
ELISA is a biochemical technique used to detect the presence of an antigen or 
antibody in a sample. The sample is immobilized on a 96 well plate either via non 
specific adsorption to the plate surface in a direct ELISA, or specifically to an 
antibody against the antigen in question, termed a sandwich ELISA. In both cases non 
specific binding is blocked by coating the plate in bovine serum albumin (BSA) or 
powdered milk which binds to all non-specific sites and prevents the sample from 
doing so. The plates are washed with PBS Tween in between each step.  A standard 
curve of the antigen with known concentrations is added concomitantly with the 
samples for quantification of antigen concentration within the sample.  A detection 
antibody conjugated to an enzyme is then added which binds to the sample and 
standards.  In the direct ELISA, this is the primary conjugate antibody, in the 
sandwich ELISA, the secondary conjugate antibody. The enzyme substrate is 
subsequently added to create a colorimetric reaction to take place, which can be read 
at certain absorbances to detect the signal of the samples compared to the standards of 
known concentration. Acid is used to stop the reaction.   
The broad advantages of ELISA are that many samples can be tested at once, with 
high specificity and sensitivity for most antigens. However, ELISA antibody kits are 
expensive and the assay can take up to two days to complete. The advantages and 
disadvantages of direct and sandwich ELISAs are summarized in the table below. 
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ELISA  Advantages Disadvantages 
Direct  Fewer incubation steps 
 No cross reactivity with 
secondary antibody 
 No signal amplification 
 Primary antibody is 
labeled thus may lose 
immunoreactivity 
Sandwich  Increased sensitivity through 
more epitopes contained in 
primary antibody 
 Immunoreactivity of primary 
antibody retained as it is not 
labeled 
 Possibility of cross 
reactivity with secondary 
antibody 
 More incubation steps so 
assay takes longer 
 
Table 2.3 Advantages and disadvantages of ELISA subsets 
 
2.7.2   ELISA analysis of cell supernatants 
Cytokine protein levels from cell culture supernatants were analysed using sandwich 
ELISAs.  All ELISAs were done in 50 µl volumes in high protein affinity EIA/ RIA 
96 well plates (Costar).  High binding ELISA plates were coated overnight with 
mouse anti-human capture antibodies against the cytokine being measured at the 
concentrations indicated in Table 2.2, and blocked with 2 % BSA for one hour at 
room temperature.  The plates were washed 5 times in between each step with PBS 
Tween.  Protein standards and cell supernatants were incubated for a minimum of 2 
hours at room temperature.  Biotinylated detection antibodies were then added for 1 
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hour at the concentrations indicated in Table 2.2, followed by incubation with 
streptavadin- horseradish peroxidase (HRP).  A solution of 50:50 TMB peroxidase 
substrate with hydrogen peroxide was used to develop the assay.  1M H2SO4 was used 
to stop the reaction.  The plates were read using a FLUOstar Omega plate reader 
(BMG Labtech) at 450 nm and the results analysed using Omega software (BMG 
Labtech).  Results were graphed as triplicate wells after subtracting the values for 
blank wells.   
 
2.8   In vitro Migration Assays 
2.8.1   Chemotaxis assays: overview of techniques 
The most common assays to determine cell chemotactic potential are variations on the 
Boyden technique, first described in 1962 (Boyden 1962). The original apparatus 
consisted of a chamber with upper and lower compartments separated by a filter 
membrane.  The cells were added to the upper compartment with the chemoattractant 
added to the lower compartment and incubated for three hours.  The filter was then 
fixed, dried and cells counted using microscopy.  More recent variations on this 
technique involve the use of multiwell plates to allow for analysis of many samples 
simultaneously followed by phenotypic analysis of migrated cells.  In some cases, the 
chambers are side by side on a glass slide connected by a bridge which allows 
development of the concentration gradient.  A glass coverslip covers the chambers 
and the migrating cells can be directly counted using microscopy (Zicha et al. 1991). 
This is called a Dunn chamber.  These are the most common quantative assays used, 
however there are other more qualitative assays available.  While very useful to 
compare chemotactic responses of cell types to different chemokines and stimuli, 
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these chemotaxis assays have one major disadvantage in that all are performed under 
static conditions, without the application of shear flow to the migrating cells.   
 
2.8.2   Chemotaxis assays to recombinant chemokines  
Tck chemotaxis was investigated using a disposable 96 well chemotaxis assay 
(Receptor Technologies, Leamington Spa, UK) based on the Boyden chamber 
(Figure 2.1).  Cells were resuspended at 4x10
6
/ ml. 96 well chemotaxis plates were 
pre- blocked with RPMI media supplemented with 1 % BSA for 30 minutes at 37 °C.  
Cell dilutions were also incubated for 30 minutes in RPMI supplemented with 0.1 % 
BSA (assay buffer) prior to use.  Recombinant chemokines were diluted to the 
required concentrations in assay buffer and placed in the lower wells of the plate at 30 
µl per well, with assay buffer only as a control.  A standard curve of cells was also 
added for later analysis.  Cells were added at a concentration of 4 x 10
6
/ ml, with 2.4 x 
10
5
 cells added per well.  A serial dilution of cells was also added to the plate as a 
standard curve for quantification of percent chemotaxis.  After a two hour incubation, 
the migrated cells were removed from the lower wells, and were stained with flow 
cytometry antibodies for analysis using the CANTOII (BD).  It was important to 
establish an incubation time that is long enough to support chemotaxis, but not too 
long as to disrupt the chemoattractant gradient and result in chemokinesis.  For this 
reason, a time point of two hours was chosen.  The stained cells were then 
resuspended in an equal volume of FACS buffer.  Each well was read for 45 seconds 
at a medium flow rate to ascertain relative cell number.  Analysis was performed 
using FlowJo to ascertain live cell numbers, and Prism to calculate percent 
chemotaxis through non linear regression compared to the standard curve.  A worked 
example is detailed in Figure 2.2. 
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Figure 2.1 Chemotaxis assay experimental layout 
A chemoattractant was placed in the bottom well of the 96-well plate at various 
concentrations in a final volume of 30 µl and the membrane is place on top.  Resting and Tck 
cells were added to the upper wells and left to migrate down the chemotactic gradient formed 
by the chemoattractant in the lower wells of the plate.  After two hours cells were counted and 
stained for FACS analysis.  Percent chemotaxis was calculated by performing non linear 
regression on the standard curve with a line through the origin, and using it to interpolate the 
percent of the original cell number (2.4x10
5
/ well) that migrated from the upper to lower 
chambers.  
 
 
 
 
 
 
 
 
 
 
 
 
Drop of 
cells 
Well 
Membrane 
Migrating 
Cells 
Gradient 
Chemokine 
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Figure 2.2 Analysis of percent chemotaxis (worked example) 
After each well was acquired on the BD CANTOII, files were uploaded and a live cell gate 
added.  Live cell numbers for each well were then collated in an Excel file and raw cell 
numbers transferred to a Prism file.  As shown in (a), a standard curve of input cells was 
graphed and analysed by non- linear regression with a line through the origin from where the 
percentage chemotaxis of each raw cell number could be interpolated, as shown in (b).  The 
mean of each triplicate expressed as percent chemotaxis is illustrated in (c). 
 
 
 
STDs:Percentage 
of 
Input:(Interpolated) 
STDs:Tck Cell 
Number:(Entered) 
4.775273 1775.000 
5.644238 2098.000 
6.56432 2440.000 
13.67208 5082.000 
13.47031 5007.000 
16.90312 6283.000 
48.68088 18095.000 
30.24967 11244.000 
32.52028 12088.000 
3.349417 1245.000 
22.35366 8309.000 
7.511303 2792.000 
3.037342 1129.000 
1.132614 421.000 
2.168378 806.000 
5.770682 2145.000 
5.227242 1943.000 
3.438196 1278.000 
4.186099 1556.000 
3.352107 1246.000 
0.05918648 22.000 
(a) (b) 
(c) 
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2.8.3   Chemotaxis assays to cultured RA fibroblast- like synoviocytes (FLS) 
Tck migration to RA FLS was performed using a modified chemotaxis assay as 
described above (Section 2.8.2).  FLS (1 x 10
4
 per well) were plated in RPMI media 
supplemented with 5 % FCS and incubated overnight.  Tck were first stained with 
Carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Carlsbad, California).  
Prior to staining, cells were washed and resuspended in 10 mls PBS to remove 
residual serum.  CSFE was added at a final concentration of 5 µM and incubated at 
room temperature for 10 minutes. FCS (1 ml) was then added to stop the reaction and 
CFSE-stained cells were incubated on ice for a further 10 minutes. Cells were then 
washed three times in RPMI 1640 supplemented with 5 % FCS to remove residual 
CFSE. CFSE- stained Tck were then added to the upper wells (2.4x10
5
 cells per well) 
in a final volume of 60 µl.   
After incubation at 37 °C for 2 hours, the migrated cells were collected from the 
lower wells.  The migrated cells were resuspended in an equal volume for analysis 
using the CANTOII (BD) based on CFSE expression.  Each well was read for 45 
seconds at a medium flow rate to ascertain relative cell number.  Analysis was 
performed using FlowJo to ascertain live cell numbers, and Prism to calculate percent 
chemotaxis through non linear regression compared to a standard curve.  
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2.8.4   Checkerboard assays 
To determine whether the migratory response of the Tck was chemotactic or 
chemokinetic for the chemoattractants tested, checkerboard analysis was performed.  
Similar to the 96 well chemotaxis assay, the range of chemokine concentrations was 
placed in both the upper and lower chambers.  The assay was completed as before 
(Section 2.8.2).  If migration occurs in both the presence and absence of a 
chemoattractant gradient, the response is chemokinetic in nature.  However if 
migration occurs only in the presence of a chemokine gradient, the response is 
chemotactic in nature.  This assay can give further information on the nature of the 
migration observed. 
 
2.8.5   Blocking studies  
In order to investigate important molecules in Tck migration, blocking antibodies and 
inhibitors were used.  The assay was executed as before, however Tck were incubated 
with a final concentration of 10 µg/ml blocking antibodies to VLA-4 or an IgG1 
isotype control, or 50 µg/ml CXCR4 small molecule inhibitor AMD3100 at room 
temperature for 30 minutes prior to the assay.  The cells were then added to the upper 
wells and incubated for 2 hours at 37 °C and 5 % CO2.  For studies investigating Tck 
migration to RA fibroblast- like synoviocytes, Tck were incubated with blocking 
antibodies as described.  FLS which had been plated out overnight were blocked by 
removal of the supernatant from the overnight incubation, followed by addition of 30 
µl media containing either isotype control or blocking antibodies at a final 
concentration of 10 µg/ml.  The membrane was placed above the lower chambers and 
incubated at room temperature for 30 minutes prior to addition of T cells.  
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2.9   Transendothelial migration assays 
2.9.1   Principle of technique 
Assays to explore in vitro transendothelial migration (TEM) are mainly based on the 
Boyden chamber and can be divided into two categories- shear stress and static.  In 
contrast to the chemotaxis assay, the filters are coated with collagen, gelatin or 
fibronectin upon which a confluent monolayer of endothelial cells is cultured.  The 
monolayer can then be stimulated by pro-inflammatory cytokines to up-regulate 
integrin ligands and chemokines.  In the static assay, cells are added to the top of the 
monolayer and they transmigrate through to the media or chemoattractant in the lower 
chamber over 24 hours.  Cells can then be counted and phenotyped using flow 
cytometry.  
Transendothelial migration assays can also be performed under shear stress.  Shear 
stress can be defined as the tangential force per unit area that is exerted by flowing 
fluid on the surface of the conduit tube (Toetsch et al. 2009).  This is a more 
physiologically relevant approach to studying TEM as shear stress also up-regulates 
integrin affinity on the monolayer, and mimics the stress exerted by blood flow in 
vivo.  These assays also have the advantage of having much shorter incubation times.  
However, it has been shown that similar results can be obtained by both methods 
(Muller 2009).  All in vitro migration assays described in this thesis were performed 
under static conditions. 
 
2.9.2   Preparation of HUVEC cell monolayers 
HUVEC were prepared as described before (Section 2.1.7).  24 hours prior to the 
assay HUVEC media was replaced with media containing 10 ng/ml TNFα.  
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Transwell
® 
6 or 12 well plate inserts with a pore size of 3 µm were coated with 1 % 
fibronectin for 90 minutes at 37 °C.  TNFα- stimulated HUVECs were washed twice 
with serum free media to remove residual serum and 4 ml of trypsin was added for 3-
5 minutes at 37 °C.  HUVEC media was added and the HUVEC washed for 10 
minutes at 250 g.  Cells were then resuspended at 1x10
5
 cells/ ml in HUVEC media 
supplemented with 10 ng/ml TNFα and added to the upper chamber of the insert.  2.6 
ml HUVEC media was added to the lower chamber and the system was left to 
equilibrate overnight.   
 
2.9.3   CD4
+
 T cell transmigration assays  
Transendothelial migration analysis of resting, Ttcr and Tck cells were performed 
using a modified Boyden chamber with confluent HUVEC monolayers on 6 or 12- 
well Transwell inserts, prepared as detailed above (Section 2.9.2).  Prior to addition 
of T cells, HUVEC experimental media was removed from upper and lower wells, 
and RPMI with 5 % FCS was added to the lower chamber.  Cells were added to the 
upper chambers of each insert; 5x10
6
 cells per well in a 6 well plate, 1x10
6
 cells per 
well in a 12 well plate.  The assay was incubated for 24 hours at 37 °C and 5 % CO2.   
To calculate the rate and total percent migration of the cell types, 100 µl was taken 
from the bottom chamber of each sample.  From this sample, 10 µl was used for cell 
counts.  Samples were taken at 2, 4, 6, 8 and 24 hours, with 100 µl RPMI replaced at 
each point.  The cells removed were then taken into account when analysing percent 
migration at each time point.   
Supernatants were taken from both top and bottom chambers for ELISA analysis of 
VCAM-1 concentrations (section 2.7) and for phenotypic analysis of the migrated and 
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non migrated cells by flow cytometry (section 2.6).  This data was compared to 
phenotypic analysis of the input cells.   
 
2.9.4   Blocking studies  
In order to investigate important molecules in Tck migration, cells were pretreated 
with blocking antibodies.  The assay was executed as before, however Tck were 
incubated with a final concentration of 10 µg/ml blocking antibodies to VLA-4 or an 
IgG1 isotype control at room temperature for 30 minutes prior to the assay.  The cells 
were then added to the upper wells and the assay conducted as outlined in section 
2.9.3.   
 
2.10   In vivo migration assays 
2.10.1   Breeding and maintenance of SCID/Beige colony 
Breeding and maintenance of the colony was carried out by Charles River UK.  A 
breeding pair of SCID/Beige mice was obtained from an existing colony and progeny 
were weened and monitored.  Mice were used from the age of 5-6 weeks and 
transported to the Kennedy Institute from a week to ten days before the experiment 
start date. 
 
2.10.2   RA tissue procurement and processing  
OA and RA tissues were procured from Bath, Central Middlesex, Swleoc, Charing 
Cross and Edinburgh hospitals.  For use in the RA/SCID mouse model the procured 
synovium was separated from the fat and cut into small circular pieces of approx 
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20mm in diameter.  These were cryopreserved in 20 % FCS in DMSO and stored in 
liquid nitrogen until use.    
 
2.10.3   Implantation of tissue into SCID/Beige mice 
SCID/Beige mice of approx 6-8 weeks old were anaesthetised using Hypnorm and 
Hypnovel.  The depth of anaesthesia was measured by testing the pain response of 
pressure on the hind paw.  When full anaesthesia was obtained, a small shallow 
incision was made behind each ear.  A piece of tissue of approx 3 mm was then 
inserted subcutaneously and the incision sutured.  The mice were closely monitored 
until recovery.  The grafts were left to vascularize for two weeks. 
 
2.10.4   PKH26 staining of resting and Tck for injection 
Cells were harvested and resuspended at 20x10
6
/ ml in Diluent C, and an equal 
measure of diluted dye was then added to obtain a final concentration of 5 µM.  The 
solution was left for 2 minutes and the reaction stopped by FCS for 1 minute.  The 
volume was brought up to 5mls using RPMI and washed three times for 5 minutes at 
1500 rpm.  The cells were then counted and resuspended as required.  
 
2.10.5   Indium labeling of resting and Tck for injection 
2 mCi 
111
Indium in sterile 0.05 M HCl (PerkinElmer, Waltham, Massachusetts) was 
purchased and stored at room temperature in lead containment.  Prior to use, 100 µl 2-
mercaptopyridine-N-oxide was added per 0.1 mCi and incubated in the dark and at 
room temperature for 10 minutes in lead containment.  Cells were resuspended as 
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required and added to the 
111
InCl3 solution, at a final activity of 10 µCi per 2x10
6
 
cells, and incubated at room temperature for 15 minutes.  Cells were then washed 
three times in 10 ml PBS for 5 minutes at 400 g.  A standard curve was obtained by 
serial dilutions of the labeled cells, for calculation of the number of cell- bound 
111
In 
counts and for later calculation of percent migration of labeled cells. 
 
2.10.6   Injection of PKH26 stained cells into SCID/Beige mice 
PKH26 stained Resting and Tck cells were washed and counted as detailed above.  
Cells were resuspended at 5x10
7
/ml, with each mouse receiving 5x10
6
 cells in a final 
volume of 100 µl.  Cells were injected intravenously through the tail vein or 
intraperitoneally using an insulin needle.  At the same time as the cells were injected, 
200 ng of TNFα diluted in RPMI supplemented with 5 % FCS was injected into each 
graft, in a final volume of 10 µl.   
 
2.10.7   Injection of Indium labelled cells into SCID/Beige mice 
Resting and Tck cells were labelled as described above and resuspended in a final 
volume of 50x10
6
/ ml, with each mouse receiving 5x10
6
 cells in 100 µl.  Mice were 
placed in a restrainer behind a lead barrier and cells were injected intravenously 
through the tail vein using an insulin needle.  At the same time as the cells were 
injected, 200 ng of TNFα diluted in RPMI supplemented with 5 % FCS was injected 
into each graft, in a final volume of 10 µl.   
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2.10.8   Culling of animals and processing of grafts after injection of PKH26-
stained cells 
Animals were culled by a CO2 overdose and a dorsal incision was made.  Grafts were 
examined for the presence of anastomoses and excised with a scissors.  From each 
mouse, one graft was snap frozen for preparation of sections for microscopy.  The 
other graft was placed in RPMI 1640 supplemented with 5% FCS for enzymatic 
dissociation.  In some cases the spleen, liver and lymph nodes were also harvested.  
Grafts were dissociated using collagenase as described in section 2.4.7.  After three 
washes, cells were counted and resuspended in FACS wash buffer.  Cells were stained 
with anti-human CD45- FITC for 25 minutes, washed, and samples were read on 
CANTOII.  PKH26 was read in the PE channel and gates were placed relative to the 
control grafts from mice which had not received cells.  To accurately quantify the 
absolute number of cells in each sample, 50 µl Countbright absolute counting beads 
(Invitrogen) were added to each sample immediately prior to reading on the flow 
cytometer.  Samples were acquired based on 10,000 Countbright bead events, and 
concentration of sample as cells/ µl was calculated based on the following equation;  
(number of cell events/ number of bead events) x (assigned bead count/ tube (beads/ 
50 µl)/ volume of sample (µl)) 
 
2.10.9   Culling of animals and processing of grafts after injection of Indium-
labelled cells 
Animals were culled using CO2.  The grafts, the liver, spleen, lymph nodes, lung, 
heart, femur, kidney and a blood sample were isolated and placed in separate tubes.  
Tissue levels of 
111
Indium were measured using a Packard Cobra 5005 gamma 
Chapter Two: Materials and Methods 
 
145 
 
counter (Connecticut, USA) with detectors normalised for the radioisotope.  Each 
sample was counted for 60 seconds over 100- 500 KeV and corrected for spilldown 
and spillup.   
 
2.10.10   Air Pouch model 
To act as an alternative model to the RA/SCID model, the air pouch model was used 
to study Tck migration.  SCID/ Beige mice of approximately 6-8 weeks of age were 
anaesthetised using isofluorane, and 5 mls of air injected subcutaneously to form a 
dorsal pouch.  Animals were monitored for 5 days and the dorsal pouch maintained by 
addition of a further 1 ml of air on day 5.  On day 6, the dorsal pouch was stimulated 
by injection of 1 mg zymosan in a final volume of 100 µl PBS directly into the graft.  
Control groups received 100 µl PBS.  In some studies zymozan was replaced with 10 
ng CXCL12 or 50 ng TNFα. Tck were stained with PKH26 (5 µM) as described 
(section 2.11.4) and 3-10 x10
6
 cells in 100 µl RPMI supplemented with 5 % FCS 
were injected intravenously 4 hours after pouch stimulation.  Control groups received 
RPMI only.  Animals were culled using CO2 at different time points after Tck 
injection, the dorsal pouch washed with 5 ml PBS and the exudates collected for 
counting and phenotypic analysis using flow cytometry.  
 
2.11   Statistics  
Graphpad Prism was the statistical package used in all data analysis in this thesis.  
Data was initially analysed for Gaussian distribution using the Kolmogarov- Smirnov 
(KS) and the D’Agostino-Pearson tests.  The data was then analysed based on the 
results of these tests.  In the case of paired groups of results, the Wilcoxon Rank Sum 
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test (non- Gaussian) or paired T test (Gaussian) were used.  If the two groups were 
unpaired, the Mann-Whitney (non- Gaussian) or unpaired T tests were used.  If more 
than two groups were being compared, the Kruskal-Wallis (Non-Gaussian), or one-
way ANOVA (Gaussian) analysis was applied.  In the case of ANOVA, Bonferroni or 
Dunn’s post tests were also used.  If the data groups represented matched observations 
and was normally distributed, a repeated- measures ANOVA was applied.  In analysis 
of standard curves to calculate unknowns in chemotaxis assays, non-linear regression 
analysis with a line through the origin was employed.  In analysis of standard curves 
for ELISA unknown calculations, 4-parametric curve analysis was applied.   
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3.0   Introduction 
It is known that the RA joint is a pro-inflammatory environment where cell-cell 
interactions between expanded joint fibroblasts and resident macrophages, and 
recruited lymphocytes, monocytes and B cells induce cytokines such as TNFα, IL-6, 
IL-1, GM-CSF and the chemokine IL-8 (Buchan et al. 1988; Buchan et al. 1988; 
Hirano et al. 1988; Brennan et al. 1990; Haworth et al. 1991).  Previous work in our 
group demonstrated that peripheral blood T cells cultured in the presence of TNFα, 
IL-6 and IL-2 for eight days could induce monocyte pro-inflammatory cytokines in an 
identical way to T cells isolated from RA synovial cell cultures.  This was found to 
occur most potently within the effector memory subset, a T cell subset known to be 
present in RA joint tissue (Brennan et al. 2008; Cope 2008). 
   
The cell surface phenotype of these cytokine- activated T cells, termed Tck, was 
extensively characterised and compared to RA synovial T cells, and was demonstrated 
to exhibit not only an activated phenotype but also a phenotype that would indicate 
support of cell-cell interactions and potentially migration (Brennan et al. 2002; Beech 
et al. 2006; Brennan et al. 2008; Cope 2008).  Previous work showed that expression 
of the activation markers CD69, CD25, CD62L, the chemokine receptor CXCR4 and 
the integrins CD18 and CD49d were upregulated after cytokine stimulation.  These 
cytokine- activated T cells have been used as a surrogate model in studies of RA T 
cells to allow more in depth studies of the RA T cell without the constraint of cell 
numbers from synovial biopsies.  
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The aim of this chapter was 
 To determine expression levels of a further panel of T cell activation markers, 
chemokine receptors, integrins and integrin ligands on resting and Tck cells, 
by flow cytometry, in addition to those previously published by our group 
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3.1   Enrichment for CD4
+
 T cells results in a pure population 
In the experiments outlined in this thesis, all analyses were performed on CD4
+ 
T cells 
enriched from peripheral blood mononuclear cells using immunomagnetic bead 
selection.  To ensure a highly enriched population of CD4
+
 T cells was obtained after 
positive selection, purity was routinely investigated using flow cytometry.  Data from 
a representative donor is shown in Figure 3.1.  In this donor the PBMC starting 
population obtained from density gradient centrifugation of peripheral blood 
constituted approximately 22 % CD4 positive cells (Figure 3.1 a).  The lymphocyte 
population was purified by elutriation prior to CD4
+
 enrichment.  A population 
approximately 98 % positive for CD4 expression was obtained (Figure 3.1 b i).  
Contamination from CD8
+
 T cells, CD56
+
 NK cells or CD19
+
 B cells was also 
measured by flow cytometry.  There was a small population of contaminating cells 
expressing CD8, CD56 and CD19 (1- 3.5 % of total population) on the day of 
isolation (Figure 3.1 b ii, iii). 
The CD4
+ 
T
 cells were then cultured in the presence of TNFα, IL-2 and IL-6 for eight 
days.  The percentage of CD4
+
 cells in the culture was maintained over this culture 
period (Figure 3.1 c i).  Contaminating CD8 T cells, NK cells and B cells were not 
significantly expanded in response to cytokine stimulation (Figure 3.1 c ii, iii).  
However for all subsequent phenotypic analysis, cells were gated on the CD4
+
 
population prior to evaluation of marker expression to ensure a homogenous 
population of cells were analysed.  In the following experiments the phenotype of 
CD4
+
 Tck cells was compared to that of resting CD4
+
 cells.  In particular, changes in 
expression of T cell activation markers, chemokine receptors and adhesion molecules 
were investigated. 
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Figure 3.1 Enrichment for CD4
+
 T cells results in a pure population 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days (Tck).  Cells were washed, stained and analysed by flow cytometry. 
Shown are dot plots from a representative donor showing a) CD4
+
 cells in the starting PBMC 
population and , i) CD4+ cells, ii) CD8
+
 / CD56
+
 cells and iii) CD19
+ 
cells post  
immunomagnetic bead selection (b) and after eight day cytokine stimulation (c).  Gates and 
quadrants applied are relative to unstained populations 
(d) 
(a) Starting PBMC population 
(b) Post immunomagnetic bead selection 
(c) Post eight day cytokine stimulation 
(i) CD4
+ 
(ii) CD8
+
/ CD56
+
 (iii) CD19
+
 
(i) CD4
+ 
(ii) CD8
+
/ CD56
+
 (iii) CD19
+
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3.2   Cytokine stimulation increases expression of CD25, CD38, CD69 and 
CD62L activation markers 
Previous studies in the lab used CFSE labelling to demonstrate that cytokine 
stimulation induced T cell proliferation (Brennan et al. 2008).  To determine if 
cytokine stimulation induced expression of T cell activation markers, flow cytometry 
analysis was performed.  Data from a representative donor is shown in figure 3.2, 
with mean fluorescent intensity (MFI) values from all donors collated in figure 3.3.  
Quadrant gates were placed based on isotype control staining counterstained with an 
anti-CD4 antibody in all cases as shown in figure 3.2 a and b, and MFI values of each 
marker calculated on the live cell population.  
 Flow cytometry analysis revealed increased expression of the IL-2 receptor alpha 
chain CD25 in response to cytokine stimulation, from 4 % on resting T cells, to 35 % 
positive cell expression on Tck relative to the isotype control (Figure 3.2 c).  This 
was accompanied by a significant mean fold increase in MFI of 10 (p< 0.0001) with 
reference to resting cells, when data from all donors were analysed (Figure 3.3 a).  
The activation marker CD38 was minimally expressed on resting T cells (3 %) which 
was increased to 25 % positive cell expression after cytokine stimulation (Figure 3.2 
d).  A significant increase in the MFI of 4.4- fold after cytokine activation was also 
observed (p= 0.001) (Figure 3.3 b).  Increased expression of the early T cell 
activation marker CD69 was also observed (Figure 3.2 e).  CD69 was not expressed 
on resting T cells; however it was expressed by approximately 43 % of Tck relative to 
the isotype control antibody, concomitant with a 6.5- fold increase in MFI after 
cytokine stimulation (p< 0.0001) (Figure 3.3 c).  L- selectin (CD62L) was expressed 
on resting cells (25 %), however there was a three- fold increase in Tck positive cell 
expression (68 %), (Figure 3.2 f).  A mean MFI fold increase of 5.5 was also 
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observed after cytokine activation (p< 0.0001) (Figure 3.3 d).  These results are in 
accordance with results published by our group (Brennan et al. 2008). 
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Figure 3.2 T cell activation markers are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were washed, stained and analysed by flow cytometry on the 
day of isolation (resting T cells- left panels) and after cytokine stimulation (Tck- right panels).  
Shown are representative dot plots of positive cell expression of a) IgG1, b) IgG2a, c) CD25, 
d) CD38, e) CD69 and f) CD62L on resting and Tck cells. Gates on c) to f) applied based on 
isotype control staining or unstained cells. 
(a) 
(b) 
(d) 
(e) 
(f) 
(a) (c) 
(a) 
(b) (a) 
(e) 
(f) 
Resting 
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Figure 3.3: T cell activation marker expression is upregulated on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown are the mean 
fluorescence intensity (MFI) values of a) CD25, b) CD38, c) CD69 and d) CD62L on resting 
and Tck cells.  Significance ascertained using the Wilcoxon Rank test, *** p< 0.001 
(a) (b) 
(d) (c) 
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Activation 
Marker 
Median 
MFI 
(Range) 
Resting 
Median 
MFI 
(Range) 
Tck 
Mean 
Fold 
increase 
(SD) 
p value n 
      
CD25 628 
(96-1851) 
4114 
(1389-
14646) 
9.8 (10) <0.0001 (***) 25 
CD38 214 
(43-694) 
900 
(174-3085) 
4.4 (4.8) 0.0010 (***) 12 
CD69 216 
(53-606) 
1309 
(268-3848) 
6.6 (7.1) <0.0001 (***) 24 
CD62L 1337 
(115-11550) 
9507 
(153-33024) 
5.5 (3.3) <0.0001 (***) 24 
      
 
Table 3.1: T cell activation markers are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4+ T cell population by positive immunomagnetic bead selection. 
CD4+ T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for each molecule calculated with reference to resting 
T cell values and significance ascertained using the Wilcoxon Rank test, *** p< 0.001. 
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3.3   Cytokine stimulation increases expression of CXC chemokine receptors 
Flow cytometry analysis was performed to investigate the expression of CXC 
chemokine receptors before and after T cell cytokine activation.  Data from a 
representative donor is shown in figure 3.4, with MFI data from all donors analysed 
illustrated in figure 3.5 and table 3.2.   
Flow cytometry analysis of the CXC receptors revealed a modest increase in 
expression of CXCR2, receptor of CXCL1 and CXCL2, in response to cytokine 
stimulation, from 4 % on resting T cells, to 11 % positive cell expression on Tck 
(Figure 3.4 a).  This was accompanied by a modest but significant mean MFI fold 
increase of 1.5 (p= 0.0181) after cytokine activation (Figure 3.5 a).  Cytokine 
stimulation also increased expression of CXCR3, receptor for CXCL9, CXCL10 and 
CXCL11, from 35 % on resting T cells, to 43 % on Tck (Figure 3.4 b).  However the 
mean MFI was not increased from resting T cells after cytokine stimulation when data 
from all donors was collated (Figure 3.5 b).  CXCR4, receptor for CXCL12, was not 
expressed on resting cells, however a marked increase in Tck positive cell expression 
was observed in response to cytokine stimulation (62 %), (Figure 3.4 c).  CXCR7, an 
alternative receptor for CXCL12, was minimally expressed on resting T cells (4 %) 
and modestly increased to 16 % positive cell expression after cytokine stimulation 
(Figure 3.4 d).  Cytokine stimulation also resulted in a significant increase in the 
mean MFI fold increase of CXCR4 (9.5- fold, p< 0.0001) (Figure 3.5 c), however the 
mean MFI of CXCR7 was only modestly increased by 1.9- fold (p= 0.0195) (Figure 
3.5 d). 
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Figure 3.4 CXC Chemokine receptors are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells- left panels) and after cytokine stimulation (Tck- right panels).  
Shown are representative dot plots of positive cell expression of a) CXCR2, b) CXCR3, c) 
CXCR4, and d) CXCR7 on resting and Tck cells. Quadrant gates applied based on isotype 
control staining. 
(f) 
(a) 
(d) 
Resting Tck 
(c) 
(d) 
(b) 
(a) 
Resting Tck 
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Figure 3.5: Expression of CXC chemokine receptors are upregulated on Tck  
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for a) CXCR2, b) CXCR3, c) CXCR4 and d) CXCR7. 
Significance was ascertained using the Wilcoxon Rank test. * p< 0.05, *** p< 0.001
(a) (b) 
(d) (c) 
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Receptor Median MFI 
(Range) 
Resting 
Median MFI 
(Range) 
Tck 
Mean 
Fold 
increase 
(SD) 
p value n 
      
CXCR2 2142 
(1197-6580) 
2557 
(1712-7636) 
1.5 (1.7) 0.0181 (*) 15 
CXCR3 1370 
(575-38799) 
1578 
(251-3139) 
- ns 16 
CXCR4 1291 
(100-4477) 
6437 
(290-29049) 
9.5 (30) <0.0001 (***) 34 
CXCR7 197 
(83-661) 
374 
(153-1234) 
1.9 (1.7) 0.0195 (*) 10 
      
Table 3.2: CXC Chemokine receptors are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for each molecule calculated with reference to resting 
T cell values and significance ascertained using the Wilcoxon Rank test. * p< 0.05,  *** p< 
0.001. 
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3.4   Cytokine stimulation increases expression of CC chemokine receptors 
To investigate if cytokine stimulation increased expression T cell CC chemokine 
receptors, cell surface expression of CC chemokines on resting and Tck were 
analysed using flow cytometry.  Data from a representative donor is shown in figure 
3.6, with MFI values from all donors analysed illustrated in figure 3.7 and table 3.3. 
Expression of CC receptors revealed that CCR5, receptor for CCL1, CCL3 and 
CCL5, was not expressed on resting T cells, which was not increased by cytokine 
stimulation (Figure 3.6 a).  However, on analysis of further donors, cytokine 
activation was found to increase the MFI, with a mean fold increase of 2 (p= 0.0106) 
with reference to resting cell values (Figure 3.7 a).  CCR6, receptor for CCL20, was 
also minimally expressed on resting T cells (2 %), and was also unaffected by 
cytokine activation in this particular donor (Figure 3.6 b).  However, analysis of data 
from all donors revealed a mean fold increase in MFI of 2.5 (p= 0.0053) (Figure 3.7 
b).  CCR7, receptor for CCL19 and CCL21, was neither expressed on resting nor Tck 
cells (Figure 3.6 c), and the MFI was unaffected by cytokine stimulation (Figure 3.7 
c).  CCR8, receptor for CCL1, was expressed on 17 % of resting cells, which was 
increased to 22 % of Tck cells after cytokine stimulation (Figure 3.6 d), with a mean 
MFI fold increase of 2.5 after cytokine activation (p= 0.0204) (Figure 3.7 d).
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Figure 3.6 CC Chemokine receptors are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells- left panels) and after cytokine stimulation (Tck- right panels).  
Shown are representative dot plots of positive cell expression of a) CCR5, b) CCR6, c) CCR7 
and d) CCR8 on resting and Tck cells. Quadrant gates applied based on isotype control 
staining or unstained cells. 
(f) 
(a) 
(d) 
Resting Tck 
(b) 
(a) 
Resting Tck 
(c) 
(d) 
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Figure 3.7: Expression of CC chemokine receptors are upregulated on Tck  
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for a) CCR5, b) CCR6, c) CCR7 and d) CCR8. 
Significance was ascertained using the Wilcoxon Rank test. * p< 0.05, ** p< 0.01
(a) (b) 
(d) (c) 
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Receptor Median MFI 
(Range) 
Resting 
Median MFI 
(Range) 
Tck 
Mean 
Fold 
increase 
(SD) 
p value n 
      
CCR5 309 
(149-1003) 
674 
(124-1616) 
2 (1.7) 0.0106 (*) 17 
CCR6 538 
(133-1761) 
868 
(160-9797) 
2.5 (5) 0.0053 (**) 18 
CCR7 314 
(134-510) 
495 
(185-801) 
- Ns 4 
CCR8 857 
(277-2645) 
1146 
(160-13064) 
2.5 (5.4) 0.0204 (*) 17 
      
Table 3.3: CC Chemokine receptors are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for each molecule calculated with reference to resting 
T cell values and significance ascertained using the Wilcoxon Rank test. * p< 0.05, ** p< 
0.01. 
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3.5   Cytokine stimulation increases expression of α and β integrins 
The effect of cytokine stimulation on the expression of T cell integrins was analysed 
by flow cytometry.  Data from a representative donor is shown in figure 3.8, with MFI 
data from all donors analysed shown in figure 3.9 and table 3.4.   
Flow cytometry analysis revealed maintenance of expression of CD29 (Integrin β1) in 
response to cytokine stimulation, from 87 % on resting T cells, to 99 % positive cell 
expression on Tck (Figure 3.8 a).  This corresponded to a mean fold increase in MFI 
values of 3.4 (p= 0.0034), (Figure 3.9 a).  Integrin β1 can associate with CD49a, 
CD49d and CD49e (integrin α chains 1, 4 and 5) to form integrins such as VLA-1, -4 
and -5.  Cytokine stimulation also modestly increased expression of CD49a (Integrin 
α1) from 2 % on resting T cells, to 9 % on Tck (Figure 3.8 b), which corresponded to 
a mean fold increase in MFI of 2.7 (p= 0.0002), (Figure 3.9 b).  CD49d (Integrin α4) 
was expressed on resting T cells (78 %), however a modest increase in Tck positive 
cell expression was observed in response to cytokine stimulation (88 %), (Figure 3.8 
c).  Cytokine activation also resulted in a mean fold increase in MFI of 2.2 (p< 
0.0001), (Figure 3.9 c).  CD49e expression of 46 % on resting T cells was maintained 
after cytokine stimulation (41 %), (Figure 3.8 d), and analysis of MFI values revealed 
a mean fold increase of 1.5, however this was not significant (Figure 3.9 d). 
CD18 (Integrin β2) was expressed on the majority of resting T cells (98 %), which 
was maintained after cytokine stimulation (100 %), (Figure 3.8 e).  However analysis 
of MFI values revealed a further significant increase in the MFI values of T cells after 
cytokine activation with a fold increase of 4.6 (p< 0.0001), (Figure 3.9 e).  CD11a 
(Integrin αL) was also expressed on all resting T cells (99 %), which was maintained 
after cytokine stimulation (99 %), (Figure 3.8 f).  Cytokine activation of T cells 
resulted in a further significant increase in MFI values, with a mean fold increase of 
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2.5 (p= 0.0029), (Figure 3.9 f).  CD18 and CD11a can associate to form the integrin 
LFA-1.   
Integrin β7 which can also associate with CD49d, was expressed by 23 % of resting T 
cells, which was modestly increased to 38 % positive cell expression on Tck (Figure 
3.8 g).  Analysis of MFI values revealed a 2.3- fold increase after cytokine activation 
(p= 0.0024), (Figure 3.9 g). 
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Figure 3.8 Integrins are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were washed, stained and analysed by flow cytometry on the 
day of isolation (resting T cells- left panel) and after cytokine stimulation (Tck- right panel).  
Shown are representative dot plots of positive cell expression of a) CD29, b) CD49a, c) 
CD49d, d) CD49e, e) CD18, f) CD11a and g) Integrin β7 on resting and Tck cells. Quadrant 
gates were applied based on isotype control values or unstained cells.  
(f) 
(d) 
(e) 
(a) 
Resting Resting Tck Tck 
(b) 
(d) (c) 
(e) (f) 
(g) 
(b) (a) 
Resting Tck Resting Tck 
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Figure 3.9: Expression of α and β integrin chains are upregulated on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for a) CD29, b) CD49a, c) CD49d, d) CD49e, e) 
CD18, f) CD11a and g) Integrin β7.  Significance was ascertained using the Wilcoxon Rank 
test. * p< 0.05, ** p< 0.01, *** p< 0.001 
(a) (b) 
(c) (d) 
(f) (e) 
(g) 
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Integrin Median 
MFI 
(Range) 
Resting 
Median 
MFI 
(Range) 
Tck 
Mean 
Fold 
increase 
(SD) 
p value n 
 
CD29 486 
(197-
2982) 
711 
(319-13320) 
3.4 (4.9) 0.0034 (**) 15 
CD49a 66.3 
(18-246) 
157 
(68-853) 
2.7 (3.4) 0.0002 (***) 15 
CD49d 3869 
(508-
12400) 
7826 
(155-29235) 
2.2 (2.5) <0.0001 (***) 40 
CD49e 166 
(48-520) 
331 
115-804) 
1.5 (1.1) 0.1763 (ns) 14 
CD18 2032 
(235-
10636) 
6613 
(776-
206787) 
4.6 (12.2) <0.0001 (***) 34 
CD11a 1659 
(145-
38310) 
4614 
(1459-
59959) 
2.5 (1.6) 0.0029 (**) 11 
 
Integrin Beta 
7 
274 
(65-405) 
549 
(160-1300) 
2.3 (3.5) 0.0024 (**) 13 
 
Table 3.4: Integrin chains are expressed on Tck  
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for each molecule calculated with reference to resting 
T cell values and significance ascertained using the Wilcoxon Rank test. * p< 0.05, ** p< 
0.01, *** p< 0.001. 
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3.6   Cytokine stimulation increases expression of integrin ligands 
To explore the possibility of homotypic interactions between integrin ligands 
expressed on Tck and those expressed on M-CSF-monocytes and endothelial cells, 
expression of Tck cellular adhesion molecules (CAMs) was measured by flow 
cytometry.  Data from a representative donor is shown in figure 3.10, with analysis of 
MFI values from all donors illustrated in figure 3.11 and table 3.5.    
Flow cytometry analysis revealed a modest increase in expression of ICAM-1, ligand 
of LFA-1, in response to cytokine stimulation, from 89 % on resting T cells, to 99 % 
positive cell expression on Tck (Figure 3.10 a).  This corresponded to a significant 
mean MFI increase of 10- fold, with reference to resting T cell values (p= 0.0156), 
(Figure 3.11 a).  Cytokine stimulation also maintained expression of ICAM-2, a 
further ligand of LFA-1, from 96 % on resting T cells, to 95 % on Tck (Figure 3.10 
b).  Analysis of MFI values revealed a significant mean increase of 10- fold (p= 
0.0078), (Figure 3.11 b).  VCAM-1, a ligand of VLA-4, was not expressed on resting 
T cells (2 %), however a modest increase in Tck positive cell expression was 
observed in response to cytokine stimulation (5 %), (Figure 3.10 c).  Cytokine 
stimulation also increased the MFI, with a mean fold increase of 1.7 (p= 0.0078), 
(Figure 3.11 c).   
Expression of the junctional adhesion molecule PECAM-1, known to undergo 
homophilic interactions, on resting T cells of 20 % was doubled after cytokine 
stimulation (40 %), (Figure 3.10 d).  This was concomitant with a significant increase 
in MFI values, with a 2.7- fold increase (p= 0.0391), (Figure 3.11 d).  The junctional 
adhesion molecule JAM-A, a ligand of LFA-1,  was expressed on the majority of 
resting T cells (97 %), which was largely maintained after cytokine stimulation (87 
%), (Figure 3.10 e).  A mean MFI fold increase of 3.2 was also observed in response 
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to cytokine activation (p= 0.0156), (Figure 3.11 e).  JAM-C was also expressed on 
resting T cells (72 %), which was also largely maintained after cytokine stimulation 
(59 %), (Figure 3.10 f), however the 1.6- fold increase in MFI was not significant 
(Figure 3.11 f). 
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Figure 3.10 Integrin ligands are expressed on Tck 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells- left panels) and after cytokine stimulation (Tck- right panels).  
Shown are representative dot plots of positive cell expression of a) ICAM-1, b) ICAM-2, c) 
VCAM-1, d) PECAM-1, e) JAM-A and f) JAM-C resting and Tck cells. Quadrant gates were 
applied based on unstained cells. 
(f) 
(a) 
Resting Resting Tck Tck 
(c) 
(b) 
(d) 
(f) (e) 
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Figure 3.11: Integrin ligands and junctional adhesion molecules are expressed on Tck  
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4+ T cell population by positive immunomagnetic bead selection. 
CD4+ T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for a) ICAM-1, b) ICAM-2, c) VCAM-1, d) PECAM-
1, e) JAM-A and f) JAM-C. Significance ascertained using the Wilcoxon Rank test, ** p< 
0.01, *** p< 0.001. 
(a) (b) 
(d) 
(f) (e) 
(d) 
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Integrin 
Ligand 
Median MFI 
(Range) 
Resting 
Median MFI 
(Range) 
Tck 
Mean 
Fold 
increase 
(SD) 
p value n 
      
ICAM-1 1145 
(649- 2535) 
13082 
(209- 27814) 
10 (14.8) 0.0156 (*) 8 
ICAM-2 820 
(604- 1353) 
8885 
(5083-13195) 
10 (12.7) 0.0078 (**) 8 
VCAM-1 486.5 
(324- 557) 
645.5 
(395- 1735) 
1.7 (5) 0.0078 (**) 8 
PECAM-1 1436 
(303- 3254) 
3387 
(249-8450) 
2.7 (2.7) 0.0391 (*) 8 
JAM-A 1269 
(370- 2443) 
4155 
(1469- 5923) 
3.2 (2.3) 0.0156 (*) 8 
JAM-C 1037 
(934- 1945) 
1594 
(1147-3469) 
1.6 (2.2) 0.2188 (ns) 7 
      
 
Table 3.5: Integrin ligands and junctional adhesion molecules are expressed on Tck  
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Cells were stained and analysed by flow cytometry on the day of 
isolation (resting T cells) and after cytokine stimulation (Tck).  Shown is the fold increase in 
the mean fluorescence intensity (MFI) for each molecule calculated with reference to resting 
T cell values and significance ascertained using the Wilcoxon Rank test. * p< 0.05, ** p< 
0.01. 
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3.7   Tck induce monocyte TNFα and IL-6 production in a contact-dependent 
manner 
It was previously shown that Tck could induce monocyte-derived TNFα and IL-6 in a 
contact dependent manner (Brennan et al. 2002; Beech et al. 2006), simulating cell-
cell contacts in the RA joint.  ELISA analysis of cell supernatants from co-cultures of 
Tck and monocytes confirmed that both monocyte TNFα and IL-6 were increased in a 
Tck to monocyte ratio- dependent manner (Figure 3.12).  The mean TNFα production 
at a ratio of 1:1 was 150 pg/ml, which was further increased to a mean of 400 pg/ml at 
a ratio of 8:1.  The increase in monocyte TNFα production at 1:1 and 8:1 compared to 
monocytes cells alone was significant (p= 0.0335, p= 0.0032 respectively).   
IL-6 production was also increased, from 370 pg/ml at a Tck: monocyte ratio of 1:1, 
to 840 pg/ml at a ratio of 8:1.  This IL-6 production was significantly increased 
compared to that of monocytes alone at both 1:1 and 8:1 (p= 0.045, p= 0.008 
respectively).   
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Figure 3.12 Cytokine- activated T cells (Tck) induce monocyte pro-inflammatory 
cytokine production in a contact- dependent manner 
Lymphocytes were isolated from peripheral blood mononuclear cells by elutriation, followed 
by purification of the CD4
+
 T cell population by positive immunomagnetic bead selection. 
CD4
+
 T cells were cultured in the presence of TNFα (25 ng/ml), IL-6 (100 ng/ml) and IL-2 
(25 ng/ml) for eight days. Monocytes were cryopreserved in DMSO supplemented with 10 % 
FCS on the day of elutriation. Tck were co-cultured with autologous monocytes at the 
indicated Tck: monocyte ratio for 18 hours. Analysis of supernatants was performed by 
sandwich ELISAs for (a) TNF and (b) IL-6.  Data represent the mean of triplicate cultures 
from six/ seven independent experiments. Significance was calculated using the Mann 
Whitney test, * p< 0.05, ** p< 0.01 
(a) 
(b) 
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3.8   Discussion 
It was previously shown that cytokine stimulation of T cells (Tck) induced 
upregulation of a number of activation markers, chemokine receptors and adhesion 
molecules.  It was also demonstrated that Tck induced pro-inflammatory mediator 
production in a contact- dependent manner when co-cultured with monocytes and 
macrophages (Parry et al. 1997; Sebbag et al. 1997).  Phenotypic and cell signaling 
analysis showed that these cells shared significant identity with RA T cells, but were 
different from T cells activated by cross-linked anti-CD3 (Brennan et al. 2002).  In 
this chapter, I confirmed and extended these studies to determine Tck expression of 
further activation markers including CD25, CD69 and CD38, chemokine receptors 
CXCR2, CXCR3, CXCR4, CCR5 and CCR6, and adhesion molecules including 
VLA-1, VLA-4, LFA-1, and Integrin β7.  Contact- dependent production of monocyte 
TNFα and IL-6 promoted by co-culture with Tck was also confirmed. 
Confirmation of previous studies showing that cytokine stimulation of T cells 
increased expression of activation markers was first performed (Brennan et al. 2008).  
Expression of activation markers CD25, CD38, CD69 and CD62L measured were 
significantly upregulated on Tck.  CD25, CD38 and CD69 were minimally expressed 
on resting T cells, in accordance with previously published studies (Testi et al. 1989; 
Testi et al. 1989; Lai et al. 1991; Deaglio et al. 2001).  Cells expressing CD69 and 
CD38 were also shown to be enriched in synovial fluid and synovial tissue of RA 
patients compared to peripheral blood, although the frequency of CD25- expressing 
cells have been debated (Seisenbaev et al. 1991; Iannone et al. 1994; van Oosterhout 
et al. 2005).  CD62L, normally expressed on naive and central memory T cells, was 
upregulated after cytokine stimulation in accordance with previous reports, however it 
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was previously shown that this molecule was cleaved from the cell surface following 
its detection in Tck supernatants by ELISA (Brennan et al. 2008).  
The analysis was further extended to investigate the cytokine-induced upregulation of 
chemokine receptors known to play a role in RA pathogenesis (Brennan et al. 1998; 
Kitani et al. 1998; Nanki et al. 2000; Tokuhira et al. 2000; Blades et al. 2002; Shadidi 
et al. 2003; Nanki et al. 2005; Zhang et al. 2005; Beech et al. 2006; Ruth et al. 2006; 
Szekanecz et al. 2006; Aggarwal et al. 2007; Desmetz et al. 2007; Kim et al. 2007; 
Silverman et al. 2007; van Lieshout et al. 2007; Iwamoto et al. 2008; Miossec 2008).  
The chemokine receptors CXCR2 and CCR5 were minimally expressed on resting T 
cells, with CXCR3 more highly expressed in accordance with previously published 
reports (Cockwell et al. 2002).  Expression of CCR6 was previously shown to be 
restricted to memory T cells but remained unaffected by cell stimulation (Liao et al. 
1999).  Donor- donor variation was evident in CCR6 expression, with increases in 
expression of CCR6 occurring only in some donors (Figure 3.7).   
The most markedly upregulated chemokine receptor was CXCR4, receptor for 
CXCL12/ SDF-1, known to induce both T cell chemotaxis and integrin activation 
during transendothelial migration (Ganju et al. 1998; Ding et al. 2001; Shahabi et al. 
2008).  CXCR4 was expressed on between 2 and 20 % of freshly isolated CD4
+
 T 
cells, and upon cytokine stimulation was upregulated to between 60 and 95 % of Tck, 
with a mean MFI fold increase of 9.5.  This was in accordance with previous reports 
(Secchiero et al. 2000; Brennan et al. 2008).  Other chemokine receptors were more 
modestly but significantly upregulated included CCR6, receptor of CCL20/ MIP3α, 
CCR5, receptor of CCL5/ RANTES and CCR8, receptor for CCL1/ I-309.  These 
chemokine receptors are characteristic of Th17, Th1 and Th2 cells respectively 
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(Loetscher et al. 1998; Zingoni et al. 1998; Liao et al. 1999), where Th1 and Th17 
cells are known to predominate in RA pathogenesis (Miltenburg et al. 1992; Dolhain 
et al. 1996; Hirota et al. 2007).  Although CCR8 is unlikely to be involved in RA 
pathogenesis, it was used as a characteristic chemokine receptor of Th2 cells, to 
establish the nature of the chemokine receptor profile upregulated by cytokine 
stimulation.  The Th1- type chemokine receptor CXCR3, receptor for IP-10, was also 
upregulated on approximately half of the donors analysed.  The chemokine receptor 
characteristic of naive T cells or central memory T cells, CCR7, was not upregulated 
by cytokine stimulation, which confirms previous findings by our group, and indicates 
Tck are of an effector memory T cell phenotype.  CXCR6, the ligand for CXCL16 
was not measured, however Tck migration to varying concentrations to CXCL16 was 
performed.  Although CCR1 expression had been upregulated in one donor out of 
three in microarray analysis of Tck, CCR1 blockade in mouse models and human 
arthritis is predominantly associated with a decrease in synovial monocyte and 
macrophage populations (Haringman et al. 2003; Szekanecz et al. 2003; Haringman et 
al. 2006) and therefore was not measured on Tck.  Based on the receptor expression 
on the majority of donors analysed, it is possible that CXCR3, CXCR4, CCR5 and 
CCR6 may be functional in Tck chemotaxis.    
Phenotypic analysis of integrins and selectins was also performed.  Significant 
upregulation of VLA-4, LFA-1, CD62L and integrin β7 was observed.  Expression of 
CD29, CD49d and CD49e were detected on resting CD4
+
 T cells in accordance with 
results described in Figure 3.8 (Shimizu et al. 1990).   Furthermore, increased LFA-1 
and CD29 expression on peripheral blood memory cells compared to naive cells 
defined a subset of memory T cells which were more responsive to stimulation than 
naive T cells (Sanders et al. 1988).  LFA-1 and VLA-4 have been shown to be 
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important in cell recruitment to the joint and mediate cell- cell interactions within the 
synovial tissue (van Dinther-Janssen et al. 1991; Koller et al. 1999).  Increased 
expression of the integrins LFA-1 and VLA-4 on Tck could indicate a capacity to 
undergo transendothelial migration. 
To explore whether integrin ligands were also expressed on resting and Tck cells, 
further phenotypic analysis was performed to investigate the possibility of homophilic 
interactions during migration.  All integrin ligands measured were upregulated to 
some degree on the donors analysed.  PECAM-1, JAM-A and JAM-C are known to 
form homophilic interactions in addition to heterophilic interactions during cell 
extravasation; therefore their expression on Tck could indicate a capacity to 
transmigrate (Sun et al. 1996; Sun et al. 1996; Santoso et al. 2005; Vedula et al. 
2008).  It is also well established that there are increased levels of soluble integrin 
ligands such as VCAM-1 and ICAM-1 in the serum of patients with RA, and that 
TNFα blockade significantly reduces these levels (Klimiuk et al. 2002; Klimiuk et al. 
2007; Klimiuk et al. 2009).  It has also been previously shown that sVCAM-1 induces 
chemotaxis of a number of cells types, including Jurkat T cells, RA synovial fluid T 
cells and monocytes, eosinophils and vascular smooth muscle cells (Kitani et al. 1998; 
Tokuhira et al. 2000; Lee et al. 2008; Ueki et al. 2009).  The increased expression of 
both integrins and integrin ligands on Tck could therefore mediate migration and 
influence RA pathogenicity. 
It was previously shown that Tck could induce monocyte TNFα and IL-6 production 
in a contact dependent manner, which had implications for RA pathogenesis (Brennan 
et al. 2002).  This effect was confirmed in my studies, although in the experiments 
described in my studies, the additional control of using an insert between the cell 
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types to demonstrate the contact- dependent nature of the response was not included.  
This data indicates integrins expressed on Tck can support T cell- monocyte 
interactions.  Further implications of Tck expression of chemokine receptors, integrins 
and integrin ligands will be explored in chapters four and five through in vitro 
migration assays. 
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4.0   Introduction 
One of the hallmarks of RA is increased angiogenesis in the area of the affected joints (Fava 
et al. 1994).  Activated by the inflammatory milieu, endothelial cells express integrin ligands 
and present chemokines on their surface (Cavender et al. 1989).  Integrins mediate the initial 
contact and arrest of the T cells on the endothelium.  In addition to mediating their 
subsequent transendothelial migration, ligation of high affinity integrins also enable arrested 
T cells to come into contact with chemokine gradients presented by the activated endothelial 
cells.  These gradients, either soluble or immobilized on the endothelium and inflamed tissue, 
are sensed by the cells.  Directional cell migration over a soluble or immobilized chemotactic 
gradient is termed chemotaxis and haptotaxis respectively, while non-directional migration in 
response to a chemoattractant is termed chemokinesis (McCutcheon 1946; Witt et al. 1994).   
It is known that chemokines and their receptors play an important role in rheumatoid arthritis 
pathogenesis.  Chemokines and chemokine receptors are promiscuous, with panels of 
receptors able to ligate other panels of chemokines, however some exceptions include the 
specific chemokine-receptor pair of CCL20/CCR6 and until recently, CXCL12/CXCR4.  A 
further chemokine receptor that binds CXCL12 has recently been identified (CXCR7), 
however its expression distribution and importance in eliciting cell migration has been 
debated (Berahovich et al. 2010).  Chemokines and their receptors involved in T cell 
recruitment to the RA joint have also been identified, most notably CXCL10/CXCR3, 
CCL5/CCR5, CXCL12/CXCR4 and CCL20/CCR6 (Nanki et al. 2000; Nanki et al. 2000; 
Shadidi et al. 2003; Desmetz et al. 2007; Jiao et al. 2007).  The recruited cells in turn can play 
a role in further cytokine and chemokine production and additional cell recruitment to the 
inflammatory site.  Soluble forms of integrin ligands such as soluble VCAM-1 and E-selectin 
have also been implicated in inducing T cell and monocyte migration in RA, acting through 
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integrin expression on the infiltrating leukocytes (Kitani et al. 1998; Tokuhira et al. 2000; 
Klimiuk et al. 2007; Klimiuk et al. 2009). 
Chronic inflammatory environments and stimuli, such as in RA, can change the phenotype of 
circulating cells and their capacity to migrate.  This is evident in the phenotypic differences 
and migratory capacity of matched donor effector memory T cells from synovial fluid and 
peripheral blood of RA patients; in the absence of a chemoattractant, T cells isolated from 
synovial fluid show an intrinsically increased capacity to migrate compared to those isolated 
form peripheral blood (Kitani et al. 1998).   
 
The aim of the experiments described in this chapter was 
 To investigate whether Tck display an increased migratory responsiveness compared 
to resting and antiCD3/CD28 activated T cells (Ttcr) using an established in vitro 
chemotaxis assay 
 To examine the pathogenic potential of Tck that are responsive to chemokines 
 To explore the involvement of RA synovial fibroblasts in promoting the migration of 
Tck using a modified in vitro chemotaxis assay  
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4.1   Tck exhibit an increased intrinsic migratory capacity compared to resting or Ttcr 
cells 
Having demonstrated that the expression of some chemokine receptors was upregulated in 
response to cytokine stimulation of CD4
+
 T cells (Tables 3.2 and 3.3), the chemotactic 
responsiveness of Tck was assessed using an in vitro chemotaxis assay.  In particular, the 
impact of increased Tck expression of CCR5, CCR6, CXCR3 and CXCR4 were explored.  In 
this assay the migration of cells through a polycarbonate filter with 3 µm pores is measured 
in response to a range of concentrations of chemokines. 
Interestingly, in the absence of any chemokine gradient, Tck demonstrated a significantly 
increased ability to migrate in these assays compared to matched donor resting or TCR-
activated T cells (p< 0.0001, p= 0.0005 respectively), (Figure 4.1).  In 30 independent 
assays, approximately 10 % of Tck displayed a ‘spontaneous’ migration in the absence of a 
chemokine gradient compared to less than 2 % of resting or Ttcr T cells.  Donor-donor 
variation was most evident within the migration of the Tck populations, which may be 
attributed to the differential up-regulation of various surface molecules between donors 
during cytokine stimulation.  
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Figure 4.1 Tck exhibit an increased intrinsic migratory capacity compared to resting or Ttcr 
cells 
Cytokine-activated (white bar), TCR-activated (thick lines) and resting CD4
+
 T cells (thin lines) were 
added to the upper wells of chemotaxis plates with 3 µm pores.  Assay buffer alone was placed in the 
lower wells and the plate incubated at 37 °C.  Following a 2-hour incubation, migrated cells were 
removed from the lower wells and counted by flow cytometry.  Results are expressed as percent 
migration of total cells added.  Data shown are mean of triplicates from 30 independent experiments.  
Significant calculated by Wilcoxon rank test, *** p< 0.001 
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4.2   Chemokine responsiveness of cytokine- activated T cells  
4.2.1   Cytokine activated T cells display a CXCR4- dependent chemotactic response to 
the chemokine SDF-1/ CXCL12 
As outlined in chapter three, cytokine activation of CD4
+
 T cells resulted in a dramatic 
upregulation of CXCR4 expression (Table 3.2).   
Consequently, in vitro chemotaxis assays were performed to determine if the observed 
increased expression of CXCR4 on CD4
+
 T cells after cytokine stimulation corresponded to 
an increased chemotactic response to its ligand, CXCL12.  Tck migrated in response to 
increasing concentrations of CXCL12 in accordance with their increased expression of the 
receptor CXCR4.  Mean Tck migration to CXCL12 concentrations of 0.3, 3 and 30 ng/ml 
was significantly higher than migration observed in the absence of a chemokine (p= 0.0135, 
p= 0.0108 and p= 0.0017 respectively).  A typical chemokine response bell shaped curve was 
observed with a decrease in migration at the highest concentration of 300 ng/ml (Figure 4.2 
a).  CXCL12- induced Tck migration was also significantly higher than matched donor 
resting T cells at CXCL12 concentrations of 0.3, 3 and 30 ng/ml (p= 0.0357, p= 0.0055 and 
p= 0.0372 respectively), in addition to migration in the absence of a chemokine (p= 0.0221) 
(Figure 4.2 b). 
Recently, a second receptor for CXCL12 was described; the previously orphan RDC-1 or 
CXCR7 (Balabanian et al. 2005; Valentin et al. 2007).  To confirm that the Tck response to 
CXCL12 was acting through CXCR4 only, Tck were pretreated with AMD3100, a CXCR4 
small molecule inhibitor prior to analysis of migration (Figure 4.2 c).  While inhibition of 
CXCR4 did not decrease Tck migration in the absence of a chemokine, pretreatment of Tck 
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with AMD3100 abrogated migration to 20 ng/ml CXCL12 (p= 0.0185), confirming that the 
effect of CXCL12 was mediated through Tck expression of CXCR4. 
 
4.2.2   CXCL12 is chemotactic for Tck cells 
In light of the observed migration of Tck in the absence of a chemokine gradient, it was 
necessary to ensure that the increased response to CXCL12 was truly chemotactic (directed 
movement) and not chemokinetic (random movement) in nature.  Results of a checkerboard 
assay confirmed that Tck migrated to a positive gradient of CXCL12 but no migration above 
control levels was observed when this gradient was absent (Table 4.1).  These results 
demonstrate that CXCL12 is indeed chemotactic and not chemokinetic for Tck. 
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Figure 4.2 Cytokine stimulation of T cells results in a CXCR4- dependent chemotactic response 
to the chemokine CXCL12 
Increasing concentrations of CXCL12 were added to the lower wells of a 96-well chemotaxis plate 
with 3 µm pores.  Cytokine-stimulated (white bars) or resting T cells (hashed bars) were added to the 
upper wells.  Following a 2-hour incubation, migrated cells were removed from the lower wells and 
counted by flow cytometry.  Results are expressed as percent migration of total cells added.  a) Tck 
migration to CXCL12; data shown are mean of triplicates from 7- 10 independent experiments, b) 
Resting and Tck migration to CXCL12, data shown are mean of triplicates from 4- 7 independent 
experiments, c) Tck pretreated with 50 µg/ml AMD3100.  Data shown are mean of triplicates from 5 
independent experiments.  Significance was calculated using paired t tests, * p< 0.05, ** p< 0.01, *** 
p< 0.001. 
(a) 
(b) 
(c) 
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Upper 0 ng/ml 3 ng/ml 30 ng/ml 300 ng/ml 
Lower      
0 ng/ml 7 6 5 6 
3 ng/ml 30 9 5 4 
30 ng/ml 26 15 9 4 
300 ng/ml 8 10 8 5 
 
 
Table 4.1 Checkerboard analysis of Tck migration in response to CXCL12 
Increasing concentrations of CXCL12 were added to upper and lower wells of a 96-well chemotaxis 
plate with 3 µm pores at the concentrations indicated.  After a 2-hour incubation, migrated cells were 
collected from the lower wells and counted by flow cytometry.  Results are expressed as percent 
migration, with numbers in bold indicative of the same concentrations in the upper and lower wells.  
Data shown are mean of triplicates from 3 independent experiments. 
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4.2.3   Upregulation of Tck expression of CXCR3, CCR5 and CCR6 does not result in 
functional chemotaxis to CXCL10/ IP-10, CCL5/ RANTES or CCL20/ MIP3α 
The phenotypic analysis of Tck outlined in chapter three demonstrated that cytokine 
activation of CD4
+
 T cells resulted in modest increases in CCR5, CCR6 and in some donors, 
CXCR3 expression (Tables 3.2 and 3.3).  In vitro chemotaxis assays were performed to 
determine if the observed increased expression of chemokine receptors on CD4
+
 T cells after 
cytokine stimulation corresponded to a chemotactic response to their ligands (Figure 4.3).   
Although the receptor for CXCL10 (CXCR3) was not significantly upregulated on all donors, 
there was a modest increase in a number of donors.  Tck migration to CXCL10 was therefore 
investigated in addition to CCL5 (ligand for CCR5) and CCL20 (ligand for CCR6)   While 
Tck migration was higher than resting T cell migration to increasing concentrations of 
CXCL10 (Figure 4.3 a), CCL5 (Figure 4.3 b) or CCL20 (Figure 4.3 c), no increase in Tck 
migration above the media control was observed.  Therefore, although expression of CCR5 
and CCR6 are significantly increased in response to cytokine stimulation, this increased 
expression does not correspond to a chemotactic response to ligands of these receptors in this 
assay.   
 
4.2.4   ‘Spontaneously’ migrated Tck are CXCR4high 
In vitro chemotaxis assays revealed that Tck displayed a higher ‘spontaneous’ migration in 
the absence of a chemokine gradient in addition to a chemotactic response to CXCL12.  
Large scale experiments were undertaken to investigate the expression of the chemokine 
receptor CXCR4 and adhesion molecules CD29, CD49d, CD18 and CD11a on migrated Tck 
in both assays to determine if the migrated population were enriched for cells expressing 
these markers. 
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Flow cytometry analysis revealed that Tck which had ‘spontaneously’ migrated in the 
absence of a chemokine were CXCR4
high
 compared to input Tck (p= 0.009).  However, 
‘spontaneous’ Tck migration was not dependent on CXCR4 given that pretreatment of Tck 
with AMD3100 did not affect ‘spontaneous’ migration (Figure 4.2 c).  No significant 
differences in CD29, CD18 or CD11a expression between populations was observed in 
migration assays performed in the absence of a chemokine.  There was enrichment of CD49d 
expression on the non migrate population compared to the input cells (p= 0.006); however 
this expression was not significantly higher than CD49d expression on the migrated 
population (Figure 4.4).   
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Figure 4.3 Upregulation of Tck expression of CXCR3, CCR5 and CCR6 does not result in 
functional chemotaxis to CXCL10/ IP-10, CCL5/ RANTES or CCL20/ MIP3α 
Increasing concentrations of CXCL10, CCL5 and CCL20 were added to the lower wells of a 96-well 
chemotaxis plate with 3µm pores.  Cytokine-stimulated (squares) or resting T cells (circles) were 
added to the upper wells.  Following a 2-hour incubation, migrated cells were removed from the lower 
wells and counted by flow cytometry.  Results are expressed as percent migration of total cells added.  
Migration to a) CXCL10, b) CCL5 and c) CCL20 is shown.  Data shown are mean of triplicates from 
a representative donor, from three independent experiment 
(a) 
(b) 
(c) 
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Figure 4.4 ‘Spontaneously’ migrated Tck are CXCR4high 
Media was added to the lower wells of a 6-well chemotaxis plate with 3µm pores.  Cytokine-
stimulated CD4
+
 T cells were added to the upper wells.  An aliquot of input Tck were kept for 
comparison.  Following a 2-hour incubation, non migrated and migrated cells were removed from the 
upper and lower wells and stained with fluorchrome- conjugated antibodies against a) CXCR4, b) 
CD29, c) CD49d, d) CD11a and e) CD18 for analysis by flow cytometry.  Results are expressed as 
mean fluorescent intensity (MFI) and shown are data from five- six independent experiments.  
Significance was determined using paired t tests, ** p< 0.01. 
(a) 
(b) (c) 
(e) (d) 
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4.2.5   CXCL12- responsive Tck are CXCR4
high
 and LFA-1
high
 
To determine the expression of CXCR4, CD29, CD49d, CD11a and CD18 on CXCL12 
responsive and non- responsive Tck populations, large scale experiments were undertaken as 
described (Section 4.2.4).   
Analysis of CXCL12 responsive Tck revealed a significant enrichment of CXCR4 expression 
compared to the input population (p= 0.0176), however this expression was less than that of 
Tck migrated in the absence of CXCL12.  This observation may be due to downregulation of 
the receptor upon binding of CXCL12 (Signoret et al. 1997).  Although no significant 
difference was seen in expression of CD29 and CD49d, CXCL12- responsive Tck were 
CD11a
high
 and CD18
high
 compared to the input populations (p= 0.03, p= 0.0149 respectively), 
(Figure 4.5). 
 
4.2.6   CXCL12- responsive Tck are more potent inducers of monocyte pro-
inflammatory cytokines  
The Tck-monocyte co-culture model was adapted to investigate if CXCL12- responsive Tck 
had an increased capacity to induce monocyte TNFα and IL-6 compared to Tck which did not 
respond to CXCL12.  After large scale chemotaxis assays were performed using inserts in six 
well plates; input, non migrated and migrated Tck were co-cultured with autologous 
monocytes at a ratio of 5:1 Tck to monocyte for 18 hours.  
ELISA analysis of supernatants revealed a markedly increased production of monocyte TNFα 
by co-culture of CXCL12- responsive (migrated) Tck with autologous monocytes at a 5:1 
ratio.  The mean TNFα concentration produced by co-culture of input Tck was 320 pg/ml, 
and co-culture of nonresponsive (non migrated) Tck was 263 pg/ml.  However co-culture of 
CXCL12- responsive Tck resulted in production of a mean TNFα concentration of 670 pg/ml, 
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which was moderately higher than that of the other populations, although this did not reach 
statistical sigfnificance (Figure 4.6 a).  To confirm that this effect was not due to the 
presence of residual CXCL12 from the migration assay or an effect that CXCL12 was having 
on the cells during the migration assay, CXCL12 was added solubly to co-cultured cells 
(Figure 4.6 b).  The presence of soluble CXCL12 did not increase baseline TNFα production 
at the 8:1 ratio of Tck to monocyte. 
A similar trend was seen in IL-6 production, however the increased IL-6 produced by co-
culture of CXCL12- responsive Tck was not significantly higher than that elicited by co-
culture of input or CXCL12 non-responsive Tck, or indeed by the addition of soluble 
CXCL12 (Figure 4.6 c, d). 
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Figure 4.5 CXCL12- responsive cells are CXCR4
high
, CD18
high
 and CD11a
high
 
CXCL12 (10 ng/ml) was added to the lower wells of a 6-well chemotaxis plate with 3µm pores.  
Cytokine-stimulated CD4
+
 T cells were added to the upper wells.  An aliquot of input Tck were kept 
for comparison.  Following a 2-hour incubation, non migrated and migrated cells were removed from 
the lower wells and stained with fluorchrome- conjugated antibodies against a) CXCR4, b) CD29, c) 
CD49d, d) CD11a and e) CD18 for analysis by flow cytometry.  Results are expressed as mean 
fluorescent intensity (MFI) and shown are data from four- five independent experiments.  
Significance was determined using paired t tests, * p< 0.05, ** p< 0.01, *** p< 0.001. 
(a) 
(b) (c) 
(e) (d) 
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Figure 4.6 CXCL12-responsive Tck have an increased capacity to induce monocyte pro-
inflammatory cytokines  
CXCL12 (20 ng/ml) was added to the lower wells of a 6-well chemotaxis plate with 3 µm pores.  
Cytokine-stimulated CD4
+ 
T cells were added to the upper wells.  An aliquot of input cells was kept 
for co-culture with monocytes simultaneously with non migrated and migrated cells.  Following a 2-
hour incubation, non migrated and migrated cells were removed from the upper and lower wells, 
washed and co-cultured with freshly thawed autologous monocytes at a Tck to monocyte ratio of 5:1 
for 18 hours (a, c). Input cells were also cultured at a ratio of 8:1 with 20 ng/ml CXCL12 added 
solubly (b, d). Analysis of supernatants was performed by sandwich ELISAs for (a, b) TNFα and (c, 
d) IL-6.  Data shown are mean of triplicate cultures from four- five independent experiments.  
 
 
 
(a) (b) 
(d) (c) 
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4.3   Soluble VCAM-1 is a chemoattractant for cytokine- activated T cells 
4.3.1   sVCAM-1 induces Tck migration which is abrogated through selective inhibition 
of VLA-4 expressed on Tck 
Given the significant upregulation of VLA-4 (CD29/CD49d) expression on Tck highlighted 
in chapter three (Table 3.4), and in light of previous studies documenting the ability of 
soluble integrin ligands to induce cell migration (van Dinther-Janssen et al. 1991; Kitani et al. 
1998; Tokuhira et al. 2000; Klimiuk et al. 2002; Klimiuk et al. 2007; Oishi et al. 2007; 
Silverman et al. 2007; Klimiuk et al. 2009); migration of Tck to recombinant human VCAM-
1 was investigated using in vitro chemotaxis assays (Figure 4.7).   
Tck displayed a concentration-dependent increase in response to sVCAM-1 (Figure 4.7 a).  
Tck migration of 34 % at 10 µg/ml sVCAM-1 was substantially higher than resting T cell 
migration levels of 7 %, and significantly higher than migration of T cells activated by anti 
CD3/ anti CD28 (Ttcr) to 10 µg/ml sVCAM-1 (p= 0.0256).  Tck migration to 10 µg/ml of 
soluble VCAM-1 was also significantly higher than Tck migration to 1 µg/ml sVCAM-1 and 
migration in the absence of a chemoattractant (p= 0.0013 and p= 0.0096 respectively).   
To confirm that sVCAM-1- induced Tck migration was mediated through the integrin VLA-4 
(CD29/CD49d), Tck were pretreated with neutralizing antibodies against both integrin chains 
prior to analysis of migration (Figure 4.7 b).  Pretreatment of Tck with antibodies against 
CD29 and CD49d significantly abrogated the increased Tck migration to 10 µg/ml sVCAM-1 
compared to treatment with an isotype control antibody, with an inhibition of 58 % after 
CD29 blockade (p< 0.0001), and 85 % inhibition on CD49d blockade (p= 0.0012).  This 
confirmed this effect was mediated through VLA-4.  However VLA-4 blockade did not 
further inhibit Tck migration in the absence of a chemoattractant.   
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Figure 4.7 sVCAM-1 induces Tck migration which is abrogated through selective inhibition of 
VLA-4 expressed on Tck 
Increasing concentrations of sVCAM-1 were added to the lower wells of a 96-well chemotaxis plate 
with 3 µm pores.  Cytokine-stimulated (white bars), Ttcr (thick lines) and resting T cells (thin lines) 
were added to the upper wells.  Following a 2-hour incubation, migrated cells were removed from the 
lower wells and counted by flow cytometry.  Results are expressed as percent migration of total cells 
added +/- SD.  a) Data shown are mean of triplicates from two- five independent experiments with 
significance calculated using paired t test.  b) Cytokine-stimulated T cells were pretreated with 10 
µg/ml antiCD29, CD49d or IgG1 control for 30 minutes and added to the upper wells with 10 µg/ml 
sVCAM-1 added to the lower wells.  Data shown are mean of triplicates from six independent 
experiments and significance calculated using paired t test, * p< 0.05, ** p< 0.01, *** p< 0.001 
(a) 
(b) 
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4.3.2   sVCAM-1 is chemokinetic for Tck 
To investigate the nature of the Tck response to sVCAM-1, checkerboard analysis was 
performed (Table 4.2).  Migration was observed both in the presence and absence of a 
concentration gradient, and when the conditions in the upper and lower wells were the same 
(illustrated by the numbers in bold).  This indicates the Tck response to sVCAM-1 is 
chemokinetic (random movement) in nature. 
 
Upper 0 µg/ml 1 µg/ml 10 µg/ml 
Lower    
0 µg/ml 7 11 11 
1 µg/ml 11 11 14 
10 µg/ml 24 21 24 
 
 
Table 4.2 sVCAM-1 is chemokinetic for Tck 
sVCAM-1 was added to upper and lower wells of a 96-well chemotaxis plate with 3 µm pores at the 
concentrations indicated.  After a 2-hour incubation, migrated cells were collected from the lower 
wells and counted by flow cytometry.  Results are expressed as percent migration, with numbers in 
bold indicative of the same concentrations in the upper and lower wells.  Data shown are mean of 
triplicates from three independent experiments 
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4.3.3   sICAM- and sICAM-2 are not chemoattractants for Tck  
Circulating levels of soluble ICAM-1 and ICAM-2 have been detected in peripheral blood of 
RA patients (Klimiuk et al. 2002; Klimiuk et al. 2007; Klimiuk et al. 2009; Navarro-
Hernandez et al. 2009).  In light of the finding that sVCAM-1 could induce Tck migration by 
acting through VLA-4, it was investigated if sICAM-1 and sICAM-2 could also induce this 
effect.  The principle ligand for both ICAM-1 and ICAM-2 is LFA-1 (CD11a/ CD18), which 
was found to be significantly upregulated on cytokine activated T cells as outlined in chapter 
three (Figure 3.9).   
Despite the upregulation of LFA-1 on cytokine activated T cells, both sICAM-1 and sICAM-
2 failed to induce Tck migration (Figure 4.8).  Tck migration in the absence of a 
chemoattractant was 20 % of total cells added, however this was not increased on addition of 
1- 10 µg/ml of sICAM-1 or ICAM-2 to the lower wells.  These results indicate that soluble 
ICAM-1 and ICAM-2 do not act as chemoattractants for Tck. 
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Figure 4.8: sICAM- 1and sICAM-2 are not chemoattractants for Tck 
sICAM-1 and -2 (10  µg/ml) were added to the lower wells of a 96-well chemotaxis plate with 3 µm 
pores.  Cytokine-stimulated T cells were added to the upper wells.  Following a 2-hour incubation, 
migrated cells were removed from the lower wells and counted by flow cytometry.  Results are 
expressed as percent migration of total cells added +/- SD. Percent migration to sICAM-1 and 
sICAM-2 (10 µg/ml) is shown, with data shown the mean of triplicates from three independent 
experiments. 
 
4.3.4   sVCAM-1 responsive Tck are VLA-4 low, CD18 
low
 and CXCR4 
high
 
To investigate the expression of molecules such as, CD29, CD49d, CD11a, CD18 and 
CXCR4 on sVCAM-1 responsive and non-responsive Tck populations, large scale 
experiments were performed as outlined (Section 4.2.4).   
Use of neutralizing antibodies revealed that Tck migration to sVCAM-1 was dependent on 
VLA-4 (CD49d/ CD29) expression (Figure 4.7 c).  Flow cytometry analysis revealed 
expression of both CD49d and CD29 were higher on non-migrated cells compared to input 
cells, a significant increase in the case of CD29 expression (p= 0.03).  However, the 
expression of these molecules on sVCAM-1 responsive Tck was moderately lower than both 
input and non-migrated populations although these differences were not significant.  This 
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suggests internalization or loss of these integrins during migration, or unavailability of the 
antigen for antibody binding due to ligand binding. 
Investigation of Tck migration to sICAM-1 and sICAM-2 revealed that Tck migrated only to 
soluble VCAM-1 (Figure 4.8).  However it was previously reported that blockade of T cell 
ICAM-1 could decrease T cell migration to sVCAM-1 (Kitani et al. 1998).  To determine if 
sVCAM-1- responsive cells were enriched for the ICAM-1 and ICAM-2 receptor LFA-1, 
flow cytometry analysis was performed.  Expression of CD11a was moderately higher on 
non-migrated cells compared to input and migrated populations, however expression of CD18 
was significantly lower on the migrated cells compared to the non migrated population (p= 
0.036).  ‘Spontaneously’ migrated Tck were shown to express significantly higher levels of 
CXCR4 despite the fact that this background migration was unaffected by CXCR4 blockade.  
CXCR4 was also expressed at higher levels on both migrated and non- migrated populations 
compared to input populations, although this increase was not significant. 
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Figure 4.9 sVCAM-1 responsive cells are VLA-4
low
, CD18
low
 and CXCR4
high
 
rhVCAM-1 (4 µg/ml) was added to the lower wells of a 6-well chemotaxis plate with 3 µm pores.  
Cytokine-stimulated CD4
+
 T cells were added to the upper wells.  An aliquot of input Tck were kept 
for comparison.  Following a 2-hour incubation, non migrated and migrated cells were removed from 
the lower wells and stained with fluorchrome- conjugated antibodies against a) CD49d, b) CD29, c) 
CD11a, d) CD18 and e) CXCR4 for analysis by flow cytometry.  Results are expressed as mean 
fluorescent intensity (MFI) and shown are data from four independent experiments.  Significance was 
determined using paired t tests, * p< 0.05, ** p< 0.01, *** p< 0.001 
(a) (b) 
(d) (c) 
(e) 
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4.3.5   sVCAM-1-responsive Tck are potent inducers of monocyte TNFα and IL-6 
production 
The Tck- monocyte co-culture model was adapted to investigate if sVCAM-1- responsive 
Tck demonstrated an increased capacity to induce monocyte TNFα and IL-6 compared to 
non-responsive Tck, in a similar manner to CXCL12- responsive Tck.  After large scale 
chemotaxis assays were performed; input, non migrated and migrated Tck were co-cultured 
with autologous monocytes at a ratio of 5:1 Tck to monocyte for 18 hours.  
ELISA analysis of supernatants revealed a moderately increased production of monocyte 
TNFα by co-culture of sVCAM-1- responsive Tck with autologous monocytes at a 5:1 ratio.  
The mean TNFα concentration produced by co-culture of input Tck was 320 pg/ml, and co-
culture of sVCAM-1 non responsive Tck was 295 pg/ml.  However on co-culture of sVCAM-
1- responsive Tck, a mean concentration of 1182 pg/ml was produced, markedly higher than 
that of the other populations, although this did not reach statistical significance (Figure 4.10 
a).  To confirm that this effect was not due to the presence of residual sVCAM-1 after the 
migration assay, or sVCAM-1 stimulating the cells to be more potent inducers of monocyte 
cytokines, sVCAM-1 was added to the co-cultured input Tck (Figure 4.10 b).  The addition 
of sVCAM-1 did not increase baseline TNFα production at the highest ratio of Tck to 
monocyte.   
A similar trend was seen in IL-6 production, with a three-fold increase in IL-6 production on 
co-culture of sVCAM-1- responsive Tck with monocytes compared to that of input Tck, 
although this increase was not statistically significant (Figure 4.10 c).  However addition of 
soluble VCAM-1 to the co-culture did not result in significant upregulation of IL-6 
production (Figure 4.10 d). 
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Figure 4.10 sVCAM-1-responsive Tck have an increased capacity to induce monocyte pro-
inflammatory cytokines  
sVCAM-1 (10 µg/ml) was added to the lower wells of a 6-well chemotaxis plate with 3 µm pores.  
Cytokine-stimulated CD4
+ 
T cells were added to the upper wells.  Following a 2-hour incubation, 
migrated cells were removed from the lower wells, washed and co-cultured with freshly thawed 
autologous monocytes at a Tck to monocyte ratio of 5:1 for 18 hours (a, c). Input cells were also 
cultured at a ratio of 8:1 with 10 µg/ml sVCAM-1 added solubly (b, d). Analysis of supernatants was 
performed by sandwich ELISAs for (a, b) TNFα and (c, d) IL-6.  Data shown are the mean of 
triplicate cultures from three- four independent experiments.  
 
 
(a) (b) 
(d) (c) 
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4.3.6   Blockade of Tck CD49d significantly decreases contact- dependent monocyte 
production of TNFα 
It was previously shown that CD49d expressed on Tck was the only molecule to positively 
correlate with the ability of Tck to induce monocyte TNFα production in a contact- 
dependent manner (Brennan et al. 2008).  In addition, given the role of CD49d and CD29 
integrin chains in eliciting sVCAM-1 dependent Tck migration (Figure 4.7) and the 
increased monocyte pro-inflammatory cytokines induced by contact with sVCAM-1- 
responsive Tck (Figure 4.10), the role of CD49d and CD29 in inducing contact- dependent 
monocyte TNFα was investigated using the co-culture model as described in chapter three. 
ELISA analysis of supernatants revealed that Tck pretreated with an isotype control antibody 
induced a mean concentration of 165 pg/ml TNFα.  This was not significantly decreased by 
Tck pretreatment with a blocking antibody against CD29, however blockade of CD49d 
significantly inhibited monocyte TNFα production to 100 pg/ml a decrease of approximately 
40 % (p= 0.0367), (Figure 4.11 a).  Donor- donor variation was observed, however there was 
a more consistent inhibition of monocyte TNFα on co-culture of Tck pretreated with anti 
CD49d in all donors examined than that observed after treatment with anti CD29 (Figure 
4.11 b). 
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Figure 4.11 Blockade of Tck CD49d significantly decreases contact- dependent monocyte 
production of TNFα  
Tck pretreated with neutralizing antibodies against CD29 and CD49d or an isotype control were co-
cultured with freshly thawed autologous monocytes at a Tck to monocyte ratio of 5:1 for 18 hours. 
Analysis of supernatants was performed by sandwich ELISAs for TNFα.  Shown is a) mean TNFα 
production for each Tck treatment, and b) each donor plotted individually.  Data shown are the mean 
of triplicate cultures from four independent experiments. Significance calculated using a paired t test, 
p< 0.05, ** p< 0.01, *** p< 0.001 
 
 
(a) 
(b) 
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4.4   RA fibroblast- like synoviocytes play a role in inducing migration of Tck 
RA pathology has previously been shown to be perpetuated by the continuous influx of T 
cells and other immune cells into the joint.  Synovial fibroblasts have been reported to be 
involved in the chemokine production that attracts these cells (Matsuyama et al. 1996; Kim et 
al. 2007; Silverman et al. 2007; McGettrick et al. 2009).  In order to ascertain if cytokine 
stimulation of T cells enabled them to migrate towards RA fibroblast- like synoviocytes 
(FLS) in vitro, a modified version of the in vitro chemotaxis assay was used.  In this modified 
version of the assay, RA fibroblasts previously isolated from synovial membranes were 
cultured in the lower wells overnight.  T cells were subsequently added to the upper wells and 
the level of migration toward FLS was measured.  
The presence of RA FLS resulted in a modest yet significant increase of Tck migration in the 
majority of donors (p= 0.0004) with a mean increase of approximately 2 fold compared to 
Tck migration in the absence of FLS (Figure 4.12 a).  RA FLS have been reported to 
produce a variety of proinflammatory mediators, including CXCL12 and VCAM-1 
(Rathanaswami et al. 1993; Matsuyama et al. 1996; Bradfield et al. 2003; Garcia-Vicuna et 
al. 2004; Santiago et al. 2011).  To investigate if the RA FLS which induced Tck migration 
were capable of producing CXCL12 and soluble VCAM-1, ELISA analysis of FLS 
supernatants was performed.  Results revealed that RA FLS were capable of spontaneous 
production of sVCAM-1, with a mean concentration of 620 pg/ml (Figure 4.12 c).  CXCL12 
was measured and although it was detected, failure to obtain an accurate standard curve 
precluded quantification of CXCL12 concentrations, however OD values are plotted in 
Figure 4.12 b. 
RA FLS production of CXCL12 and VCAM-1 has also been previously shown to support B 
and T cell pseudoemperipolesis (migration underneath the FLS layer) (Burger et al. 2001; 
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Takeuchi et al. 2002; Bradfield et al. 2003).  The effect of CXCR4 inhibition on Tck 
migration to FLS was therefore investigated.  Pretreatment of Tck with the CXCR4 small 
molecule inhibitor AMD3100 decreased Tck migration to FLS by up to 67% (p= 0.0423) 
(Figure 4.12 d).  To investigate if the sVCAM-1 detected was responsible for the increased 
Tck migration observed, Tck and FLS were pretreated with neutralizing antibodies against 
VLA-4 (CD49d/ CD29) and VCAM-1 respectively.  Tck migration was inhibited by up to 62 
% after VLA-4 blockade compared to an isotype control antibody, however this was also 
variable between donors (Figure 4.12 e).   
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Figure 4.12: RA FLS play a role in inducing migration of Tck cells 
RA FLS were cultured overnight in the lower wells of 96-well chemotaxis plates with 3 µm pores. 
Tck were stained with CFSE and added to the upper wells.  After a two hour incubation, migrated 
cells were collected and counted using flow cytometry, gating on CFSE
+
 cells. Results are shown as 
percent migration. a) Migration of Tck to media and RA FLS, n=12, significance ascertained using 
Wilcoxon Rank test. Supernatants from cultured FLS were analysed for b) CXCL12 by ELISA, 
results shown as OD values +/- SD, n= 3, and c) sVCAM-1 by ELISA, results shown as pg/ml, +/- 
SD, n= 3, n= 14 respectively . d) Tck were pretreated with 50 µg/ml AMD3100 for 30 mins prior to 
addition to the upper wells, n= 4, significance calculated using paired t test. e) Tck and FLS were 
pretreated with 10 µg/ml neutralizing antibodies against VLA-4 and VCAM-1 respectively for 30 
mins prior to addition to the upper wells, n=4. p< 0.05, ** p< 0.01, *** p< 0.001  
(a) 
(c) (b) 
(e) (d) 
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4.5   Discussion 
The studies described in this chapter aimed to determine whether the phenotype of cytokine- 
activated T cells (Tck), as described in chapter three, resulted in an increased migratory 
capacity.  Having confirmed and extended previous studies of the phenotypic analysis of Tck, 
the impact of the upregulation of these markers was explored using an in vitro chemotaxis 
assay.  Interestingly, Tck exhibited increased migration in the absence of a chemokine 
gradient compared to resting memory T cells and T cells activated by antiCD3/ antiCD28 
(Ttcr).  Despite upregulation of some chemokine receptors associated with RA pathogenesis, 
CXCR4, receptor for the chemokine CXCL12/ SDF-1, was the most markedly upregulated 
and the only one to elicit Tck chemotaxis.  These CXCL12 responsive Tck were also potent 
inducers of monocyte TNFα and IL-6 production.  Upregulation of the integrin VLA-4 
(CD49d/ CD29) also resulted in Tck migration to a soluble form of its ligand, VCAM-1.  
sVCAM-1 responsive Tck were also potent inducers of monocyte TNFα and IL-6 production.  
Results of a modified chemotaxis assay using cultured RA fibroblast-like synoviocytes also 
revealed Tck migration to these cells, which was partially dependent on fibroblast CXCL12 
and sVCAM-1 production. 
Previous studies have shown that CXCR4 is up-regulated on effector memory T cells by the 
cytokine IL-15, produced by RA fibroblasts, and that the CXCR4/ CXCL12 axis plays an 
important role in the infiltration of CD4
+
 memory cells into the RA synovial tissue 
(Oppenheimer-Marks et al. 1998; Nanki et al. 2000).  It has also been reported that IL-15 has 
similar effects to IL-2, IL-6 and TNFα stimulation on activation of effector memory T cells 
(McInnes et al. 1996).  This indicates that CXCR4 upregulation by inflammatory cytokines in 
the joint may well play a role in influx of effector memory T cells into the joint or retention 
of these cells at this site, and that blockade of CXCR4 may be efficacious in inhibiting this 
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process.  This CXCL12- induced response was inhibited by the CXCR4 small molecule 
inhibitor AMD3100.  Concentrations up to 25 µg/ml have been shown to efficiently inhibit T 
cell responses to CXCL12 (Hatse et al. 2002), and in preliminary experiments this 
concentration proved effective in reducing Tck chemotaxis to CXCL12.  However in further 
experiments this concentration was doubled to 50 µg/ml which completely inhibited the 
response without affecting cell viability as determined by flow cytometry.  This dose was 
also used to ascertain if background Tck migration could also be inhibited.  However this was 
not the case; Tck background migration was not inhibited even with a high concentration of 
AMD3100. 
Phenotypic analysis of CXCL12- responsive Tck revealed lower levels of surface CXCR4 
expression on the CXCL12- responsive population compared to ‘spontaneously’ migrated 
Tck, which suggests internalization of the receptor (Signoret et al. 1997) (Figures 4.4, 4.5).  
CXCL12- responsive Tck were also enriched for integrin alpha L and beta 2 (LFA-1) 
expression (Figure 4.5).  Previous studies have shown that CXCL12 treatment of T cells 
increases their adhesion to ICAM-1 through activation of LFA-1 and increase in the affinity 
of CD11a and CD18 (Weber et al. 2001; Pasvolsky et al. 2008; Horn et al. 2009).  This 
increased expression of LFA-1 could account for the increased potency of CXCL12- 
responsive Tck to induce monocyte TNFα and IL-6 production compared to CXCL12- non 
responsive Tck, potentially through increased cell- cell interactions with monocytes 
expressing the LFA-1 ligand, ICAM-1 (Figure 4.6).  In support of this, previous work by our 
group showed a significant decrease in monocyte TNFα on pretreatment of co-cultured Tck 
with a CD18 neutralizing antibody (Brennan et al. 2008). 
Despite being upregulated by cytokine activation, Tck expression of CXCR3, CCR5 and 
CCR6 did not result in a chemotactic response.  Tck chemotaxis to CXCL16 was also 
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performed on two donors over varying concentrations, however no response above 
background migration levels was observed.  A recent paper examining cytokine- induced and 
antiCD3/ antiCD28- induced CCR6 expression on T cells also reported that CCR6 expression 
can be induced in vitro through stimulation with pro-inflammatory cytokines.  Memory T 
cells which had acquired expression of CCR6 in vivo were found to be fully demethylated in 
a region of the CCR6 locus which displays unmethylated CpG motifs, resulting in stable 
expression of CCR6 on the cell surface.  However, naive T cells which had been driven to 
express high levels of CCR6 through cytokine activation remained fully methylated at this 
region and as a result, CCR6 expression at the cell surface was not stable (Steinfelder et al. 
2011).  It is therefore possible that the stable expression of chemokine receptors by memory 
T cells induced by cytokines in vitro is under the control of epigenetic mechanisms, however 
this would required further study. 
It is well established that there are increased levels of soluble integrin ligands such as 
VCAM-1 and ICAM-1 in the serum of patients with RA, and that TNFα blockade 
significantly reduces these levels (Klimiuk et al. 2002; Klimiuk et al. 2007; Klimiuk et al. 
2009).  It has also been previously shown that sVCAM-1 induces chemotaxis of a number of 
cell types, including Jurkat T cells, RA synovial fluid T cells and monocytes, eosinophils and 
vascular smooth muscle cells (Kitani et al. 1998; Tokuhira et al. 2000; Lee et al. 2008; Ueki 
et al. 2009).  Given the significant upregulation of CD49d and CD29 (VLA-4) expression on 
Tck compared to resting cells (Figure 3.5), Tck migration to soluble VCAM-1 was 
investigated.  Significant, concentration -dependent migration of Tck was observed compared 
to background migration levels, and which was mediated through Tck VLA-4 expression 
(Figure 4.7).  Checkerboard analysis of the Tck response revealed that, in contrast to the 
CXCL12- induced response, sVCAM-1 induced migration was chemokinetic (non- 
directional) in nature (Table 4.2).  This confirms previous studies reporting the involvement 
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of the sVCAM-1- VLA-4 axis in the migration of IL-2 dependent T cells and synovial fluid 
effector memory T cells by Kitani et al however in this case the response was reported to be 
chemotactic (directional) in nature.  The authors reported evidence of G- protein signalling 
which induced directional migration.  However it is possible that this signalling is not 
induced in my system; this merits further investigation.  It may also mean that the presence of 
soluble VCAM-1 in the circulation and the synovium, whether forming a gradient or not, 
could induce T cell migration; whereas a gradient must be formed in the case of CXCL12- 
induced T cell migration.  Tck migration to sICAM-1 and sICAM-2 up to a concentration of 
10 µg/ml was not observed, and although these concentrations could be suboptimal to elicit a 
response, this is unlikley given the biological levels of soluble ICAM-1 in RA patients 
average approximately 400 ng/ml, and soluble ICAM-2 levels in acute viral infection average 
approximately 900 ng/ml (Klimiuk et al. 2002; Qi et al. 2006; Klimiuk et al. 2007)  
Phenotypic analysis of soluble VCAM-1- responsive Tck revealed decreased CD49d, CD29 
and CD18 expression compared to input and non migrated Tck (Figure 4.9).  This could 
indicate internalization of these integrins in response to soluble VCAM-1 ligation, with 
possible integrin trans-regulation in the case of CD18 expression.  It has been shown that on 
engagement of Jurkat cell VLA- 4 with VCAM-1, LFA-1- stimulated Jurkat migration was 
observed (Rose et al. 2003).  However this study was conducted using immobilized VCAM-1 
with CXCL12 as a stimulus.  Additionally, it is possible that decreased cell surface 
expression of VLA-4 could be due to soluble VCAM-1 binding (Kitani et al. 1996).  
Similarly to CXCL12- responsive Tck, sVCAM-1 responsive Tck were potent inducers of 
monocyte TNFα and IL-6 production.  Increased LFA-1 binding to monocyte ICAM-1 could 
also be responsible for this effect.  However blockade of Tck expression of CD49d in the 
Tck: monocyte co-culture system resulted in a significant decrease in monocyte TNFα 
production (Figure 4.11).  Additionally, there was a positive correlation of CD49d with 
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monocyte TNFα production as previously shown by our group (Brennan et al. 2008), and 
although lower VLA-4 expression was observed on sVCAM-1 responsive cells, its affinity 
could be increased by cell migration to its ligand, and therefore play a role in Tck: monocyte 
interactions leading to increased proinflammatory cytokine production.    
It has been previously reported that synovial fibroblasts play an important role in RA 
pathogenesis, and can migrate to spread arthritis to unaffected joints (McGettrick et al. 2009; 
Neumann et al. 2010).  The presence of RA fibroblast- like synoviocytes in the lower wells of 
the in vitro chemotaxis assays described above increased Tck migration compared to the 
media control in the majority of donors.  Although this was not very marked in some donors, 
it is possible that this could be increased by prolonging the assay incubation time past the two 
hours tested in this chapter.  Blockade of VLA-4/VCAM-1 ligation on Tck and FLS 
respectively resulted in inhibition of migration observed in all donors tested, albeit to 
different degrees.  VCAM-1 expression in both synovial tissue and associated blood vessels 
in RA patients has been reported (Morales-Ducret et al. 1992).  Although exact CXCL12 
concentrations produced by FLS could not be accurately measured, a previous study had 
documented the requirement for both VCAM-1 and CXCL12 in B cell migration to RA FLS 
(Burger et al. 2001).  CXCR4 blockade resulted in increased inhibition of Tck chemotaxis 
compared to VLA-4/VCAM-1 blockade, indicating a potential role for both axes in inducing 
T cell migration to the synovium.   
Use of AMD3100 in treatment of CIA reduced the severity of disease and resulted in 
significant inhibition of cell infiltration and synovial cell proliferation (Matthys et al. 2001).  
Moreover, CIA disease induced in CXCR4 conditional knockout mice showed reduced 
incidence of disease concomitant with reduced T cell infiltration to the joint (Chung et al. 
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2010).  These studies provide further evidence of the suitability of CXCR4 as a target for RA 
treatment.  
Despite the specific blockade of CXCL12 and sVCAM-1-induced chemotaxis and 
chemokinesis, neither blockade of CXCR4 nor VLA-4 reduced the increased ‘spontaneous’ 
Tck migration observed in the absence of a chemoattractant (Figure 4.1).  Although CXCR4 
expression was increased on ‘spontaneously’ migrated Tck, this migration was not dependent 
on CXCR4, as it was unaffected by CXCR4 inhibition.  This increased propensity to migrate 
compared to resting and Ttcr cells could be related to their increased activated state as 
demonstrated by their cell surface phenotype, described in chapter three.  As previously 
demonstrated by our group, the Tck are a surrogate model of the RA T cell.  Other studies 
have shown that when comparing migration of effector memory T cells from peripheral blood 
and synovial fluid from RA patients, synovial fluid T cells displayed an increased 
‘spontaneous’ migratory response compared to matched peripheral blood T cells, in the 
absence of a chemoattractant (Kitani et al. 1998).  This is similar to my observations of Tck 
and matched resting cell migration. 
In conclusion, the data presented in this chapter extends previous observations regarding 
cytokine activation of T cells.  These results indicate that this ‘bystander’ activation 
upregulates a range of molecules that enables the cells to undergo chemotaxis and 
chemokinesis.  These phenotypic changes associated with migration are similar to those of 
RA synovial T cells and highlights further evidence that the Tck can be used as a surrogate 
model of the RA T cell.  Importantly, this migratory phenotype and function was not 
observed when the T cells were activated by antigen.  Furthermore, the data described 
underscores the complexity of receptor- ligand interactions involved in cell migration.  
Although RA is considered a Th1- driven disease, not all the Th1 chemokine receptors were 
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upregulated on Tck, and the markers that were upregulated demonstrated a hierarchy of 
function.  Although this inducible migration could be selectively blocked, Tck migration 
could not be completely abolished.  Thus, while the data suggests that interactions between 
both sVCAM-1/ VLA-4 and CXCL12/ CXCR4 could be useful targets of therapeutic 
intervention, the complexity of T cell migration as a whole illustrates why monotherapies 
targeting single chemokine receptors trialled in the past may have been unsuccessful.  The 
question of whether the phenotype of the Tck reflects an increased ability to undergo 
transendothelial migration using an in vitro model of leukocyte extravasation in addition to 
undergoing chemotaxis, and whether this can be more specifically inhibited will be addressed 
in chapter five. 
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5.0   Introduction 
As described in chapter four, Tck expression of CXCR4 and VLA-4 resulted in functional 
chemotaxis and chemokinesis to their ligands, CXCL12 and soluble VCAM-1.  In this 
chapter, the role of integrins identified as upregulated on Tck in chapter three will be 
explored using an in vitro model of leukocyte extravasation.  This model involves the 
migration of cells through an endothelial monolayer.  
Extravasation and migration of effector T cells into sites of inflammation is a controlled, 
multi-step process involving ligation of selectins, integrins and junctional adhesion molecules 
resulting in diapedesis of cells (reviewed in (Muller 2009))  Initial T cell adhesion and rolling 
to cytokine-activated endothelial cells presenting chemokines and integrin ligands is 
mediated by the selectin family (Alon et al. 1997). Firm adhesion of T cells follows through 
ligation of LFA-1 by ICAM-1 dimers and VLA-4 by VCAM-1 leading to clustering and an 
increase of ICAM-1 and VCAM-1 affinity (Miller et al. 1995; Reilly et al. 1995; Cook-Mills 
2002).  This has been reported to occur within a docking structure described as a 
‘transmigratory cup’, where finger-like projections of the endothelial cell apical surface rich 
in ICAM-1 and VCAM-1 surround the lower part of the adhered cell; however it is unclear to 
what extent these structures play a role in transendothelial migration (Barreiro et al. 2002; 
Carman et al. 2003; Carman et al. 2004).   
Cross- linking of ICAM-1 and VCAM-1 on the endothelial cell surface leads to an increase in 
cytosolic calcium ions and reactive oxygen species, resulting in weakening of endothelial 
tight junctions (Miller et al. 1995; Reilly et al. 1995; Cook-Mills 2002; Muller 2009).  Homo- 
and heterophilic interactions of molecules such as JAM-A and –C and PECAM-1 on the 
endothelial cell surface and lymphocytes then allow cells to transmigrate through the 
endothelial tight junctions (Mamdouh et al. 2003).  Complex signalling events are initiated 
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throughout T cell transmigration, leading to the recruitment of integrin-binding proteins such 
as paxillin and talin to focal contact sites, which recruits Focal Adhesion Kinase (FAK) 
(reviewed in (Mitra et al. 2005)). Phosphorylation of FAK then leads to the recruitment of 
other cytoskeletal proteins which induce cell motility (Mitra et al. 2005).  
In this chapter I will use an in vitro model of leukocyte extravasation, where T cells migrate 
through an endothelial monolayer over a twenty-four hour period through ligation of their 
integrins with ligands expressed on the endothelium.  This is highly regulated, and includes 
interactions between integrins and ligands such as VLA-4/ VCAM-1, LFA-1/ ICAM-1, LFA-
1/ ICAM-2 and homophilic interactions of PECAM-1 on the T cell and endothelial cell.  This 
model will be used as follows: 
 To ascertain whether Tck show increased adhesion to, and migration through an 
endothelial monolayer, and to determine the most important molecules involved 
 To compare this to lymphocytes isolated from RA blood and synovial tissue 
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5.1   TNFα stimulation of HUVEC monolayers upregulates expression of integrin 
ligands over a 48 hour time period 
The model of leukocyte extravasation described in this chapter involved culture of a TNFα- 
stimulated endothelium monolayer (Human Umbilical Vein Endothelial Cells/ HUVEC) on 
12- well Transwell inserts, through which T cells migrate.  To confirm HUVEC expression of 
the integrin ligands which bind integrins expressed by Tck, flow cytometry analysis of 
HUVEC stimulated with TNFα was performed. 
Expression of VCAM-1, ligand of VLA-4, was significantly increased by TNFα after 24 
hours (3.5-fold, p= 0.0078) with a similar trend at 48 hours (3-fold).  Approximately 12 % of 
cells showed positive cell expression at both time points; however untreated HUVEC showed 
no expression.  Expression of ICAM-1, a ligand of LFA-1, was significantly upregulated by 
TNFα treatment at 24 hours compared to untreated HUVEC (24-fold, p= 0.0156) with a 
similar trend by 48 hours (8-fold) and expressed by approximately 75 % of treated cells at 
both time points.  Expression of ICAM-2, another ligand of LFA-1, was maintained at both 
time points, with positive cell expression of between 60 % and 95 % of cells.  The fibronectin 
receptor CD49e/ integrin α5 was upregulated by TNFα treatment at 48 hours by 
approximately 2-fold with a maximum positive cell expression of 12 %.  Expression of 
junctional adhesion molecule-A (JAM-A), a ligand of LFA-1, was maintained over all time 
points, with a positive cell expression of between 70 % and 92 %.  PECAM-1 expression was 
maintained with a slight decrease with TNFα treatment, however PECAM-1 was expressed 
by up to 96 % of HUVEC.   
The expression of integrin ligands on HUVEC indicate that it is a suitable cell type to use as 
an endothelial monolayer in Tck adhesion and transmigration studies 
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Figure 5.1 TNFα stimulation of HUVEC monolayers upregulates expression of integrin ligands 
over a 48 hour time period 
HUVECs were stimulated with TNFα and cultured for 48 hours. Untreated cells were used as a 
reference. Cells were sampled at 24 and 48 hours and stained with fluorchrome- conjugated antibodies 
against a) VCAM-1 n= 9, b) ICAM-1 n= 9, c) ICAM-2 n= 9, d) CD49e/ Integrin α5 n= 3, e) JAM-A 
n= 4, f) PECAM-1 n= 4, and analysed by flow cytometry.  Significance was ascertained using the 
Wilcoxon rank Sum Test. * p< 0.05, ** p< 0.01 
(a) (b) 
(d) (c) 
(e) (f) 
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5.2   Cytokine stimulation increases T cell transendothelial migration  
The impact of increased integrin chain expression on Tck was further investigated using an in 
vitro transendothelial migration assay.  Tck demonstrated a significantly increased capacity to 
transmigrate through an endothelial monolayer (28 %), fourteen-fold and four- fold higher 
than resting and Ttcr cells respectively over a 24 hour period (2 %, p< 0.001 and 7 % p< 0.01 
respectively) (Figure 5.2). 
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Figure 5.2: Tck exhibit increased transmigration compared to matched donor resting and Ttcr 
cells 
Tck, Ttcr and resting cells were added to TNFα- stimulated HUVEC monolayers cultured on 
Transwell inserts with a pore size of 3 µm for 24 hours.  Migrated cells were removed and counted at 
time points indicated.  Percent transmigration of resting, Ttcr and Tck cells is shown.  Data shown are 
the result of four independent experiments, significance calculated using ANOVA with Bonferroni 
correction. ** p< 0.01, *** p< 0.001 compared to Tck values 
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5.3   TNFα- stimulated HUVEC monolayers are required for optimal Tck 
transmigration 
To confirm that Tck were undergoing transendothelial migration and not merely migration 
through a filter, transmigration assays were performed in the presence and absence of TNFα- 
stimulated HUVEC monolayers (Figure 5.3 a).  Tck migrated to some degree through the 
filter alone, as seen with the ‘spontaneous’ migration observed in the chemotaxis assays 
outlined in chapter three.  However the presence of the HUVEC monolayer significantly 
increased Tck migration; (13 % compared to 28 %, p= 0.0084).  
In addition, further assays were performed to confirm the role of TNFα stimulation of 
HUVEC monolayers in Tck transmigration (Figure 5.3 b).  As shown in Figure 5.1, TNFα 
stimulation of HUVEC up-regulated or maintained expression of integrin ligands important 
in T cell transmigration.  Tck migration was measured through unstimulated or TNFα- 
stimulated monolayers.  Although Tck transmigration occurred in the absence of TNFα- 
stimulation, it was significantly increased in the presence of TNFα; (19 % compared to 28 %, 
p= 0.0083).  This confirms that molecules expressed in the absence of TNFα such as ICAM-
1, ICAM-2, PECAM-1 and JAM-A can support Tck transmigration, however this is enhanced 
by the further upregulation of ICAM-1 and VCAM-1 expression.  
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Figure 5.3: TNFα- stimulated HUVEC monolayers are required for optimal Tck transmigration 
Tck transmigrated through a) Transwell inserts with a pore size of 3 µm, in the presence or absence of 
TNFα- stimulated HUVEC monolayers, or b) HUVEC monolayers cultured on Transwell inserts in 
the presence or absence of TNFα (10 ng/ml) for 24 hours.  Migrated cells were removed from the 
lower wells and counted.  Percent Tck transmigration is shown.  Data shown are results of a) four 
independent experiments (+/- SD, significance calculated using paired t test) and b) six independent 
experiments (+/- SD, significance calculated using paired t test, ** p< 0.01) 
 
 
 
(a) 
(b) 
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5.4   Tck transmigration is significantly inhibited through VLA-4/ VCAM-1 blockade 
Given the increased expression of CD49d and CD29 (VLA-4) observed on T cells after 
cytokine activation as outlined in chapter three and the increased expression of VCAM-1 on 
TNFα- stimulated HUVEC (Figure 5.1); the role of VLA-4 and VCAM-1 in T cell migration 
was further investigated using blocking antibodies. 
In a representative donor, Tck transmigration was moderately inhibited through Tck 
pretreatment with neutralizing antibodies against CD29 and CD49.  CD29 blockade resulted 
in consistent inhibition at 2, 4, 6, 8 and 24 hour time points, however CD49d blockade did 
not inhibit migration until the later time point of 24 hours.  Although blockade of VCAM-1 
on the HUVEC monolayer did not abrogate Tck transmigration, there was an additive effect 
when CD49d, CD29 and VCAM-1 were simultaneously blocked (Figure 5.4).   
This analysis was extended to further donors.  Pretreatment of Tck with neutralizing 
antibodies against CD29 and CD49d (VLA-4) resulted in significant inhibition of Tck 
transmigration at the 24 hour time point.  Tck transmigration of 28 % was observed when 
cells were pretreated with an isotype control antibody.  This was significantly decreased to 
13.5 % (p= 0.0007) on CD29 blockade; a mean decrease of 52 %.  Isotype control levels of 
Tck transmigration were also significantly reduced to 18 % (p= 0.0068) on blockade of 
CD49d, which was further inhibited to 11 % (p= 0.0007) with concomitant blockade of CD29 
and CD49d.  This equated to a 61 % decrease of isotype control transmigration levels.  
HUVEC pretreatment with an anti-VCAM-1 antibody resulted in modest inhibition of Tck 
migration, from a mean of 35 % to 26 % of total cells added, but this was not significant.  
Pretreatment of Tck and HUVEC with neutralizing antibodies against VLA-4 (CD49d/CD29) 
and VCAM-1 respectively resulted in inhibition of Tck transmigration levels of 35 % to 12 
%; a decrease of 67 % (Figure 5.5).   
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Figure 5.4: Tck transmigration is partially mediated through VLA-4/VCAM-1  
Tck (T) and HUVEC (H) were pretreated with neutralizing antibodies against a) CD29, b) CD49d, c) 
CD49d/ CD29, d), anti VCAM-1 and e) CD29/ CD49d/ VCAM-1, or an isotype control antibody at 
10 µg/ml for 30 minutes prior to Tck addition to upper wells. Tck were added to HUVEC monolayers 
cultured on Transwell inserts with a pore size of 3 µm for 24 hours.  Migrated cells were removed 
from the lower wells and counted at time points indicated. Results are expressed as percent migration. 
Data from a representative donor from four- eight independent experiments is shown.  
(d) (c) 
(e) 
(a) (b) 
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Figure 5.5: Tck transmigration is significantly decreased  through VLA-4/VCAM-1 blocakade  
Tck (T) and HUVEC (H) were pretreated with neutralizing antibodies against a) CD29, b) CD49d, c) 
CD49d/ CD29, d) anti VCAM-1 and e) CD29/ CD49d/ VCAM-1, or an isotype control antibody at 10 
µg/ml for 30 minutes prior to Tck addition to upper wells. Tck were added to HUVEC monolayers 
cultured on Transwell inserts with a pore size of 3 µm for 24 hours.  Migrated cells were removed 
from the lower wells and counted. Results are expressed as percent migration. Data shown are results 
of four- eight independent experiments.  Significance was ascertained using paired t tests, * p< 0.05, 
** p< 0.01, *** p< 0.001 
 
(a) (b) 
(c) (d) 
(e) 
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5.5   Tck transmigration is not significantly abrogated after LFA-1/ ICAM-1 blockade 
As described in chapter three, expression of the integrins CD11a/ CD18 (LFA-1) were 
upregulated on T cells after cytokine activation.  Given the upregulation of ICAM-1 
expression and maintenance of ICAM-2 expression on HUVEC after TNFα stimulation in 
(Figure 5.1), the impact of CD11a, CD18, ICAM-1, ICAM-2 and ICAM-3 blockade was 
investigated using blocking antibodies. 
Pretreatment of a representative Tck donor with neutralizing antibodies against CD11a and 
CD18 modestly inhibited migration, with an additive effect observed on simultaneous 
blockade with both molecules.  Blockade of HUVEC expression of ICAM-1- 3 also resulted 
in modest inhibition of Tck migration, with a more marked effect observed on ICAM-1 and 
ICAM-2 blockade (Figure 5.6).    
On extension of the analysis to further donors, blockade of Tck expression of CD11a (23 %) 
and CD18 (20 %) resulted in only modestly decreased transmigration in some donors 
compared to the isotype control antibody (24 %), however this inhibition was not significant.  
However on Tck pretreatment with both anti CD11a and anti CD18, a significant decrease in 
transmigration was observed (14 % compared to isotype control levels of 21 %, p= 0.048).  
Inhibition of HUVEC expression of ICAMs1-3 modestly decreased Tck transmigration 
compared to isotype control levels (33 %),  however no blockade resulted in a significant 
inhibition of Tck transmigration (Figure 5.7). 
However no neutralizing antibody used could completely eliminate Tck transendothelial 
migration, indicating the involvement of a number of integrin- ligand pairs.  
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Figure 5.6: Tck transmigration is partially mediated through LFA-1/ ICAM-1 
Tck (T) and HUVEC (H) were pretreated with neutralizing antibodies against a) CD11a, b) CD18, c) 
CD11a/ CD18, d), anti ICAM-1 e) anti ICAM-2 and f) anti ICAM-3, or an isotype control antibody at 
10 µg/ml for 30 minutes prior to Tck addition to upper wells. Tck were added to HUVEC monolayers 
cultured on Transwell inserts with a pore size of 3 µm for 24 hours.  Migrated cells were removed 
from the lower wells and counted at time points indicated. Results are expressed as percent migration. 
Data from a representative donor from three- four independent experiments is shown.   
(a) (b) 
(c) (d) 
(f) (e) 
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Figure 5.7: Tck transmigration is modestly inhibited  through LFA-1/ ICAM-1 blockade 
Tck (T) and HUVEC (H) were pretreated with neutralizing antibodies against a) CD11a, b) CD18, c) 
CD11a/ CD18, d), anti ICAM-1 e) anti ICAM-2 and f) anti ICAM-3, or an isotype control antibody at 
10 µg/ml for 30 minutes prior to Tck addition to upper wells. Tck were added to HUVEC monolayers 
cultured on Transwell inserts with a pore size of 3 µm for 24 hours.  Migrated cells were removed 
from the lower wells and counted. Results are expressed as percent migration. Data shown are results 
of three- six independent experiments.  Significance was ascertained using paired t tests, * p< 0.05 
(a) (b) 
(d) (c) 
(e) (f) 
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5.6   TNFα stimulation increases sVCAM-1 production by HUVEC, which plays a role 
in Tck transmigration 
It has been shown that both cell-surface bound and soluble forms of VCAM-1 are 
upregulated in the RA synovium compared to healthy controls (Kitani et al. 1996; 
Matsuyama et al. 1996; Burger et al. 2001; Klimiuk et al. 2007).  Previous data confirmed the 
increased HUVEC expression of cell surface- bound VCAM-1 on stimulation with TNFα 
(Figure 5.1), and the significant effect of VLA-4/ VCAM-1 blockade on Tck transmigration 
was confirmed (Figure 5.5).  Based on these results it was hypothesised that TNFα 
stimulation may increase soluble VCAM-1 production by HUVEC monolayers (Figure 5.8 
a), and addition of sVCAM-1 may restore the decreased Tck transmigration observed in the 
presence of HUVECs that had not been stimulated with TNFα (Figure 5.8 b). 
ELISA analysis revealed that there was a six- fold increase in mean sVCAM-1 production 
after TNFα stimulation of HUVEC at 24 and 48 hours; 57 pg/ml compared to 350 pg/ml.  
Tck transmigration assays were subsequently performed in the presence of unstimulated or 
TNFα- stimulated HUVEC monolayers, and in the presence or absence of recombinant 
human VCAM-1 (400 pg/ml).  Decreased Tck transmigration through unstimulated HUVEC 
monolayers was observed in line with previous results (19.5 %) however addition of 
rhVCAM-1 increased migration to a level comparable to migration observed in the presence 
of TNFα (25.6 % and 28 % respectively).  Addition of rhVCAM-1 further increased Tck 
transmigration through TNFα- stimulated HUVEC monolayers to 38.5 %, indicating 
sVCAM-1 produced by TNFα- stimulated HUVEC could play a role in Tck transmigration. 
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Figure 5.8 TNFα stimulation increases sVCAM-1 production by HUVEC, which plays a role in 
Tck transmigration 
HUVEC were stimulated with TNFα (10 ng/ml) or left unstimulated. a) Samples were taken between 
24 and 48 hours and analysed by sandwich ELISA.  Data shown are results of four independent 
experiments (+/- SD).  b) Tck were added to HUVEC monolayers cultured on Transwell inserts with a 
pore size of 3 µm in the presence or absence of TNFα (10 ng/ml) and rhVCAM-1 (400 pg/ml) for 24 
hours.  Migrated cells were removed from the lower wells and counted.  Percent Tck transmigration is 
shown.  Data shown are results of three independent experiments 
(a) 
(b) 
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5.7   The mean fluorescence intensity of phosphorylated FAK is increased with T cell 
transmigration, with a partial dependence on PI3K activation 
Integrin engagement is followed by activation of outside- in signalling pathways which lead 
to cell migration.  FAK, activated after integrin engagement, is a central regulator of integrin 
function which leads to the actin cytoskeletal rearrangements necessary for cell motility 
(Webb et al. 2004).  To investigate if the extent to which focal adhesion kinase (FAK) was 
phosphorylated reflected the capacity of resting, Ttcr and Tck to transmigrate, transmigrated 
cells were analysed using intracellular flow cytometry.  
Analysis of the mean fluorescence intensity of pFAK (pS910) revealed that while migrated 
resting, Ttcr and Tck cells exhibited levels of phosphorylated FAK, the mean fluorescent 
intensity was lowest in the resting population (mean of 3642, which was increased to a mean 
of 3417 in the Ttcr population.  The highest MFI was measured within the Tck population, 
with a mean of 5393, significantly higher than the resting transmigrated population (p= 
0.0089), (Figure 5.9 a).   
It is known that activation of FAK leads to recruitment and activation of PI-3 kinase (PI3K), 
which in turn leads to actin cytoskeletal rearrangements and cell migration (Giancotti et al. 
1999).  However, other studies have challenged the requirement for PI3K activation in T cell 
transendothelial migration (Ward 2004).  To investigate the extent to which PI3K plays a role 
in Tck transendothelial migration, Tck were pretreated with the PI3K inhibitor LY294002 or 
a vehicle control and migration was assessed.  LY294002 was previously confirmed by our 
group to inhibit phosphorylation of protein kinase B (PKB) (Foey et al. 2002).  PI3K 
blockade resulted in a modest inhibition of Tck transendothelial migration without affecting 
cell viability; vehicle control migration levels of 21 % were reduced to 15 % after PI3K 
Chapter Five: Characterization of Tck extravasation 
 
237 
 
blockade (Figure 5.9 b).  Although only performed with two donors, this data indicates a 
partial dependence of Tck transendothelial migration on PI3K activation. 
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Figure 5.9 The mean fluorescence intensity of phosphorylated FAK is increased with T cell 
transmigration, with a partial dependence on PI3K activation 
Tck, Ttcr and resting cells were added to TNFα- stimulated HUVEC monolayers cultured on 
Transwell inserts with 3 µm pores for 24 hours.  a) Migrated cells were removed from the lower wells 
and the cells fixed and permeabilised, followed by incubation with fluorochrome- conjugated 
antibodies against pFAK (pS910) or an isotype control.  Data shown are expressed as MFI, and are 
results from four- five independent experiments.  Significance was ascertained using the paired t test,  
** p< 0.01. b) Tck were pretreated with LY294002 (5 µM) or DMSO as a vehicle control for 60 
minutes prior to assessment of transmigration, results expressed as percent migration with data shown 
the results of two independent experiments. 
(a) 
(b) 
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5.8   Cells isolated from RA blood and tissue samples exhibit low levels of 
transmigration  
To investigate whether unstimulated CD3
+
 cells isolated from blood and synovial tissue 
samples of RA patients could transmigrate, and if this was comparable to Tck, transmigration 
assays were performed as previously described.  Phenotypic analysis of input and migrated 
cells was also performed. 
After 24 hours, between 0.7 and 2.5 % of tissue cells had migrated, compared to between 1.5 
and 5.5 % of blood cells (Figure 5.10 a, b) Although cells isolated from blood migrated at 
marginally higher levels than those isolated from tissue, neither of these were comparable to 
Tck transmigration.  
Despite the low transmigration observed, measurement of CD29, CD49d, CD18 and CD11a 
(VLA-4 and LFA-1) expression revealed similarities in modulation of expression between the 
two cell types and Tck (Figure 5.10 c, d, e, f).  CD29 was expressed at higher levels by Tck 
(mean of 4106 compared to 1842 (tissue) and 636 (blood)), however expression on all 
migrated populations was lower compared to input populations, in line with previous results, 
however these differences were not statistically significant.  Interestingly CD49d expression 
was highest on the tissue input population, although donor- donor variation was evident.  
However the mean expression within the migrated populations was similar.  All input 
populations expressed similar levels of CD18, however higher expression levels were seen 
within the migrated Tck compared to migrated blood and tissue cells.  CD11a expression was 
markedly higher within Tck input and migrated populations, although all migrated 
populations exhibited reduced expression compared to the input cells, in line with previous 
results.  The pattern of expression which most accurately mirrored transmigration was that of 
CD11a input and migrated populations.   
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Figure 5.10 Cells isolated from RA blood and tissue samples exhibit low levels of transmigration  
Cells isolated from blood and synovial tissue samples of RA patients were enriched for the CD3
+
 
population using positive selection.  Transmigration assays using the unstimulated enriched cells were 
performed as described and compared to CD3
+
 Tck. Cells transmigrated for 24 hours and were 
removed, counted and phenotyped using flow cytometry.  Shown is percent transmigration of a) 
synovial tissue cells and b) blood cells, and mean fluorescent intensities of c) CD29, d) CD49d, e) 
CD18 and f) CD11a for input and migrated populations of RA synovial tissue cells, RA blood cells 
and Tck.  Data shown are results of three independent experiments. 
 
 
 
 
(e) 
(f) 
Chapter Five: Characterization of Tck extravasation 
 
241 
 
5.9   Discussion 
Findings described in chapter four elucidated a role for CXCR4 in chemotaxis of Tck to its 
ligand CXCL12, and a role for VLA-4 in Tck chemokinesis to soluble VCAM-1.  In this 
chapter, the roles of VLA-4, and the integrin LFA-1 was further determined using an in vitro 
transendothelial migration assay, where cells migrated through a TNF- stimulated HUVEC 
monolayer cultured on Transwell inserts with 3 µm pores.  Results from the transmigration 
assay revealed that Tck demonstrated an increased capacity to migrate through the HUVEC 
monolayer compared to matched donor resting and Ttcr cells.  The use of neutralizing 
antibodies against VLA-4 and LFA-1 on Tck, and their ligands VCAM-1 and ICAMs 1-3 on 
HUVEC showed that Tck transmigration was predominantly dependent on VLA-4- VCAM-1 
ligation; however LFA-1- ICAM-2 also played a role in this process.  Further investigation of 
VCAM-1 production by HUVEC revealed that both surface- bound and soluble VCAM-1 
was upregulated by TNFα stimulation of HUVEC.  Moreover, addition of recombinant 
human VCAM-1 to unstimulated HUVEC monolayers resulted in Tck transmigration 
comparable to migration through TNFα- stimulated HUVEC, indicating the soluble VCAM-1 
produced by HUVEC plays a role in Tck transmigration.  Given that Tck are a surrogate 
model of the RA T cell, investigation of transmigration CD3
+
 T cells isolated from the 
synovial tissue and blood of RA patients was performed, and compared to that of Tck.  
Although there was a small increase in RA peripheral blood T cells migration compared to 
synovial T cells, overall migration was very modest compared to Tck.    
Through the use of transendothelial migration assays, it was shown that T cell surface 
expression of integrins was reflected in migration of resting, Ttcr and Tck cells.  The relative 
contributions of VLA-4 and LFA-1 ligation in T cell adhesion to endothelial cell monolayers 
and subsequent transmigration have been debated (Oppenheimer-Marks et al. 1991; 
Greenwood et al. 1995).  Ligation of LFA-1 with its ligands ICAM-1 and -2 is known to 
Chapter Five: Characterization of Tck extravasation 
 
242 
 
mediate lymphocyte strong adhesion and transmigration (Springer 1994).  Although no 
integrin inhibition completely abrogated Tck transmigration, blockade of both VLA-4 chains 
on Tck and VCAM-1 on HUVEC resulted in significant inhibition of Tck transmigration, 
with a modest inhibition observed on blockade of LFA-1 (Figures 5.5, 5.7)  Although 
HUVEC blockade of ICAM-1, -2 and -3 resulted in varying degrees of inhibition of Tck 
migration, ICAM-2 inhibition was the most significant which could be indicative of 
preferential Tck LFA-1 binding to ICAM-2, which is constitutively expressed on HUVEC.  
However recently published studies have implicated ICAM-1 as the predominant CAM 
which ligates LFA-1 during effector T cell migration under flow, in addition to the ability of 
JAM-A to bind LFA-1 to facilitate extravasation through endothelial tight junctions 
(Wojcikiewicz et al. 2008; Manes et al. 2011).  These studies not only highlight further 
differences between static assays and assays conducted under shear flow but also 
combinations of receptor/ ligand binding which occur under different conditions.  The 
absence of shear flow in this system may therefore also have had an impact on these results. 
Results from chapter four revealed a role for soluble VCAM-1 in attracting Tck.  To 
investigate if soluble VCAM-1 played a role in Tck transmigration, soluble VCAM-1 was 
measured by ELISA and found to be increased on TNFα stimulation of HUVEC.  Moreover, 
the addition of the comparable concentration of recombinant soluble VCAM-1 to 
unstimulated HUVEC resulted in comparable Tck transmigration to TNFα stimulated 
HUVEC, which was further increased on addition of both TNFα and rhVCAM-1.  Taken 
together, this data indicates an additional role for soluble VCAM-1 acting as a 
chemoattractant via its receptor VLA-4 and promoting migration of cytokine activated T 
cells.  In support of these findings is a recent study of Natalizumab (anti CD49d therapy) 
treatment in MS patients (Millonig et al. 2010).  The authors found that Natalizumab 
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treatment decreased leukocyte transendothelial migration by reducing both leukocyte cell 
surface expression of VLA-4 and soluble VCAM-1 levels produced by activated endothelia.     
Phosflow analysis of FAK S910 also revealed a relationship between increased levels of 
phosphorylation and transmigrated cells numbers.  It is known that focal adhesion kinase 
(FAK) is a central link between integrins and the cytoskeleton and is a positive regulator of 
cell migration (Parsons 2003).  FAK is found within focal adhesions and is activated by 
autophosphorylation on Tyr397, which then leads to recruitment of SH2- and SH3- domain- 
containing proteins such as Src family kinases (Zheng et al. 2009).  Src family kinases then 
phosphorylate FAK on further tyrosine residues, which enhance its activity and leads to the 
recruitment and activation of proteins such as p130Cas and Rac1, and Grb2 and ERK (Zheng 
et al. 2009; Flinder et al. 2010).  In order for cells to spread and migrate, focal adhesions must 
be constantly turned over.  ERK activated through FAK phosphorylation is required for FAK- 
mediated focal adhesion disassembly, through its phosphorylation of S910 on FAK (Webb et 
al. 2004).  Furthermore, a significantly higher mean of cells expressing phosphorylated FAK 
was detected in the synovial tissue and peripheral blood monocytes and lymphocytes of RA 
patients compared to healthy controls (Shahrara et al. 2007).  FAK activation also mediates 
the recruitment and activation of PI3K which has been reported to play a role in T cell 
migration (Giancotti et al. 1999).  Pretreatment of Tck with a PI3K inhibitor modestly 
reduced Tck transendothelial migration without affecting cell viability, therefore it could be 
hypothesized that Tck focal adhesion disassembly and migration could be mediated in part 
through ERK phosphorylation of FAK residue S910 and in part through activation of PI3K.  
However this would need to be investigated further.  
Given that Tck is a surrogate model of the RA T cell, the transmigratory capacity of RA 
blood and synovial tissue CD3
+
 T cells was determined.  However results revealed modest 
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levels of transmigration compared to Tck cells.  The majority of donor cells were isolated 
from frozen samples, and although they were rested to re-acquire expression of receptors, 
they were not restimulated.  This could account for the low transmigration.  However, cells 
from blood samples were modestly more migratory than those from synovial tissue samples, 
although more donors would be required to further investigate this.  This could be due to the 
fact that synovial tissue cells have previously migrated to the synovium and may have 
subsequently downregulated their integrins, resulting in a decreased capacity to migrate 
compared to RA blood cells in the experiments described in this chapter.  Although the 
phenotypic analysis of these cells was largely inconclusive, previous studies have 
documented the phenotypic differences between cells isolated from the synovium and 
peripheral blood of RA patients (Cush 1988; Kitani et al. 1998). 
It is known that LFA-1 and VLA-4, and their ligands are implicated in RA pathogenicity (van 
Dinther-Janssen et al. 1991; Kitani et al. 1996; Kitani et al. 1998; Nanki et al. 2000; Burger et 
al. 2001; Ding et al. 2001; Blades et al. 2002; Kim et al. 2007; Singh et al. 2008).  This 
chapter further elucidates the roles of both LFA-1 and VLA-4 and their ligands in Tck 
transendothelial migration.  Chapter six will explore these findings in vivo using the RA/ 
SCID mouse model, where the role of shear flow can be considered.   
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6.0 Introduction 
Mouse models are widely used to study cell migration and have proved useful tools to widen 
our knowledge of biological processes involved in disease pathogenesis.  In the study of RA 
pathogenesis, murine models such as collagen-induced arthritis, antigen- induced arthritis and 
antibody- induced arthritis have elucidated the mechanisms of cell migration to affected 
joints (Carter et al. 2002; Bao et al. 2005; Suchard et al. 2010).  Investigation of human cell 
migration in RA has also been achieved through use of the RA/SCID chimera model.  In this 
model, inflamed RA synovial tissue obtained from patients undergoing joint replacement 
surgery is subcutaneously engrafted onto the back of SCID beige mice and left for up to two 
weeks to vascularise.  This creates a stimulus for cell migration.   
SCID beige mice are suitable for use in this model due to their deficient recombinase system 
and an inability to assemble T cell receptors or immunoglobulins, coupled with a mutation in 
lysosomal budding that eliminates NK cells (Bosma et al. 1983; Christianson et al. 1996).  
The absence of NK cells reduces the risk of graft- versus- host disease once the human tissue 
is engrafted.  Cells are labelled with fluorescent dyes such as PKH26, or radioisotopes such 
as 
111
Indium to track their migration.  This model has been successfully used in studies 
investigating migration of different cell types to inflamed synovial tissue stimulated by 
cytokines and chemokines including TNFα, IL-15 and CXCL12 (Rendt et al. 1993; Mima et 
al. 1995; Oppenheimer-Marks et al. 1998; Sack et al. 1999; Wahid et al. 2000; Blades et al. 
2002; Matsuno et al. 2002; Zhang et al. 2005).   
The air pouch model has also been used to investigate cell migration, predominantly of 
neutrophils and eosinophils, however it has been used in studies of T cell and monocyte 
migration (Grieder et al. 1990; Bertini et al. 1999; Sohy et al. 2009; Wei et al. 2010).  A 
dorsal pouch is generated by subcutaneous introduction of air, which, after five days, is re-
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inflated and activated using a TLR ligand such as zymosan or LPS, with or without a 
chemokine.  This creates an inflammatory environment which stimulates migration of cells, 
which can then be extracted and phenotyped.   
The advantage of the RA/ SCID model is that not only can human tissue be engrafted without 
rejection, and human cells tracked within the animal, but it can be used to investigate the 
therapeutic potential of human disease treatments.  Although a murine model, 
physiologically- relevant experiments using human cells and tissues under shear flow can be 
performed, and the effect of human- specific treatments can be more easily examined, prior to 
potential use in human subjects.   
The aims of this chapter are as follows: 
 To establish the RA/SCID mouse model, including tissue engraftment and T cell 
labelling, detection and characterization  
 To examine in vivo Tck migration using the RA/SCID model and the air pouch model  
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6.1 T cell fluorescent labelling and detection 
6.1.1 The optimum PKH26 concentration for cell labelling is 5µM 
In order to identify the migrated cells within a mixed synovial cell population, cells were 
labelled with a red fluorescent dye, PKH26, with emission and excitation spectra maximums 
of 551 nm and 567 nm respectively.  PKH26 could also be detected in the PE channel on a 
flow cytometer, which would allow cells liberated from the graft tissue to be further 
phenotyped.  To investigate optimum label concentration for cell identification and the effect 
of the label on cell death, resting peripheral blood lymphocytes (PBL) were purified by 
elutriation and labelled with PKH26 concentrations of 0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM 
and 20 µM. 
Labelling was assessed by flow cytometry at time zero and cell death measured using 7-
AAD.  PBLs were most efficiently labelled at concentrations 5 µM and 10 µM, although 
successful cell labelling was observed at lower concentrations.  Cells were not efficiently 
labelled at the lowest concentration of 0.5 µM (Figure 6.1). 
PBLs were then labelled with further concentrations of PKH26 and cell death assessed.  Cell 
death of below 2 % was observed using concentrations of 1 µM- 5 µM.  However, this was 
increased to 10 % and 55 % after labelling with concentrations of 10µM and 20µM 
respectively (Table 6.1).   
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Figure 6.1 T cells can be efficiently labelled with PKH26 
Resting peripheral blood lymphocytes were enriched by elutriation, and labelled with PKH26 over a 
range of concentrations.  Labelling was assessed using flow cytometry.  Data from a representative 
donor is shown. Shown is T cell staining with PKH26 concentrations of a) 0.5 µM, b) 1µM, c) 2µM, 
d) 5µM, e) 10 µM and f) 20 µM  
5 µM PKH26 2 µM PKH26 (d) (c) 
(f) 
0.5 µM PKH26 1 µM PKH26 
10 µM PKH26 20 µM PKH26 
(a) (b) 
(e) 
2 µM PKH26 5 µM PKH26 
(c) (d) 
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Table 6.1 PKH26 labelling does not induce T cell death at concentrations of 5 µM and below 
Resting peripheral blood lymphocytes were enriched by elutriation, and labelled with PKH26 over a 
range of concentrations.  Labelling was assessed using flow cytometry and cell death measured using 
7-AAD.  Data from a representative donor is shown. Shown is percent cell death of the total cell 
population, which had been stained with PKH26 at the indicated concentrations. 
 
6.1.2 PKH26- labelling has no effect on T cell proliferation 
To determine the effect of PKH26 labelling on T cell proliferation, PKH26- labelled T cells 
were stimulated for three days with anti CD3 and anti CD28, or media only.   
After three days in culture, cell proliferation was assessed by flow cytometry using 
histograms based on labelling at time zero.  In a representative T cell donor (donor 1), 
proliferation was at its highest between 1 µM and 5 µM, while labelled T cells cultured in 
media did not proliferate.  Cells stained with PKH26 concentrations of 10 µM and 20 µM 
showed high cell death and little to no proliferation was observed in this donor at these 
concentrations (Figure 6.2).  T cells from a further donor were also analysed (donor 2), and 
although overall proliferation was lower in this donor,  it was at its highest at concentrations 
of between 1 µM and 10 µM, however at 10 µM, cell death on day zero was markedly higher 
than that at 5 µM in this donor (Table 6.2).   
PKH26 
Concentration 
(µM) 
0 1 2 3 4 5 10 20 
Cell death 
(%) 
0.7 1.8 0.7 0.6 0.8 1.5 9.7 55 
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T cell labelling with 5 µM PKH26 was chosen as the optimum concentration based on the 
balance between successful cell staining, cell death on day zero, and cell proliferation.  
 
6.1.3 CD45
+
 cells can be accurately detected in a mixed cell population 
One of the aims of the migration studies detailed in this chapter was to extract, digest and 
phenotype the synovial tissue grafts after the cells had been injected.  Given that the expected 
number of migrating cells was approximately 5 % of the total cells injected (C. Pitzalis, 
personal communication), it was important to ascertain how accurately these cells could be 
detected in a mixed cell population and quantified.  One method to determine this is to use an 
internal counting standard.  For this, Countbright absolute counting beads were used; a 
standardised concentration of microspheres which are added to a known volume of sample 
and analysed using flow cytometry.   
To determine the efficacy of this method, a known volume of Countbright beads were added 
to a known number of serially diluted T cells, and 10,000 bead events were acquired on the 
flow cytometer.  Based on the volume of the cells, the known number of beads added, and the 
overall cell events acquired, the number of T cells acquired could be calculated.  This number 
was then plotted against the known number of cells in each sample, to see if they were 
comparable (Figure 6.3 a).  In all samples, the expected number of T cells per tube 
corresponded with the sample number calculated using the Countbright beads, indicating that 
this method could be used to accurately determine absolute cell numbers. 
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Figure 6.2 The optimum PKH26 concentration for cell labelling is 5µM 
Resting T cells were enriched by elutriation, and labelled with PKH26 over a range of concentrations.  
PKH26- stained cells were cultured in the presence of plate bound anti- CD3 (2µg/ml) and soluble 
anti- CD28 (4µ/ml) (right panels) or media (left panels) for three days.  Proliferation was assessed 
using flow cytometry.  Data from a representative donor is shown. Shown is T cell staining and 
proliferation with PKH26 concentrations of a) 0.5 µM, b) 1 µM, c) 2µM and d) 5 µM. 
0.5 µM PKH26 (Media) 0.5 µM PKH26 (αCD3/ α28) 
1 µM PKH26 (Media) 1 µM PKH26 (αCD3/ α28) 
2 µM PKH26 (Media) 2 µM PKH26 (αCD3/ α28) 
5 µM PKH26 (Media) 5 µM PKH26 (αCD3/ α28) 
(a) 
(b) 
(c) 
(d) 
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PKH26 Concentration (µM) % Proliferation (Day Three) 
Donor 1  
 
Donor 2 
   
Unlabelled - - 
0.5 57 - 
1 74 27.3 
2 83 25.2 
3 - 27.1 
4 - 28.5 
5 78 26.4 
10 6 29.3 
20 - 17.4 
 
 
Table 6.2 The optimum PKH26 concentration for cell labelling is 5µM 
Resting T cells were enriched by elutriation, and labelled with PKH26 over a range of concentrations.  
PKH26- stained cells were cultured in the presence of plate bound anti- CD3 (2µg/ml) and soluble 
anti- CD28 (4µ/ml) for three days.  Labelling on day zero and day three was assessed using flow 
cytometry.  Data from two representative donors are shown.  Proliferation at day three was assessed 
with reference to each concentration at day zero.  Shown is a summary of all PKH26 concentrations 
investigated 
 
This analysis was extended to calculation of absolute CD45
+
 cells in a mixed cell population.  
Decreasing numbers of labelled CD45
+
 lymphocytes were added to suspensions of OA 
synovial cells, and Countbright beads were used to calculate the absolute numbers of CD45
+
 
cells in each sample.  After acquiring 10,000 bead events on the flow cytometer, the total 
number of cells per sample, and the total number of CD45
+
 cells per sample could be 
determined and compared to the expected number (Figure 6.3 b).  These values were found 
Chapter Six: Establishing the RA/ SCID model and investigation of in vivo Tck migration 
 
254 
 
to be comparable, indicating the sensitivity of this method to calculate absolute T cell 
numbers in a mixed cell population.  
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Figure 6.3 T cells can be accurately quantified in a mixed cell population  
Resting T cells were enriched by elutriation and serially diluted.  A known volume of Countbright 
beads (50,000) were added immediately before acquisition and 10,000 bead events acquired on the 
CANTOII flow cytometer, corresponding to one fifth of the FACS sample.  Total cell number was 
calculated by multiplying the acquired cell number which corresponded to 10,000 bead events by 5.  
Shown is a) Comparison of acquired versus expected T cell numbers based on analysis using 
Countbright beads and b) comparison of acquired versus expected PKH26- labelled lymphocytes 
within an OA synovial cell suspension.  Data from a representative donor is shown.   
 
(a) 
(b) 
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6.1.4 PKH26- labelled cells can be detected after collagenase treatment  
It was hypothesised that once the cells had migrated, the graft tissue could be digested by 
collagenase and the liberated migrated cells phenotyped by flow cytometry.  To assess the 
effect of collagenase digestion on the stability of PKH26 dye, an in vitro simulation of the 
final step of the model (graft excision and digestion) was performed.  In this experiment, Tck 
were first labelled with PKH26.  OA synovial tissue (Figure 6.4 a) was dissociated using 
collagenase either with or without prior addition of labelled Tck.  All liberated cells from the 
OA grafts were cultured for 48 hours, in addition to PKH26- labelled Tck alone.  These 48- 
hour cultured labelled Tck were then added to the liberated synovial cells which had been 
dissociated without prior addition of labelled Tck, and detection of PKH26- labelled Tck was 
assessed by flow cytometry.  
Phenotypic analysis revealed that the strength of the PKH26 label was reduced by 
approximately half a log after two days in culture (Figure 6.4 b, c).  A similar finding was 
observed in the synovial tissue that had been digested in the presence of PKH26 labelled Tck 
and cultured for two days, which could be attributed to the culture period rather than the 
collagenase treatment (Figure 6.4 e).  Day two PKH26- labelled Tck which had been added 
to digested synovial cells could be detected (Figure 6.4 d), however there were twice as 
many detected as those that had been treated using collagenase.  However this was due to 
differing numbers of OA synovial cells, as although similar pieces of tissue were digested in 
the presence and absence of Tck, resulting cell numbers could not be controlled for.  
However, although the strength of the PKH26 label was modestly affected after two days of 
culture, treatment with collagenase did not abrogate the ability to detect PKH26- labelled 
Tck. 
    
Chapter Six: Establishing the RA/ SCID model and investigation of in vivo Tck migration 
 
256 
 
   
Figure 6.4 PKH26- labelled cells can be detected after collagenase treatment  
Tck were labelled with PKH26 (5µM) and labelling efficacy was assessed by flow cytometry.  Tck 
were placed in a 12 well plate and cultured for 48 hours in RPMI with 10 % FCS.  OA synovial tissue 
pieces of similar sizes were dissociated by collagenase digestion as previously described in the 
presence or absence of 1 x 10
6
 PKH26- labelled Tck, and cultured in a 12 well plate for 48 hours.  48 
hours later, 1 x10
6
 Tck were then added back to the digested synovial cells and analysed by flow 
cytometry.  PKH26 is plotted on the x axis with side scatter on the y axis, with percentages denoting 
PKH26 positive cell populations.  Shown is a) OA synovial cells, b) day zero PKH26- labelled Tck, c) 
day two PKH26- labelled Tck, d) OA synovial cells dissociated in the presence of Tck and e) OA 
synovial cells with Tck added in after dissociation.  A representative donor is shown.   
 
(a) 
 
(b) (c) 
(e) (d) 
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6.2 Successful engraftment of tissue requires cellular tissue 
As described in the introduction to this chapter, the RA/ SCID model involves engraftment of 
synovial tissue, which vascularises to allow migration of cells.  Anastomoses were 
determined by eye after the animals were sacrificed, and it was determined that the most 
effective grafts were derived from the most ‘cellular’ (activated T cell and macrophage 
content) tissue as elucidated using flow cytometry.  In the initial experiment a time course 
was performed, where tissue was engrafted and animals were sacrificed at one week intervals 
and examined by eye to observe the degree to which the tissue had vascularised.  From this 
experiment it was determined that the optimum time for formation of anastomoses and 
prevention of graft necrosis was two weeks.  Figure 6.5 illustrates engraftment of 
representative animals, before and after graft excision. 
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Figure 6.5 Illustration of surgical procedure in RA/ SCID mouse model 
SCID Beige mice were anaesthetized and a small incision placed subcutaneously.  3mm pieces of 
synovial tissue were placed on either side of the spine adjacent to the ears.  Shown is a) a naive mouse 
without grafts, b) a graft showing sutures to close the incision, c) a graft once sutures have been 
removed, d) two exposed grafts two weeks after implantation, before graft excision and e) a graft 
showing anastomoses  
 
 
 
(a) (b) (c) 
(d) (e) 
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6.3 Determination of in vivo Tck migratory responsiveness 
6.3.1 PKH26- labelled cells could not be detected in collagenase- treated individual graft 
explants after cell injection 
The pilot experiment to determine if PKH26- labelled Tck could be detected and removed 
from the graft tissue was performed on ten animals; five mice received PKH26- labelled 
resting T cells, five received PKH26- labelled Tck (Figure 6.6).  The grafts were stimulated 
with TNFα and cells injected intravenously, and after 48 hours the animals sacrificed, grafts 
excised and dissociated with collagenase.  The liberated cells were then assessed by flow 
cytometry to determine if PKH26- labelled cells could be detected.   
Although PKH26- labelling of Tck was successful (Figure 6.6 a), only a very small 
proportion of PKH26- labelled cells could be detected in any of the five mice which received 
labelled Tck (Figure 6.6 b- f).  However this was most likely due to autofluorescence of the 
synovial cells, an issue which was resolved in future experiments by adjusting the settings on 
the CANTOII flow cytometer, and the inclusion of an additional group of animals which 
were engrafted but received no PKH26- labelled cells.  Although PKH26- labelled resting T 
cells and PKH26- labelled cells from the Jurkat T cell line were also injected, no migration 
was seen for either of these cells populations (data not shown). 
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Figure 6.6 PKH26- labelled cells could not be detected in collagenase- treated individual graft 
explants after cell injection 
Mice were engrafted with synovial tissue for two weeks, grafts subsequently stimulated with TNFα 
and mice divided into two experimental groups of five mice each.  Tck were labelled with 5 µM 
PKH26 and injected intravenously.  Mice were sacrificed after 48 hours and the two grafts from each 
mouse pooled and digested with collagenase.  Isolated cells were analysed using flow cytometry.  
Shown is a) PKH26- labelled Tck prior to injection and b)- f) Mice 1- 5. Gates placed based on 
PKH26
+
 labelled Tck in a), and percentages refer to PKH26
+
 cells.    
 
(a) 
(b) 
(e) 
(c) (d) 
(f) 
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6.3.2 PKH26- labelled cells could not be detected in collagenase- treated pooled graft 
explants after cell injection 
To investigate if the detection of PKH26- labelled cells could be improved by pooling graft 
samples from each group rather than each individual animal, animals were engrafted with 
synovial tissue for two weeks and stimulated with TNFα.  To determine if blockade of 
CD49d had any effect on migration, Tck were also pretreated with an anti- CD49d 
neutralizing antibody or an isotype matched control antibody.  Untreated and antibody- 
pretreated Tck were then injected intravenously.  Grafts were excised, each group pooled and 
treated with collagenase, and the liberated cells phenotyped by flow cytometry. 
Tck cell donors were successfully labelled with PKH26 (Figure 6.7 a, b).  However after 
collagenase treatment of grafts, although CD45 positive cells could be detected by flow 
cytometry, these cells were not also PKH26 positive (Figure 6.7 c, d, e).  Results obtained 
from untreated Tck and IgG1- pretreated Tck were comparable.  It is likely that these CD45
+
 
cells were resident cells in the graft tissue 
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Figure 6.7 PKH26- labelled cells could not be detected in collagenase- treated graft explants 
after cell injection 
Mice were engrafted with synovial tissue for two weeks, grafts subsequently stimulated with TNFα 
and mice divided into four experimental groups of four- five mice each.  Tck were labelled with 5 µM 
and left untreated, or pretreated with anti- CD49d neutralizing antibody or an isotype control, and 
injected intravenously.  One group received no cells.  Mice were sacrificed after 48 hours and grafts 
from each group pooled and digested with collagenase.  Isolated cells were stained with anti- CD45 
FITC and analysed using flow cytometry.  Shown is a) donor 1 PKH26- labelled Tck, b) donor 2 
PKH26- labelled Tck, c) pooled graft tissue with no cells injected (sham group), d) pooled graft tissue 
with isotype control- pretreated Tck injected and e) pooled graft tissue with anti- CD49d- pretreated 
Tck injected.  Gates placed based on unstained cells, and percentages refer to CD45
+
 cells.    
 
(a) (b) 
(d) (c) 
(e) 
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6.4 Evaluation of in vivo Tck migratory responsiveness using 
111
Indium radiolabeling  
6.4.1 Indium labelling is a sensitive method of detecting small numbers of T cells 
Although it was established that Tck could be efficiently labelled with PKH26, detected by 
flow cytometry, and that this detection was neither significantly affected by collagenase 
treatment of the labelled cells, nor two days in culture, PKH26- labelled Tck could not be 
detected in graft tissue after intravenous injection.   
It is possible that due to high autofluorescence of the synovial cells from the graft tissue, the 
cells have migrated but the fluorescent label is not sensitive enough to detect them in the 
mixed cell population.  Previous migration studies have been performed using 
111
Indium 
labelling as a method of cell detection due to its high sensitivity (Taylor et al. 2000).  To 
determine the sensitivity of 
111
Indium labelling in detection of fewer than 10000 Tck, a serial 
dilution of 
111
Indium labelled Tck was performed and analysed on a gamma- scintillation 
counter (Figure 6.8).  Analysis of gamma counter readings revealed that as low as 4500 Tck 
could be detected should they migrate to the graft tissue.  This would be the equivalent of less 
than 0.1 % of total cells injected, and this method would give a definitive answer as to 
whether the Tck had migrated or not.  Therefore all future experiments were performed using 
111
Indium as a method of Tck labelling and detection. 
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Figure 6.8 Indium labelling is a sensitive method of detecting small numbers of T cells 
Tck were labelled with 
111
Indium and a serial dilution was performed, from 5 x 10
6 
 to 4 x 10
3
 cells.  
Each sample was read on the gamma counter.  Shown is each sample plotted on a log10 scale. 
 
 
6.4.2 Tck migrate predominantly to the liver, kidney and lung 
The initial experiment investigating Tck migration to implanted synovial tissue was 
performed on four animals to determine the efficacy of the labelling method (Figure 6.9).  
111
Indium labelled Tck were injected intravenously, and six hours later, and a blood sample, 
the grafts, spleen, liver, heart, kidney, lung and the femur were isolated for analysis using the 
gamma counter.  Of the four mice, the majority of the cells migrated to the liver, with a 
smaller number to the kidney and the lung.  A proportion were detected in the tail, however 
this was most likely due to the route of administration.  There was no signal in the graft tissue 
higher than the background values of graft tissue when no cells had been injected.   
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Figure 6.9 Tck predominantly migrate to the liver, the lung and the kidney 
Four SCID Beige mice were anaesthetized and synovial tissue implanted subcutaneously.  After two 
weeks, 
111
Indium labelled Tck were injected intravenously and after 6 hours animals were sacrificed 
and organs isolated.  Percent migration was calculated using non- linear regression based on a 
standard curve of serially diluted labelled cells and the number of cells injected to each animal.  Each 
organ was placed in a tube and read by a gamma counter.  Shown are pooled data of four animals, 
expressed as counts per minute (CPM).  
 
 
 
 
6.4.3 Route of administration affects distribution of Tck migration 
To determine if the route of administration affected Tck migration, Tck were injected 
intravenously and intraperitoneally. 
Intravenous injection of Tck resulted in migration of the majority of cells to the liver and the 
lung, with a small proportion trafficking to the spleen and some remaining in the tail.  
However, when Tck were injected intraperitoneally, an equal number of cells trafficked to the 
liver and spleen, with fewer detected in the lung (Figure 6.10).   
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Figure 6.10 Route of administration affects distribution of Tck in vivo 
Ten SCID Beige mice were anaesthetized and synovial tissue implanted subcutaneously.  After two 
weeks, 
111
Indium labelled Tck were injected intravenously, intraperitoneally or intragraft and after 6 
hours animals were sacrificed and organs isolated.  Each organ was placed in a tube and read by a 
gamma counter.  Shown are a) pooled data from three animals, where Tck were injected intravenously 
and b) pooled data from five animals, where Tck were injected intraperitoneally.  Data are expressed 
as counts per minute (CPM).  
 
 
 
 
 
(a) 
(b) 
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6.4.4 Tck show a similar migration distribution in vivo to resting T cells 
To determine if Tck demonstrated the same distribution pattern in vivo compared to resting T 
cells, 
111
Indium labelled resting and Tck cells were injected intraperitoneally.  Six hours after 
injection, animals were sacrificed and organs isolated for analysis on the gamma counter 
(Figure 6.11). 
Although only two animals were compared, the relative cell numbers of Tck were increased 
in all organs where cells could be detected- spleen, heart, liver, lung, kidney and femur.  
However no signal for either cell type was detected in the graft tissue.  
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Figure 6.11 Tck demonstrate a similar pattern of distribution to resting T cells 
Two SCID Beige mice were anaesthetized and synovial tissue implanted subcutaneously.  After two 
weeks, 
111
Indium labelled resting and Tck cells were injected intraperitoneally and after 6 hours 
animals were sacrificed and organs isolated.  Each organ was placed in a tube and read by a gamma 
counter.  Shown are data from two animals, with data expressed as relative cell number based on a 
standard curve.  
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6.4.5 Tck injected into the graft do not egress from implanted synovial tissue 
Given the large number of T cells detected in the synovial joint in RA, it was hypothesized 
that if Tck migrated to the graft tissue, their expression of integrins would result in them 
being retained there.  To investigate if injection of Tck directly into the graft resulted in them 
being retained in the graft tissue or egressing to the peripheral blood, Tck were injected 
directly into one of the grafts of each mouse.  This resulted in the cells failing to egress from 
the implanted synovial tissue in this donor (Figure 6.12 a).  This could have resulted from a 
lack of functional anastomoses emanating from the graft, or because Tck integrins lead to the 
cells accumulating within the synovial tissue and merits further investigation.   
 
6.4.6 Tck, resting and Tck pretreated with anti- CD49d neutralizing antibody show 
modestly different distribution patterns when injected intragraft 
To determine if Tck injected directly into the graft tissue were truly accumulating due to 
integrin ligation as described in chapter five, or not undergoing egress due to lack of graft 
vascularisation, untreated Tck and Tck pretreated with an anti- CD49d neutralizing antibody 
from a further donor were directly injected into the graft to examine the effect of integrin 
blockade.  Resting T cells were injected as a comparison.   
The results from this experiment revealed that the majority of all three cell types were 
retained in the graft tissue, however cell distribution to other organs showed some 
differences.  Tck migrated only to the liver; however a proportion of Tck treated with anti- 
CD49d neutralizing antibody migrated to the lung and the liver.  Resting T cells were 
detected in the liver and the lung, and in one mouse, in the other graft (Figure 6.12 b).  
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Although there were only four animals in each group, this data indicates that the graft tissue 
had become vascularised.  Additionally, Tck demonstrated the least egress from the graft 
tissue, which could indicate ligation of Tck integrins and accumulation in the synovial tissue.  
This is supported by the observation that when CD49d was blocked, there were cells detected 
in more organs that seen with control Tck.  However, again further investigation is required 
to confirm these results.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Six: Establishing the RA/ SCID model and investigation of in vivo Tck migration 
 
270 
 
Liver Spleen Graft R Graft L Heart Fermur Tail Blood Lung
0
100000
200000
300000
400000
C
P
M
 
 
 
Liver Spleen Graft R Graft L Heart Femur Blood Lung Kidney
0
10000
20000
30000
40000
50000
60000
70000
0
50
100
Tck Tck anti CD49dResting
C
e
ll
 N
u
m
b
e
r
%
 M
ig
r
a
tio
n
 
 
Figure 6.12 Tck demonstrate decreased egress from graft tissue compared to resting and anti- 
CD49d- treated Tck  
SCID Beige mice were anaesthetized and synovial tissue implanted subcutaneously.  After two weeks, 
111
Indium labelled resting, control Tck and Tck pretreated with antiCD49d neutralizing antibody 
(10µg/ml) for 30 minutes, were injected directly into the graft on the right side of the animal.  After 6 
hours animals were sacrificed and organs isolated.  Each organ was placed in a tube and read by a 
gamma counter.  Shown are a) pooled data from two animals, expressed as CPM and b) pooled data 
from twelve animals, with four animals per group.  Data expressed as relative cell number based on a 
standard curve.  
 
 
 
 
(b) 
(a) 
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6.5 Tck migration was not detected using the air pouch model 
To investigate if Tck migration to an inflammatory stimulus could be detected in an 
alternative model, the air pouch model was used.  SCID beige mice were given a dorsal 
subcutaneous injection of air to form a pouch.  After five days the pouch was activated using 
the TLR ligand zymosan, and PBS, TNFα or CXCL12 was subsequently administered to 
stimulate Tck migration.  As there was no human tissue engrafted in this model, Tck were not 
labelled prior to intravenous injection.  Two days after cell injection, the exudate from the 
pouch was then collected by washing with PBS, exudates from within each group pooled, 
stained for anti- human CD45 and CD4, and analysed using flow cytometry.  Antibodies had 
previously been tested for human/ mouse cross-reactivity and were found only to bind human 
cells. 
Results from one experiment of three are shown in figure 6.12.  Total Tck, that is cytokine 
activated lymphocytes which had been purified by elutriation but had not been enriched for 
the CD4
+
 population by immunomagnetic bead separation were injected intravenously and 
then cultured for two days.  On the day of culling, they were stained with anti- human CD45 
and CD4 antibodies (Figure 6.13 a), and compared to CD45 and CD4- stained exudates from 
each treatment group of animals (Figure 6.13 b- f).   
As shown in figure 6.12, the injected Tck were approximately 90 % positive for CD45, and 
33 % positive for CD4 (Figure 6.13 a).  However no more CD45
+
 or CD4
+
 cells could be 
detected in the group which received Tck and PBS only (Figure 6.13 b), or CXCL12 or 
TNFα (Figure 6.13 d, f) compared to the two control groups which received CXCL12 and 
TNFα but no cells (Figure 6.13 c, e).  This result was reproducible, suggesting that the air 
pouch model, while effective in studies of neutrophil migration, is not suitable for studies of 
T cell migration.  
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Figure 6.13 Tck migration was not detected using the air pouch model 
SCID Beige mice were administered subcutaneously with 5 mls of air to induce formation of a  
pouch.  Five days later, then pouch was reinflated and activated with zymosan and six hours before 
injection, CXCL12 (20 ng/ml), TNFα (10 ng/ml) or PBS.  Tck were injected intravenously and the 
exudate collected by injecting PBS into the pouch and washing out the cells.  Exudate was pooled 
within each group and stained with fluorochrome- conjugated antibodies against human CD45 and 
CD4.  Shown are a) Injected Tck stained with anti- CD4 and anti CD45, c) Injected Tck stained with 
anti- CD4, d) air pouches stimulated with PBS with Tck injection, e) air pouches stimulated with 
CXCL12 and no Tck, f) air pouches stimulated with CXCL12 with Tck injection, g) air pouches 
stimulated with TNFα and no Tck and g) air pouches stimulated with TNFα with Tck injection.  25 
animals were used with 5 animals in each group  
 
(b) (c) 
(e) (f) 
(d) 
(a) 
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6.6   Discussion 
Results detailed in chapter five indicated that Tck demonstrated an increased capacity to 
transmigrate through an endothelial cell monolayer, and this was predominantly dependent on 
the VLA-4/ VCAM-1 axis.  Although the assay was performed under static conditions, the 
findings support previous work documenting the role of the VLA-4/ VCAM-1 axis in 
promoting cell infiltration into the RA synovial tissue (van Dinther-Janssen et al. 1991; 
Morales-Ducret et al. 1992; Kitani et al. 1996; Burger et al. 2001).  In this chapter, the aim 
was to use the RA/ SCID mouse model to examine Tck migration to inflamed synovial tissue 
in vivo, which would add the parameter of shear flow and the opportunity to determine if 
blockade of VLA-4 on Tck could be exploited for therapeutic potential.   
Based on the literature, the expectation was that this model was robust and could be used to 
look at resting and Tck migration, in addition to modulating the response with blocking 
antibodies, inhibitors and other cell types.  Initially the model was set up within the Institute 
and surgical technique and successful tissue implantation was achieved.  However, although 
the PKH26 fluorescent label was not disintegrated by collagenase digestion, no cells 
expressing the label could be detected in the graft tissue after Tck injection.  A strategy for 
more sensitive detection of Tck was then devised; labelling Tck with 
111
Indium, which is an 
extremely sensitive method of cell detection.  
Studies using this method revealed a wide distribution of Tck in the animals after injection, 
and that this varied depending on the route of administration.  Moreover, direct injection of 
Tck into the graft showed minimal egress in comparison to Tck treated with a neutralizing 
antibody against CD49d, or resting T cells.  These findings suggest that the grafts are 
vascularised, however further studies are required to investigate whether Tck have the 
capacity to accumulate within the synovial tissue. 
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In an effort to examine Tck migration to an inflammatory stimulus in addition to the RA/ 
SCID model, the air pouch model was employed.  This model has been extensively used to 
study murine neutrophil and eosinophil migration (Hirasawa et al. 1991; Perretti et al. 1994; 
Bertini et al. 1999; Ryckman et al. 2003; Okigami et al. 2007; Costa et al. 2008; Vigil et al. 
2008), however it proved unsuitable for investigation of Tck migration.  It was noted that the 
cell recovery from each air pouch, even when pooled within each group, was quite variable.  
However based on CD45 and CD4 expression, there were proportionally no more cells 
present in the groups which had received injected cells compared to those which had not. 
Several problems were encountered while using the RA/ SCID model.  Initially it was 
observed that only tissue with a high content of activated T cells and macrophages would 
result in successful engraftment, however even stimulation of these grafts with TNFα did not 
positively affect Tck migration.  It was thought that the fluorescent label was potentially 
damaged after digestion with collagenase, however results from an in vitro experiment 
showed that this was not the case, and that the label remained intact over culture for several 
days (Figure 6.3).  Despite several experiments in which every parameter was investigated, 
no migration to the graft tissue was observed.  It is known that radiolabelling cells with 
111
Indium is a very sensitive method of tracking macrophages and monocytes in animal 
models (Gorantla et al. 2006; Kircher et al. 2008; Harb et al. 2009), and once this alternative 
strategy of T cell labelling was devised, all subsequent studies employed this technique.  
Despite determining where Tck cells migrated within the animal and that migration varied 
depending on route of administration, Tck migration to the graft tissue was still not observed.   
As an alternative to the use of this model in Tck migration studies, the capacity of Tck to 
egress from the graft tissue was explored.  It is known that in RA, cells accumulate in the 
synovium through ligation of integrins and chemokine receptors detailed in chapters three- 
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five (Cush et al. 1992; Buckley et al. 2000; Nanki et al. 2000; Bradfield et al. 2003).  Based 
on this, the impact of Tck CD49d expression was investigated by antibody- mediated 
blockade to determine if this integrin played a role in Tck retention within the graft tissue.  
When the cells were injected directly into the graft, the majority were detected there six hours 
after injection.  Although there was modest Tck migration to the liver, resting T cells and Tck 
treated with an anti- CD49d neutralizing antibody migrated from the graft to the liver and the 
lung, and in one animal, the other graft.  However this result was inconclusive and must be 
further examined in future studies. 
The RA/ SCID model was used primarily due to its potential in targeting routes for therapy.  
Although a decrease in chemotaxis and transendothelial migration of Tck was observed on 
blockade of the CXCR4/ CXCL12 and VLA-4/ VCAM-1 axes in vitro, this could not be 
confirmed using this model.  Other potential models which could be used to properly 
investigate Tck migration in vivo are detailed in chapter seven.  
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7.0   Discussion 
It was previously shown by our group that activation of T cells with IL-2, IL-6 and TNFα for 
eight days resulted in a T cell phenotype which was identical to that of T cells isolated from 
RA synovial tissue.  These cells were designated cytokine-activated T cells, or Tck.  In this 
thesis, I investigated whether the upregulation of T cell expression of chemokine receptors 
and integrins resulted in an increased migratory responsiveness in vitro and in vivo.   
The rationale behind the project is as follows.  Although current RA therapies are extremely 
efficacious in disease treatment, some patients remain non-responsive and high costs of 
biologics mean further pathways must continue to be exploited for therapeutic gain.  It has 
long been shown that chronic inflammation concomitant with influx of immune cells, 
particularly effector memory T cells, into the synovium drives tissue destruction and 
disability in RA.  There is also evidence that while T cells specific for a number of potential 
autoantigens have been detected in the synovium, a large proportion of the activated T cells 
in the joint appear to have been activated in a bystander manner within the inflammatory 
environment in the joint.  Moreover, these cells participate in perpetuating inflammation 
through cell- cell interactions with other populations in the synovial tissue (Brennan et al. 
2002; Beech et al. 2006; Tran et al. 2007; Brennan et al. 2008).  Through these studies our 
group have determined that cytokine activation of T cells is a suitable surrogate model for 
RA T cells, which allows for more in depth studies of these cells without the constraint of cell 
numbers.  Although the contribution of bystander- activated T cells to pathology and tissue 
destruction has been debated, studies have shown that bystander- activated cells have been 
demonstrated to secrete pro-inflammatory mediators and participate in the inflammatory 
response in a number of conditions including virus- induced CNS disease (McGavern et al. 
2004), dengue infection (Suwannasaen et al. 2010), Hashimoto’s thyroiditis (Mori et al. 
2010), and MS (Bar-Or et al. 2010).   
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In this project I sought to determine if cytokine activation of T cells conferred an increased 
responsiveness to migrate, to elucidate the pathways involved in this process, and to 
investigate if these pathways could be exploited therapeutically using an in vivo model of 
human T cell migration. 
In chapter three, I sought to determine upregulation of both molecules previously identified 
by our group, and a panel of chemokine receptors and integrins implicated in RA 
pathogenesis.  Cytokine activation of T cells resulted in upregulation of expression of 
activation markers including CD69, CD62L, CD38 and CD25, chemokine receptors CXCR3, 
CXCR4, CCR5 and CCR6 and integrin chains which associate to form VLA-1, VLA-4 and 
LFA-1.  The suitability of cytokine activation of T cells as a surrogate model for the RA T 
cell based on phenotypic differences is supported by the literature.  Expression of CD69 and 
CD38 has been detected on synovial fluid and synovial tissue T cells (Fernandez-Gutierrez et 
al. 1995; van Oosterhout et al. 2005), and T cells expressing the chemokine receptors 
CXCR3, CXCR4, CCR5 and CCR6 have been identified in synovial tissue and fluid 
(Buckley et al. 2000; Nanki et al. 2000; Matsui et al. 2001; Patel et al. 2001; Bradfield et al. 
2003; Norii et al. 2006; Desmetz et al. 2007; Hirota et al. 2007; Byrne et al. 2009).  In 
addition, integrins VLA-4 and LFA-1 have been shown to be expressed on T cell isolated 
from synovial tissue (van Dinther-Janssen et al. 1991; Nakatsuka et al. 1997).  The Tck cell 
surface phenotype indicated that the cells may demonstrate an increased capacity to migrate 
to ligands of the upregulated molecules observed and to engage in cell- cell interactions, as 
compared to resting T cells.  The phenotype of Tck also indicates that they could migrate to 
both secondary lymphoid organs and sites of inflammation, based on their expression of 
CD62L (although it is also shed) and CXCR4. 
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In chapter four, the migratory responsiveness of Tck was determined.  In addition to 
increased ‘spontaneous’ Tck migration, increased expression of CXCR4 resulted in CXCR4- 
dependent Tck chemotaxis to its ligand, CXCL12, with CXCL12 responsive Tck 
demonstrating an increased capacity to promote contact- dependent monocyte TNFα and IL-6 
production.  The CXCR4/ CXCL12 axis has been implicated in stimulating T cell migration 
to the synovium (Buckley et al. 2000; Nanki et al. 2000; Bradfield et al. 2003; Santiago et al. 
2006; Kim et al. 2007), and additionally it was shown that blockade of CXCR4 through the 
small molecule inhibitor AMD3100 mobilized haematopoietic stem cells from the bone 
marrow (Cashen et al. 2007).  This indicates that while full blockade of chemokine pathways 
could be deleterious to homeostatic immune responses, inhibition of the CXCR4/ CXCL12 
axis could be advantageous in stimulating mobilization of stem cells.  Re-establishment of 
tolerance in patients with severe RA through chemotherapy and subsequent autologous stem 
cell transplantation has been investigated (Verburg et al. 2005), and in this setting, treatment 
with AMD3100 to mobilize haematopoietic stem cells could be advantageous.   
It was previously shown that sVCAM-1 induces chemotaxis of a number of cells types, 
including RA synovial fluid T cells and monocytes (Kitani et al. 1998; Tokuhira et al. 2000).  
Concentration- dependent migration of Tck was observed compared to background migration 
levels, and which was mediated through Tck VLA-4 expression.  Furthermore, sVCAM-1 
responsive Tck were more adept at promoting monocyte TNFα and IL-6 production than non- 
responsive cells, indicating that these cells could be pathogenic in vivo. 
It has been reported that synovial fibroblasts play an important role in RA pathogenesis, and 
can migrate to spread arthritis to unaffected joints (McGettrick et al. 2009; Neumann et al. 
2010).  The presence of RA fibroblast- like synoviocytes increased Tck migration compared 
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to the media control in the majority of donors and this migration was inhibited through 
blockade of the CXCR4/ CXCL12 and VLA-4/ VCAM-1axes. 
In chapter five, the role of VLA-4 and LFA-1 and their ligands in Tck transendothelial 
migration assay was investigated.  Blockade of both axes resulted in inhibition of Tck 
transmigration, with more significant effect observed when VLA-4/ VCAM-1 blockade was 
performed.  Given the high level of literature reporting the importance of LFA-1/ ICAM-1 
over that of VLA-4/ VCAM-1, this comparison merits analysis of further donors.  In addition, 
soluble VCAM-1 was shown to play a role in mediating Tck transmigration.  Combined with 
findings discussed in chapter four, this data indicates that blockade of VLA-4/ sVCAM-1 
could potentially be exploited for therapeutic gain.  In support of these findings is a recent 
study which used Natalizumab (anti CD49d therapy) as a treatment in MS (Millonig et al. 
2010).  The authors found that Natalizumab treatment decreased leukocyte transendothelial 
migration by reducing both leukocyte cell surface expression of VLA-4 and soluble VCAM-1 
levels produced by activated endothelia.  
In this chapter, extravasation of Tck was compared to T cells isolated from blood and 
synovial tissue of RA patients.  While further donors are required to confirm initial results, 
percent Tck transmigration was surprisingly higher than that of CD3
+
 T cells isolated from 
blood and synovial tissue samples.  However this may be attributed to the fact that the cells 
had been cryopreserved prior to T cell enrichment, and the cells had not been restimulated.  
This comparison merits further investigation. 
In chapter six, the in vivo migration of Tck was explored using the therapeutic RA/ SCID 
mouse model and the air pouch model.  These models also allowed the inclusion of the 
parameter of shear flow, which was not a component of the in vitro assays.  For reasons 
discussed in this chapter, these models did not provide a definitive answer as to whether Tck 
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could migrate to inflamed synovial tissue in vivo.  Although the distribution and egress of 
Tck and resting T cells, and the role Tck expression of CD49d played in these processes were 
investigated, definitive results were not forthcoming and further work is required.  This 
model did not prove to be as robust as was reported in the literature; it is possible that ease of 
use and complexity of the model was not made clear in published reports.   
Cytokine stimulation of CD4
+
 T cells described in this thesis include populations of central 
memory and effector memory T cells.  Previous work by our group has shown that the T cell 
subset with the most potent ability to stimulate monocyte pro-inflammatory cytokines resides 
within the effector memory subset (Brennan et al. 2008).  Although many of these cells have 
previously experienced antigen and are poised to be reactivated with that antigen, they also 
show the ability to be further differentiated in an antigen- independent manner by cytokines.  
Previous reports of the stability of central or effector memory phenotypes have indicated that 
although differentiated, memory cells can be reprogrammed according to the cytokine 
environment they are in (Ahmadzadeh et al. 2002; Schwendemann et al. 2005).  It has also 
been shown that epigenetic mechanisms such as methylation status and chromatin 
modifications can affect the expression, either stable or transient, of genes involved in T cell 
homing and activation (Nagar et al. 2008), and these mechanisms can be affected by cytokine 
stimulation (Nagar et al. 2008; Steinfelder et al. 2011).  This data suggests that T cell 
differentiation is plastic and can be modified by environmental cues, and that this could 
potentially be exploited in treatment of diseases (Janson et al. 2009).   
Indeed, the question of where Tck are likely to be activated must be raised.  Tck 
demonstrated an increased intrinsic capacity to migrate and undergo transendothelial 
migration compared to resting or Ttcr cells, which was not completely abrogated through 
blockade of any of the pathways discussed.  Although this was not observed in vivo using the 
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models discussed in chapter six, further investigation into Tck egress and the role that 
integrins play in this is merited.  Collectively, this suggests that the chemokine receptors and 
integrins upregulated by cytokine activation are functional and could potentially play a role in 
accumulation and maintenance of T cells in the synovium.  Previous studies have described 
an increased expression of activation molecules and intrinsic migratory responsiveness of 
peripheral blood T cells from RA patients compared to healthy controls, and within RA 
patients, an increased migratory capacity of synovial fluid T cells compared to peripheral 
blood T cells (Cush et al. 1992; Kitani et al. 1998).   
Moreover, studies have shown that not only are there increased levels of circulating 
proinflammatory cytokines in the blood of RA patients both before onset of symptoms and 
during full blown disease, but that RA T cells have a lower threshold for TCR activation than 
peripheral blood lymphocytes from healthy controls due to their sustained expression of 
CD70 and absence of CD28  (Charles et al. 1999; Lee et al. 2007; Hueber et al. 2009; 
Kokkonen et al. 2010).  T cells could therefore potentially be activated by cytokines in the 
blood.  However it is more likely that resting and /or previously activated T cells are recruited 
to the synovium through expression of both homeostatic and inflammatory chemokine 
receptors, and become further activated by cytokines in a bystander manner on entry to the 
synovial tissue.  Cytokine- activated cells could then be organised into aggregates within the 
tissue and interactions with FLS through their response to CXCL12 and sVCAM-1.  This 
could then lead to T cell accumulation and further production of pro-inflammatory mediators 
through cell- cell interactions.   
The question of whether chemokines and integrins are a viable therapeutic option must also 
be raised.  As previously discussed, therapies directed against CD49d and CXCR4 have been 
licensed for use in other diseases.  Blockade of CXCR4 has been shown to mobilize stem 
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cells from the bone marrow to the peripheral blood by disturbing ligation of CXCR4 with 
CXCL12 and releasing the cells retained in the tissue.  While CXCR4 and CD49d blockade 
may inhibit migration of T cells to the synovium, it could lead to the release of pathogenic T 
cells which are retained in the joint, which could then migrate elsewhere in the body and 
cause damage.  In addition, CXCR4 and CD49d mediate homeostatic processes as well as 
their roles in inflammation, and interruption of naive and memory T cell migration could 
potentially lower the capacity of the individual to fight infection, although the level of 
redundancy of these axes with others could prevent deleterious effects of that nature.  
However the promiscuity of chemokine receptors and their ligands also make their blockade 
for therapeutic potential difficult.  In support of this is the low efficacy of chemokine- 
directed monotherapies which have been investigated in clinical trials.  It could therefore be 
beneficial to administer CXCR4 or CD49d blockade in conjunction with other therapies 
which function to reduce pro-inflammatory cytokine levels. 
 
7.1   Future Work 
To definitively determine if Tck possess the capacity to migrate in vivo, an alternative model 
for studying this needs to be employed.  A potential candidate for this is engraftment of 
human RA fibroblasts and cartilage under the renal capsule of SCID mice.  The cells and 
cartilage are implanted into a sterile sponge to ensure close contact, and then implanted under 
the renal capsule for 30 days (Muller-Ladner et al. 1996).  Necrosis of cartilage was not 
observed, and no other cell type was detected in the graft.  This could be a suitable model to 
study Tck migration given the problems encountered with implanting whole tissue; and to 
investigate the role that fibroblast- like synoviocytes and their production of VCAM-1 and 
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CXCL12 play in inducing Tck migration in vivo through CXCR4 and CD49d/ CD29 
respectively.  Therapeutic intervention could also be explored using this model. 
In addition to exploring Tck migration and blocking the pathways involved to determine 
therapeutic potential, lentiviral infection of Tck could also be pursued.  This technique has 
been established by the lab in an attempt to knock down key genes of interest; genes which 
have been identified from in vitro studies and subsequent in vivo work.  This approach would 
include knockdown and overexpression of genes of interest.  Overexpression of Foxp3 has 
been established in the lab at this time.  The gene is cloned into a plasmid and a marker gene 
such as GFP.  This vector is packaged by HEK293 cells with an envelope vector and 
packaging vector to create the Lentivirus.  The lentivirus is then grown in these cells, the 
supernatants concentrated, and applied to the Tck, resulting in overexpression of that gene.  
Given the potential therapeutic effect of regulatory T cells, FoxP3- transduced T cells could 
also be co-injected with Tck to examine the effect on pro-inflammatory cytokine production 
by Tck in vivo. 
 
7.2   Conclusion 
The findings detailed in this thesis demonstrate that cytokine- activation of T cells induces a 
migratory and pathogenic phenotype.  This is reflected in their ability to migrate in a 
‘spontaneous’ manner, to a number of molecules implicated in RA pathogenesis and through 
an endothelial monolayer, and their ability to promote contact- dependent monocyte pro-
inflammatory cytokine production.  These findings have expanded knowledge of Tck and 
have documented further similarities between Tck and T cells isolated from RA synovial 
tissue, further demonstrating the suitability of Tck as a surrogate model for studying RA T 
cells.  However whether Tck migrate in vivo, and how this compares to T cells isolated from 
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synovial tissue and blood of RA patients still needs to confirmed.  In addition, pathways such 
as the CXCR4/ CXCL12 and VLA-4/ VCAM-1 axes have been identified which could be 
exploited for therapeutic gain in finding alternative treatments for RA.   
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